chlorthalidone has been researched along with Hypertension in 975 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of chlortalidone plus amiloride and amlodipine on blood pressure (BP) variability in patients with hypertension and obstructive sleep apnea syndrome (OSA)." | 9.69 | Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial. ( Borges, RB; Cichelero, FT; Fuchs, FD; Fuchs, SC; Hirakata, VN; Jorge, JA; Lucca, MB; Martinez, D, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 9.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 9.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "We randomly assigned patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12." | 9.41 | Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Dickinson, JH; Ouyang, F; Sinha, AD; Tu, W, 2021) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 9.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension." | 9.30 | Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. ( Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019) |
| "Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ)." | 9.27 | Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Lloyd, E; Weber, MA; White, WB; Wu, J, 2018) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 9.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of stage I hypertension." | 9.22 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. ( Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; de Alencastro, PR; de Mello, RB; de Sousa, MR; E Silva, RP; Filho, DC; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Neto, AA; Neto, JA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| " Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment." | 9.22 | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial. ( Alves, JG; Berwanger, O; Bordignon, A; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Consolim-Colombo, FM; de Alencastro, PR; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Mota Gomes, M; Neto, AA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Silva, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is also being developed in fixed-dose combinations with chlorthalidone, a potent, long-acting thiazide-like diuretic." | 9.16 | Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. ( Bakris, GL; Cushman, WC; Kupfer, S; Lloyd, E; Roberts, A; Sica, D; Weber, MA; White, WB, 2012) |
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 9.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 9.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "In the Systolic Hypertension in the Elderly Program (SHEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a lower rate of cardiovascular events than placebo but effects on mortality were not significant." | 9.15 | Association between chlorthalidone treatment of systolic hypertension and long-term survival. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Pressel, SL, 2011) |
| "To survey the prevalence of hyperuricacidemia and serum uric acid (SUA) changes and electrolyte changes after 6 weeks antihypertensive treatment with thiazide diuretics, losartan or losartan+hydrochlorothiazide (Hyzaar) in patients with essential hypertension (EH)." | 9.13 | [Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension]. ( Chen, H; Gui, W; Lu, LH; Wu, XY; Yang, LQ; Yu, L, 2008) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 9.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "The study was conducted to evaluate the vascular effects of chlorthalidone, a distal tubule-acting natriuretic agent, in hypertensive patients with nondiabetic metabolic syndrome, an insulin-resistant condition characterized by endothelial dysfunction and high risk for diabetes mellitus development." | 9.11 | Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Penno, G, 2005) |
| "The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage 1 isolated systolic hypertension (ISH)." | 9.10 | Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. ( Black, H; Ghadanfar, M; Grimm, RH; Lewin, A; Rowen, R; Shi, H, 2002) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "In elderly hypertensive patients with coronary artery disease, chlorthalidone reduced myocardial ischemia similarly to diltiazem." | 9.09 | Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease. ( de Paula, RS; Gebara, O; Gruppi, C; Moffa, P; Nussbacher, A; Pereira-Barreto, AC; Pierri, H; Pinto, L; Serro-Azul, JB; Wajngarten, M, 2001) |
| "The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes." | 9.08 | Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. ( Zanchetti, A, 1995) |
| "A multicentric, prospective, 16-week open study evaluated the effectivity and tolerance of the fixed combination of the beta-blocking agent bopindolol with the diuretic chlorthalidone--Sandoretic in 81 patients with mild to moderate hypertension." | 9.08 | [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)]. ( Balazovjech, I; Havlík, V; Havránek, P; Hulínský, V; Kroupa, E; Lánská, V; Nikodýmová, L; Pátek, F; Svihovcová, P; Svítil, F; Widimský, J, 1996) |
| "In a double-blind, partial cross-over study of 141 patients with mild to moderate hypertension, chlorthalidone 50 mg was compared with chlorthalidone 50 mg/triamterene 50 mg combination treatment." | 9.08 | Double-blind parallel study of a combination of chlorthalidone 50 mg and triamterene 50 mg in patients with mild and moderate hypertension. ( Spiers, DR; Wade, RC, 1996) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 9.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "The Verapamil in Hypertension and Atherosclerosis Study (VHAS) is a prospective randomized study the objective of which was to compare the long-term effects of verapamil and chlorthalidone on the blood pressure, clinical safety, and the progression/regression of carotid wall lesions in members of a large population of hypertensive patients." | 9.08 | Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1997) |
| "Antihypertensive therapy with low-dose chlorthalidone (supplemented if necessary) for isolated systolic hypertension lowers blood pressure and its cardiovascular disease complications and has relatively mild effects on other cardiovascular disease risk factor levels." | 9.08 | Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Re ( Applegate, WB; Black, HR; Cohen, J; Curb, JD; Davis, BR; Frost, P; Gonzalez, N; Guthrie, GP; Oberman, A; Pressel, SL; Probstfield, JL; Rutan, G; Savage, PJ; Schron, EB; Smith, W; Stamler, J, 1998) |
| " The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS)." | 9.08 | The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1998) |
| "5 mg and atenolol 50 mg (C-A) in adult black patients with mild to moderate hypertension (a resting supine diastolic blood pressure (DBP) between 95 and 115 mmHg after a two week placebo washout period)." | 9.07 | Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. ( Maharaj, B; van der Byl, K, 1993) |
| " To assess whether chlorthalidone affected levels of putatively atherogenic small, dense LDL (LDL 3), we conducted a 12 week double blind randomized, placebo controlled clinical trial in 34 nonsmoking men aged 35 to 57 years with mild hypertension (DBP 90 to 104 mm Hg)." | 9.07 | Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. ( Belcher, J; Bradley, K; Elmer, P; Flack, JM; Grimm, R; Miller, P, 1993) |
| " The Verapamil in Hypertension Atherosclerosis Study is an ongoing multicentre randomised double-blind parallel group trial comparing the antihypertensive efficacy of verapamil SR 240 mg/day with that of chlorthalidone 25 mg/day in 1464 patients with essential hypertension aged 40 to 65 years." | 9.07 | Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| "Sixteen patients with severe hypertension were treated for 1 year with extended release nifedipine, during which time serial changes in left ventricular mass index and associated alterations in left ventricular systolic function, left ventricular filling, plasma renin activity, atrial natriuretic peptide and catecholamines were evaluated." | 9.07 | Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. ( Ardeljan, M; Eison, HB; Garbowit, DL; Goldman, ME; Krakoff, LR; Phillips, RA; Shimabukuro, S, 1991) |
| "Guanfacine, an alpha-2 adrenoceptor agonist, was compared with methyldopa as step-2 therapy for patients with mild-to-moderate essential hypertension in a 12-week, double-blind, randomized, parallel evaluation of efficacy and safety." | 9.07 | Antihypertensive efficacy of guanfacine and methyldopa in patients with mild to moderate essential hypertension. ( Blackshear, J; Lovallo, WR; Mathur, P; Parsons, OA; Wilson, MF, 1991) |
| "The effectiveness and safety of sustained action nifedipine (NF) were compared to those of chlorthalidone (CL) in two groups of 35 and 37 patients with mild to moderate hypertension followed up for 4 months." | 9.06 | [Comparison of chlorthalidone and sustained-action nifedipine in the treatment of mild to moderate arterial hypertension]. ( Calderón de la Barca Gázquez, JM; de Diego Cabrera, MS; González Santos, C; Iribarren Marín, MA; Martínez de la Iglesia, J; Pérula Torres, L, 1990) |
| "The aim of the study was to compare the effect of slow-release (SR) nicardipine, placebo and chlorthalidone on hypertension-related arrhythmias evaluating 24-h ambulatory ECG." | 9.06 | Hypertension and arrhythmias: effects of slow-release nicardipine vs chlorthalidone: a double-blind crossover study. ( Celentano, A; de Divitiis, O; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1990) |
| "The antihypertensive effect of slow-release (SR) nicardipine (40 mg twice a day) and chlorthalidone (25 mg once a day), was evaluated in 36 patients with mild to moderate hypertension by casual and 24-h BP monitoring." | 9.06 | Effects on casual and 24-h ambulatory blood pressure of slow-release nicardipine and chlorthalidone in arterial essential hypertension: double-blind, crossover study. ( Celentano, A; de Divitiis, O; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1990) |
| "A close comparative study of the hypotensive effects of verapamil and chlorthalidone was carried out on 60 patients affected with mild essential hypertension showing systemic." | 9.06 | [Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension]. ( Hergueta García de Guadiana, G; Paumard Fraguas, A, 1989) |
| "The effect of adding placebo, a calcium antagonist, nicardipine and a thiazide diuretic, chlorthalidone, each for 2 weeks, to ongoing treatment with the ACE inhibitor, enalapril was evaluated in seven patients with essential hypertension." | 9.06 | Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "Sixty patients were treated for 1 year for essential uncomplicated hypertension, 30 with beta-blockers alone (BB) and 30 with BB and chlorthalidone (CTD)." | 9.06 | Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. ( Baumeler, HR; Cesana, B; Cocco, G; Iselin, HU; Strozzi, C, 1987) |
| "Two hundred and one patients with essential hypertension, whose supine diastolic blood pressure (SDBP) was greater than or equal to 95 mmHg following 2 weeks of treatment with the optimal dose of a beta blocker-diuretic combination (Phase 1), were randomly assigned to the addition of either 25 or 50 mg captopril BID for 6 weeks (Phase 2)." | 9.06 | A multicenter trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker-diuretic treatment. ( Agabiti-Rosei, E; Alicandri, C; Buoninconti, R; Cagli, V; Carotti, A; Corea, L; Dal Palù, C; Innocenti, PF; Muiesan, G; Paciaroni, E, 1987) |
| "Previous studies have shown that single dose or short-term administration of celiprolol does not impair pulmonary function in patients with asthma." | 9.06 | Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. ( Clauzel, AM; Etienne, R; Jean, T; Michel, F; Visier, S, 1988) |
| "In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic)." | 9.06 | Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. ( Curry, RC; Schwartz, KM; Urban, PL, 1988) |
| "We evaluated the safety and efficacy of transdermal clonidine (TC) in 23 patients with essential hypertension over a two-year period." | 9.06 | Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. ( Horning, JR; McNulty, R; Simmons, JL; Williams, L; Zawada, ET, 1988) |
| "To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67." | 9.06 | [Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. ( Achilli, L; D'Amico, F; Latini, R; Lombi, V; Pierandrei, G, 1987) |
| "One hundred seventy-one patients, 60 years of age or older with isolated systolic hypertension, were randomly assigned to receive chlorthalidone 12." | 9.06 | Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. ( Aranda, J; Barra, P; Davidov, M; Ettinger, B; Gorwit, J; McBarron, F; Morledge, JH, 1986) |
| "Guanfacine, an alpha-adrenoceptor agonist, may exhibit distinct dose-related curves for efficacy and adverse effects in the step-2 therapy of essential hypertension." | 9.06 | A multicenter, randomized, double-blind dose-response evaluation of step-2 guanfacine versus placebo in mild to moderate hypertension. ( Alderman, MH; Canosa, FL; Finnerty, FA; Kessler, WB; Marlon, AM; Materson, BJ; McMillen, JI; Savran, SV, 1986) |
| "After a run-in period on placebo, 26 patients with essential hypertension were prescribed single-blind tibalosine, 150 mg daily." | 9.06 | Chronic treatment with tibalosine in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; M'Buyamba-Kabangu, JR; Staessen, J, 1986) |
| "A systematic review of literature published from 1990 to 2018 was performed by using the following key words: Edarbyclor, azilsartan, chlorthalidone, pharmacokinetic, and hypertension." | 9.05 | Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review. ( Kim, GH; Kwon, A, 2020) |
| "Nineteen patients with uncomplicated essential hypertension and low activity of plasma renin in response to a change from recumbency to an upright posture along with furosemide administration were given spironolactone, 400 mg/d, or chlorthalidone, 100mg/d, in a double-blind, random-sequence, crossover trial." | 9.05 | Comparison of chlorthalidone and spironolactone in low--renin essential hypertension. ( Kreeft, JH; Larochelle, P; Ogilvie, RI, 1983) |
| "A prospective study of propranolol versus chlorthalidone has been performed in eleven patients with renal hypertension and one with essential hypertension." | 9.05 | Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. ( Bachmann, H, 1984) |
| "Thirty-two patients with moderate to severe essential hypertension whose supine diastolic blood pressure (SDBP) was greater than or equal to 95 mm Hg following 2 weeks' treatment with the optimal dosage of beta blocker-diuretic combination were randomly assigned to the addition of either captopril 25 mg or 50 mg b." | 9.05 | Efficacy of low-dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic. ( Agabiti-Rosei, E; Alicandri, C; Boni, E; Cinquegrana, A; Fariello, R; Montini, E; Muiesan, G; Muiesan, ML; Zaninelli, A, 1984) |
| "The acute and chronic effects of fixed dosages of clonidine and prazosin on supine and upright blood pressure, the renin-angiotensin-aldosterone system, and plasma catecholamines were compared in 24 patients with essential hypertension." | 9.05 | Comparative antihypertensive and endocrinologic effects of clonidine and prazosin in patients with essential hypertension. ( Drayer, JI; Hubbell, FA; Rose, DE; Weber, MA, 1984) |
| "A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension." | 9.05 | A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients. ( Born, A; Emanueli, A; Lavezzari, M, 1984) |
| "Twenty-four black patients (Zulus) with hypertension participated in a double-blind, placebo-controlled cross-over trial of the efficacy of a beta-blocking agent (atenolol) 100 mg once daily as compared with chlorthalidone 25 mg once daily." | 9.05 | Trial of atenolol and chlorthalidone for hypertension in black South Africans. ( Seedat, YK, 1980) |
| "Seventy-one patients with mild-to-moderate essential hypertension completed 14 weeks' treatment with a single daily dose of fixed combination of metoprolol tartrate 100 mg and chlorthalidone 25 mg (Logroton; Geigy)." | 9.05 | A fixed combination of metoprolol and chlorthalidone in hypertension. A clinical trial in general practice. ( Govind, U; Munro, BF; Robertson, LI, 1981) |
| "The dose response curve for 25, 50, 75 and 100 mg doses of chlorthalidone was studied in double blind fashion over an 8 week period in patients who presented with untreated mild hypertension." | 9.05 | Chlorthalidone in mild hypertension - dose response relationship. ( Humphries, IS; Mayhew, SR; Russell, JG, 1981) |
| "In a multicenter, single-blind, interpatient study, 103 outpatients with mild to moderate hypertension were given, after 2 weeks of placebo wash-out, 160 mg oxprenolol slow-release in fixed combination with chlorthalidone (20 mg per tablet) (SROC 160) once daily or conventional oxprenolol (80 mg) in fixed combination with chlorthalidone (10 mg per tablet) (COC 80) twice daily for 8 weeks." | 9.05 | A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension. ( Agabiti-Rosei, E; Buoninconti, R; Carotti, A; Fariello, R; Innocenti, P; Motolese, M; Muiesan, G; Toso, M; Valori, C, 1981) |
| "A double-blind crossover study was designed to compare the antihypertensive and hypokalaemic effects of chlorthalidone administered at 10h00 and 22h00 to sixteen patients with primary hypertension." | 9.05 | Influence of the administration time on the antihypertensive and hypokalaemic effects of chlorthalidone in patients with primary hypertension. ( Carpentiere, G; Castello, F; Marino, S, 1985) |
| "After a control period on a placebo, 45 patients with mild to moderate hypertension were treated with metoprolol, 100 mg twice daily alone and in free combination with chlorthalidone 50 mg daily using a double-blind crossover technique." | 9.04 | Metoprolol with and without chlorthalidone in hypertension. ( Ebbutt, A; John, V; Kendall, M; Kubik, M, 1979) |
| "The antihypertensive effect of atenolol, with and without chlorthalidone, on hypertension was assessed in an outpatient as well as in an inpatient study." | 9.04 | Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Teeuw, AH, 1979) |
| " Group A: In 14 patients with essential hypertension on chlorthalidone treatment, an additional daily dose of 640 mg propranolol for two months led to a significant reduction of the MAP (from 124 to 105 mm Hg) and PRA (from 5." | 9.04 | Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Mees, EJ; Vos, J, 1975) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 8.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| " The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan medoxomil or angiotensin receptor blockers or renin angiotensin system or chlorthalidone and hypertension." | 8.89 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? ( Barrios, V; Escobar, C, 2013) |
| "Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension." | 8.88 | Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. ( Bleske, BE; Dorsch, MP; Shuster, JE, 2012) |
| "Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits." | 7.96 | Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. ( Chen, R; Hripcsak, G; Krumholz, HM; Madigan, D; Pratt, N; Ryan, PB; Schuemie, MJ; Shea, S; Suchard, MA; You, SC, 2020) |
| "To study effects of a fixed azilsartan medoxomil/chlorthalidone combination (Edarbi Clo) on clinical, ambulatory and central blood pressure (BP) in patients with uncontrolled arterial hypertension (AH))." | 7.85 | [Antihypertensive Efficacy of Fixed Combination Azilsartan Medoxomil / Chlorthalidone in Patients With Uncontrolled Arterial Hypertension]. ( Kobalava, ZD; Kulakov, VV; Villevalde, SV, 2017) |
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 7.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| "This study assessed the risk of new-onset gout following prescribing of hydrochlorothiazide (HCTZ) compared with chlorthalidone (CTD)." | 7.80 | Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. ( Nair, KV; Saseen, JJ; Wilson, L, 2014) |
| "Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension." | 7.79 | Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. ( Dhalla, IA; Gomes, T; Hellings, C; Juurlink, DN; Mamdani, MM; Nagge, J; Persaud, N; Yao, Z, 2013) |
| "In patients with hypertension already taking HCTZ, switching to chlorthalidone seems to further reduce systolic and diastolic blood pressures without any clinically significant changes in renal function or electrolyte levels." | 7.79 | Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. ( Brenner, AC; Brenner, MJ; Matthews, KA, 2013) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "To evaluate the hemodynamic effects of low doses of chlorthalidone (CHT) in patients with systemic arterial hypertension (SAH)." | 7.68 | [Hemodynamic effects of low doses of chlorthalidone in patients with mild systemic arterial hypertension]. ( da Luz, PL; Hueb, W; Mansur, Ade P; Pileggi, F; Ramires, JA; Rati, M; Solimene, MC, 1993) |
| "To evaluate the effects of the use of chlorthalidone on left ventricular mass of patients with mild and moderate systemic arterial hypertension (SAH)." | 7.68 | [Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension]. ( César, LA; da Luz, PL; Francischetti, E; Mansur, Ade P; Marcondes, M; Oigman, W; Pileggi, F; Ramires, JA, 1993) |
| "In the present work the clinical, biological, radiological, electrocardiographic and hormonal characteristics are analyzed in 51 patients suffering mild essential hypertension, in whom treatment with captopril in monotherapy or associated to chlortalidone managed to normalize arterial pressure and maintained the pressure control during a period of one year." | 7.68 | [Do clinical parameters exist that permit predicting the need to combine a diuretic with captopril in the initial treatment of essential arterial hypertension?]. ( Aguilera, MT; Closas, J; Coca, A; de la Sierra, A; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "The effect of the angiotensin converting enzyme (ACE) inhibitor fosinopril sodium on regional cerebral blood flow (rCBF) was investigated in 8 patients with moderate essential hypertension." | 7.68 | The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. ( Andersen, AR; Ibsen, H; Paulson, OB; Rasmussen, S; Strandgaard, S; Waldemar, G, 1990) |
| "In ten patients with essential hypertension, 6 weeks of treatment with a clonidine/diuretic combination (1 retard capsule/day, 75 micrograms or 150 micrograms clonidine, and 15 mg chlortalidon) was suddenly discontinued." | 7.67 | [Clonidine-diuretic combination in patients with essential hypertension. Modification of sympathetic activity and blood pressure as well as the reaction following sudden withdrawal]. ( Beckenbauer, UE; Planz, G, 1984) |
| "The effects of chlorthalidone and metoprolol on fasting plasma lipids and lipoprotein levels were compared in two similar nonrandomized groups of patients with mild hypertension." | 7.67 | Different effects of metoprolol and chlorthalidone on serum lipoprotein levels in mild hypertension. Possible implications for coronary heart disease risk status. ( Goldbourt, U; Holtzman, E; Rosenthal, T; Segal, P, 1984) |
| "In 13 patients, affected by hypertrophic obstructive cardiomyopathy (HOCM) and essential hypertension, antihypertensive-efficacy and effects of a new calcium-channel blocker (gallopamil) associated with a diuretic agent (chlorthalidone) on left ventricular systolic and diastolic performance assessed by phonocardiographic methods." | 7.67 | [Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle ( Brandini, V; Chieppa, S; De Simone, R; Giuliani, F; Iarussi, D; Langella, S; Lobascio, C, 1989) |
| "We evaluated the effect of additional chlorthalidone therapy on blood pressure and body fluid volumes in 10 patients with essential hypertension who did not respond to chronic converting enzyme inhibition with enalapril." | 7.67 | Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril. ( Geyskes, GG; Mees, EJ; Roos, JC; van Schaik, BA, 1986) |
| "In 12 patients with essential hypertension who remained hypertensive despite chronic chlorthalidone treatment, the effect of 2 weeks of additional therapy with the converting enzyme inhibitor (CEI) enalapril on blood pressure and body fluid volumes has been evaluated." | 7.67 | Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Schaik, BA, 1986) |
| "Interaction of thiazide diuretics and the serum uric acid and creatinine levels was studied in 3693 stepped care participants in the Hypertension Detection and Follow-up Program not receiving treatment at baseline." | 7.67 | Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. ( Blaufox, MD; Borhani, NO; Curb, JD; Langford, HG; Molteni, A; Pressel, S; Schneider, KA, 1987) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 7.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| "The role of the renin-aldosterone axis in mediating responses to antihypertensive treatment was examined in patients with essential hypertension treated with propranolol (n=50) or chlorthalidone (n=50)." | 7.66 | The role of aldosterone in the response to treatment of primary hypertension. ( Drayer, JI; Laragh, JH; Purdy, RE; Weber, MA, 1982) |
| "A fixed combination of metoprolol slow-release 200 mg and chlorthalidone 25 mg was given once daily over a 3 months period in forty out-patients with mild-to-moderate arterial hypertension stage I or II WHO." | 7.66 | A fixed combination of metoprolol slow-release and chlorthalidone, given once daily, in the long-term treatment of arterial hypertension. ( Bichisao, E; Floris, B; Franchetta, G; Palestini, N; Sonaglioni, G; Verdecchia, P, 1982) |
| "Two studies of systolic time intervals (STIs) in patients with mild to moderate hypertension (HBP) revealed that no mean change in systolic intervals occurred with pindolol therapy, although some patients had significant alterations in their STIs." | 7.66 | Pindolol and systolic time intervals in patients with hypertension. ( Carliner, NH; Fisher, ML; Hamilton, BP; Hamilton, JH; Hammond, JJ; Jacks-Nagle, VL; Janoski, AH; Kirkendall, WM; Plotnick, GD; Robinson, M, 1982) |
| "Minoxidil is a potent antihypertensive drug widely used in severe arterial hypertension and in that refractory to treatment." | 7.66 | Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone. ( Cotorruelo, JG; Flórez, J; Llamazares, C, 1982) |
| "Intrarenal handling of uric acid was studied in 12 patients with essential hypertension under spironolactone treatment (200 mg/day)." | 7.66 | Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension. ( Boer, P; Dorhout Mees, EJ; Peuker, KH; Roos, JC, 1982) |
| "Eleven patients suffering from WHO stage II essential arterial hypertension were treated with the combination of labetalol plus chlorthalidone in the reciprocal ratio of 10:1 in the form of once-a-day administration in the morning." | 7.66 | Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy. ( Rossi, AG, 1981) |
| "Two fixed-combination drugs commonly used in the step 2 treatment of hypertension, chlorthalidone plus reserpine and hydrochlorothiazide plus methyldopa, were compared in an evaluation of efficacy and adverse reactions." | 7.66 | A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension. ( Adlin, EV; Channick, BJ; Kessler, WB; Marks, AD, 1981) |
| "The long-term antihypertensive efficacy and tolerability of a fixed combination of oxprenolol 160 mg slow-release + chlortalidone 20 mg was studied in 40 out-patients with mild to moderate essential hypertension followed during one year with monthly clinical visits." | 7.66 | One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension. ( Ambroso, G; Lazzaretto, R; Masoni, A; Pirani, R; Tomasi, AM, 1981) |
| "In 26 patients with essential hypertension who were on continuous chlorthalidone therapy, 1 and 3 daily doses of propranolol were compared in a crossover study." | 7.66 | One and three doses of propranolol a day in hypertension. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Asten, P; van den Brink, G, 1980) |
| "In a multicentre double-blind study, 92 out-patients with mild to moderate hypertension who had a resting blood pressure greater than or equal to 160/100 mmHg after a two-weeks' placebo wash-out were treated for 6 weeks with a fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg per tablet or chlorthalidone alone (1 tablet = 10 mg)." | 7.66 | Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension. ( Agabiti-Rosei, E; Carotti, A; Innocenti, P; Montervino, C; Motolese, M; Muiesan, G; Solinas, E; Toso, M, 1980) |
| "Twenty-five women were treated with propranolol during 26 pregnancies complicated by hypertension." | 7.66 | Propranolol for the treatment of hypertension in pregnancy. ( Eliahou, HE; Mashiach, S; Reisin, E; Romem, I; Serr, DM; Silverberg, DS, 1978) |
| "In 50 patients with essential hypertension treated with chlorthalidone, 100 mg daily for 6 weeks, treatment responders (fall in mean pressure, greater than or equal to 10%) and nonresponders experienced similar weight and electrolyte changes." | 7.65 | Disparate patterns of aldosterone response during diuretic treatment of hypertension. ( Drayer, JI; Laragh, JH; Rev, A; Weber, MA, 1977) |
| "The antihypertensive effect and the tolerance of the association of spironolactone and chlorthalidone were evaluated clinically and by numerous laboratory examinations in a group of 18 patients affected with non-complicated essential hypertension." | 7.65 | [Spironolactone combined with chlorthalidone in the treatment of essential arterial hypertension]. ( Favilli, R; Gragnoli, G; Nami, R; Puccetti, F; Tanganelli, I, 1975) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 7.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| "Hypertension is a leading risk factor for cardiovascular disease mortality." | 7.11 | Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. ( Armstrong, ND; Arnett, DK; Chekka, LMS; Claas, SA; Cooper-DeHoff, RM; Gong, Y; Hidalgo, BA; Irvin, MR; Johnson, JA; Jones, AC; Limdi, NA; McDonough, CW; Nahid, NA; Nguyen, NHK; Srinivasasainagendra, V; Tanner, RM; Tiwari, HK, 2022) |
| "Population pharmacokinetic and exposure-response models for azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) were developed using data from an 8-week placebo-controlled phase 3, factorial study of 20, 40, and 80 mg AZL-M every day (QD) and 12." | 6.82 | Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. ( Kupfer, S; Tsai, MC; Vakilynejad, M; Wu, J, 2016) |
| " The most common adverse events, irrespective of treatment, were dizziness (8." | 6.80 | Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. ( Barger, B; Handley, A; Kipnes, MS; Lloyd, E; Roberts, A, 2015) |
| "High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality." | 6.74 | Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. ( Chandurkar, NB; Karnik, ND; Pareek, A; Salagre, SB; Zawar, SD, 2009) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| " The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection." | 6.72 | Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review. ( Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 6.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| " Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable." | 6.67 | Low-dose clonidine administration in the treatment of mild or moderate essential hypertension: results from a double-blind placebo-controlled study (Clobass). The Clobass Study Group. ( , 1990) |
| " The double regimen caused a drop in pressure of 16/11 mm Hg after one month (daily doses 25 mg chlorthalidone, 103 +/- 25 mg propranolol), and this reduction did not change at the third month in spite of dosage increases (daily doses 25 mg chlorthalidone, 222 +/- 77 mg propranolol)." | 6.65 | A crossover trial of oxdralazine in hypertension. ( Criscuolo, D; Galli, F; Salvadeo, A; Segagni, S; Villa, G, 1983) |
| "1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients." | 6.65 | Atenolol and chlorthalidone in combination for hypertension. ( Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979) |
| "Prazosin was better tolerated, with side effects tending to diminish with time." | 6.64 | Prazosin and clonidine for moderately severe hypertension. ( Hammond, JJ; Kirkendall, WM; Overturf, ML; Thomas, JC; Zama, A, 1978) |
| "Treatment with propranolol resulted in marked suppression of the plasma renin activity (1." | 6.64 | Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. ( Benraad, TJ; Drayer, JI; Festen, J; Kloppenborg, PW; van't Laar, A, 1975) |
| "For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically significant for cardiovascular disease outcomes (RR = 0." | 6.55 | Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication. ( Arroll, B; Wallace, H, 2017) |
| "To compare the effects of chlortalidone plus amiloride and amlodipine on blood pressure (BP) variability in patients with hypertension and obstructive sleep apnea syndrome (OSA)." | 5.69 | Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial. ( Borges, RB; Cichelero, FT; Fuchs, FD; Fuchs, SC; Hirakata, VN; Jorge, JA; Lucca, MB; Martinez, D, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Recent US guidelines recommend chlorthalidone over other thiazide-type diuretics for the treatment of hypertension based on its long half-life and proven ability to reduce CVD events." | 5.51 | Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "The aim of this clinical trial was to assess the efficacy and safety of low-dose triple combinations of amlodipine, telmisartan, and chlorthalidone in patients with essential hypertension." | 5.51 | Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. ( Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 5.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 5.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "We randomly assigned patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12." | 5.41 | Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Dickinson, JH; Ouyang, F; Sinha, AD; Tu, W, 2021) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of JNC 7 Stage I hypertension in patients with type 2 diabetes mellitus." | 5.41 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, JE; Chaves, H; Consolim-Colombo, FM; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Nobre, F; Nóbrega, AC; Pereira E Silva, R; Poli-de-Figueiredo, CE; Scala, LCN; Schlatter, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2021) |
| "Chlorthalidone in Chronic Kidney Disease (CLICK) is a phase II, single-institution, multicenter, double-blind randomized control trial to test the hypothesis that CTD improves BP, through reduction of extracellular fluid volume, and results in target organ protection in patients with stage 4 CKD and poorly controlled hypertension." | 5.34 | Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Ouyang, F; Sinha, AD; Tu, W, 2020) |
| "This is a factorial (2 × 2) randomized double-blinded clinical trial comparing the association of a thiazide diuretic (chlorthalidone 25 mg/day or hydrochlorothiazide 50 mg/day) with a potassium-sparing diuretic (amiloride 10 mg/day or amiloride 20 mg/day) in patients with primary hypertension." | 5.30 | Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial. ( Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019) |
| "Participants with hypertension from an urban Internal Medicine practice were randomized to view 5 web pages in PALS orWebMD containing information about chlorthalidone." | 5.30 | Evaluation of the Patient Activated Learning System (PALS) to improve knowledge acquisition, retention, and medication decision making among hypertensive adults: Results of a pilot randomized controlled trial. ( Carmel, AS; Cornelius-Schecter, A; Frankel, B; Jannat-Khah, D; Pelzman, F; Safford, MM; Sinha, S, 2019) |
| "Captopril was applied the first two weeks in a dose of 25 mg 3 times daily." | 5.28 | [Captopril from Pharmachem in the treatment of arterial hypertension]. ( Belovezhdov, N; Monova, D, 1989) |
| "9 years-old, with stage I hypertension at baseline and after 18 months of treatment with chlorthalidone/amiloride or losartan." | 5.27 | Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study. ( Bertoluci, C; Branchi, TV; Foppa, M; Fuchs, FD; Fuchs, SC; Santos, ABS, 2018) |
| " We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy." | 5.27 | S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial. ( Cho, HJ; Choi, DJ; Han, KR; Jo, SH; Kim, EJ; Kim, SJ; Park, JJ; Park, SJ; Shin, J; Shin, JH; Song, JM, 2018) |
| "Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ)." | 5.27 | Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. ( Bakris, GL; Cushman, WC; Ferdinand, KC; Lloyd, E; Weber, MA; White, WB; Wu, J, 2018) |
| "Prazosin has been reported to reduce the hypotensive and/or bradycardic effect of clonidine in various animal models." | 5.27 | Prazosin partly blocks clonidine-induced hypotension in patients with essential hypertension. ( Farsang, C; Kapocsi, J; Vizi, ES, 1987) |
| " After 3 and 6 months of maintenance therapy, blood pressures were measured 24 hours after the previous day's dosing to evaluate the persistence of the antihypertensive effect." | 5.27 | The management of severe hypertension with minoxidil in a once-a-day treatment regimen. ( Bayley, A; Fraser, HS; Hassell, TA; Nicholson, GD, 1985) |
| "Chlorthalidone (50 mg daily) was given for 14 days." | 5.26 | Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction. ( Landmann-Suter, R; Struyvenberg, A, 1978) |
| "When chlorthalidone was prescribed in addition to diet, serum cholesterol rose by 12 mg/dl and triglyceride by 36 mg/dl (P less than 0-005 vs pretreatment value for both)." | 5.26 | Increase in serum-lipids during treatment of hypertension with chlorthalidone. ( Ames, RP; Hill, P, 1976) |
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 5.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| " We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance." | 5.24 | Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Marcus, GM; Simpson, LM; Soliman, EZ; Yamal, JM, 2017) |
| "In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension." | 5.24 | Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. ( Bangalore, S; Black, HR; Calhoun, DA; Cushman, WC; Davis, BR; Kostis, JB; Muntner, PM; Pressel, SL; Probstfield, JL; Rahman, M; Whelton, PK, 2017) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Enablement of more persistent spironolactone use with newer potassium-binding agents, the clinical development of novel nonsteroidal MRAs with a more favourable benefit-risk profile and the recently proven blood pressure lowering action of chlorthalidone are three therapeutic opportunities for more effective management of hypertension in high-risk patients with advanced CKD." | 5.22 | Management of hypertension in advanced kidney disease. ( Agarwal, R; Georgianos, PI, 2022) |
| "Recent evidence supports expanded indications for diuretics in patients with kidney disease, including chlorthalidone for hypertension in advanced CKD." | 5.22 | Revisiting diuretic choice in chronic kidney disease. ( Ali, S; Gregg, LP; Navaneethan, SD; Virani, SS, 2022) |
| " Doxazosin in the management of arterial hypertension was associated with a higher risk of cardiovascular disease, particularly heart failure, than chlorthalidone." | 5.22 | Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. ( Kienberger, G; Mann, E; Mansbart, F; Sönnichsen, A, 2022) |
| "This 12-week comparative, double-blind, outpatient study randomized 54 patients with stage 1 hypertension to receive either chlorthalidone, 6." | 5.22 | Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. ( Agarwal, MA; Chandurkar, NB; Dharmadhikari, SK; Godbole, AV; Kshirsagar, PP; Kumbla, MM; Mathur, SL; Messerli, FH; Pareek, AK; Sharma, KH, 2016) |
| "To compare the blood pressure (BP)-lowering efficacy of a chlorthalidone/amiloride combination pill with losartan, during initial management of stage I hypertension." | 5.22 | Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. ( Alves, JG; Berwanger, O; Bortolotto, LA; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; de Alencastro, PR; de Mello, RB; de Sousa, MR; E Silva, RP; Filho, DC; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gomes, MM; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Neto, AA; Neto, JA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| " Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment." | 5.22 | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial. ( Alves, JG; Berwanger, O; Bordignon, A; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Consolim-Colombo, FM; de Alencastro, PR; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, RS; Fuchs, FC; Fuchs, FD; Fuchs, SC; Gus, M; Jardim, PC; Moreira, LB; Mosele, F; Mota Gomes, M; Neto, AA; Nobre, F; Nóbrega, AC; Poli-de-Figueiredo, CE; Scala, LC; Schlatter, R; Silva, RP; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF; Whelton, PK, 2016) |
| "This is a randomized double-blind clinical trial, comparing the use of chlorthalidone with amiloride versus amlodipine as a first drug option in patients older than 40 years of age with stage I hypertension (140 to 159/90 to 99 mmHg) and moderate OSA (15 to 30 apneas/hour of sleep)." | 5.19 | The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial. ( Cichelero, FT; Fuchs, FD; Fuchs, SC; Gus, M; Martinez, D; Moreira, LB, 2014) |
| "We examined the effect of chlorthalidone-based stepped care on the competing risks of cardiovascular (CV) versus non-CV death in the Systolic Hypertension in the Elderly Program (SHEP)." | 5.19 | Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Kostis, WJ; Messerli, FH; Sedjro, JE; Swerdel, JN, 2014) |
| " We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29." | 5.19 | Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014) |
| "The paper represents the dynamics of hemostasis values in 42 patients with arterial hypertension of the second stage in complex treatment with combined drug tonorma (atenolon - 100 mg, nifedipine - 10 mg, chlorthalidone - 25 mg)." | 5.19 | [Dynamics of the hemostasis parameters in patients with arterial hypertension in treatment with combined antihypertensive agents]. ( Bula, MS; Virna, MM; Zaremba, IeKh; Zaremba, OV; Zaremba-Fedchyshyn, OV, 2014) |
| "Azilsartan medoxomil, an effective, long-acting angiotensin II receptor blocker, is a new treatment for hypertension that is also being developed in fixed-dose combinations with chlorthalidone, a potent, long-acting thiazide-like diuretic." | 5.16 | Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. ( Bakris, GL; Cushman, WC; Kupfer, S; Lloyd, E; Roberts, A; Sica, D; Weber, MA; White, WB, 2012) |
| "Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium." | 5.16 | Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012) |
| "This is a randomized, double-blind, titrate-to-target blood pressure trial comparing the single-pill combination of azilsartan medoxomil and chlorthalidone versus co-administration of azilsartan medoxomil and hydrochlorothiazide in participants with stage 2 primary hypertension." | 5.16 | Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. ( Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012) |
| "This is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage I hypertension." | 5.15 | A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial. ( Afiune Neto, A; Alves, JG; Berwanger, O; Bortolotto, L; Brandão, AA; Castro, I; Cesarino, EJ; Chaves, H; Coelho, EB; Consolim-Colombo, F; de Mello, RB; de Sousa, MR; Figueiredo Neto, JA; Franco, R; Fuchs, FD; Fuchs, SC; Ghizzoni, F; Gus, M; Irigoyen, MC; Jardim, PC; Mion, D; Moreira, LB; Moreno, H; Mosele, F; Mota, M; Nobre, F; Nóbrega, AC; Pereira e Silva, R; Poli-de-Figueiredo, CE; Ribeiro, AL; Scala, LC; Schlatter, R; Sobral Filho, DC; Steffens, AA; Vilela-Martin, JF, 2011) |
| "Chlorthalidone (CTD) reduces 24-hour blood pressure more effectively than hydrochlorothiazide (HCTZ), but whether this influences electrocardiographic left ventricular hypertrophy is uncertain." | 5.15 | Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. ( Collins, G; Ernst, ME; Grimm, RH; Neaton, JD; Prineas, RJ; Soliman, EZ; Thomas, W, 2011) |
| "In the Systolic Hypertension in the Elderly Program (SHEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a lower rate of cardiovascular events than placebo but effects on mortality were not significant." | 5.15 | Association between chlorthalidone treatment of systolic hypertension and long-term survival. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Pressel, SL, 2011) |
| "The objectives were to determine effects of spironolactone and chlorthalidone on SNA and the role of SNA on diuretic-induced insulin resistance in human hypertension." | 5.14 | Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Menon, DV; Vongpatanasin, W; Wang, Z, 2009) |
| "Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| " To determine whether thiazide-induced diabetes is mediated by changes in potassium, we analyzed data from 3790 nondiabetic participants in the Systolic Hypertension in Elderly Program, a randomized clinical trial of isolated systolic hypertension in individuals aged >or=60 years treated with chlorthalidone or placebo." | 5.13 | Changes in serum potassium mediate thiazide-induced diabetes. ( Appel, LJ; Klag, MJ; Miller, ER; Parekh, RS; Shafi, T, 2008) |
| "5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial." | 5.13 | Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Basile, JN; Bastien, A; Courtney, DL; Cushman, WC; Davis, BR; Einhorn, PT; Ford, CE; Hamilton, BP; Kirchner, K; Louis, GT; Preston, RA; Retta, TM; Vidt, DG; Weiss, RJ; Whelton, PK; Wright, JT, 2008) |
| "To survey the prevalence of hyperuricacidemia and serum uric acid (SUA) changes and electrolyte changes after 6 weeks antihypertensive treatment with thiazide diuretics, losartan or losartan+hydrochlorothiazide (Hyzaar) in patients with essential hypertension (EH)." | 5.13 | [Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension]. ( Chen, H; Gui, W; Lu, LH; Wu, XY; Yang, LQ; Yu, L, 2008) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 5.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| " Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4." | 5.11 | Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005) |
| "The study was conducted to evaluate the vascular effects of chlorthalidone, a distal tubule-acting natriuretic agent, in hypertensive patients with nondiabetic metabolic syndrome, an insulin-resistant condition characterized by endothelial dysfunction and high risk for diabetes mellitus development." | 5.11 | Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Penno, G, 2005) |
| "In high-risk patients with hypertension, the higher risk for heart failure while taking doxazosin compared with chlorthalidone is attenuated but not eliminated by adding other antihypertensive drugs." | 5.10 | Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t ( Cutler, JA; Davis, BR; Farber, MA; Felicetta, JV; Furberg, CD; Stokes, JD; Wright, JT, 2002) |
| "Our aim was to compare the effect of lacidipine and chlorthalidone on cardiovascular outcome as a primary parameter and blood pressure as a secondary in elderly patients with isolated systolic hypertension in a prospective study with an open design." | 5.10 | Treatment of isolated systolic hypertension: the SHELL study results. ( Coppini, A; Malacco, E; Mancia, G; Menotti, A; Rappelli, A; Zuccaro, MS, 2003) |
| "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD." | 5.10 | Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003) |
| "The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage 1 isolated systolic hypertension (ISH)." | 5.10 | Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. ( Black, H; Ghadanfar, M; Grimm, RH; Lewin, A; Rowen, R; Shi, H, 2002) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "In elderly hypertensive patients with coronary artery disease, chlorthalidone reduced myocardial ischemia similarly to diltiazem." | 5.09 | Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease. ( de Paula, RS; Gebara, O; Gruppi, C; Moffa, P; Nussbacher, A; Pereira-Barreto, AC; Pierri, H; Pinto, L; Serro-Azul, JB; Wajngarten, M, 2001) |
| "The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction or cerebrovascular episodes." | 5.08 | Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study. ( Zanchetti, A, 1995) |
| "A multicentric, prospective, 16-week open study evaluated the effectivity and tolerance of the fixed combination of the beta-blocking agent bopindolol with the diuretic chlorthalidone--Sandoretic in 81 patients with mild to moderate hypertension." | 5.08 | [Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)]. ( Balazovjech, I; Havlík, V; Havránek, P; Hulínský, V; Kroupa, E; Lánská, V; Nikodýmová, L; Pátek, F; Svihovcová, P; Svítil, F; Widimský, J, 1996) |
| "A double-blind clinical trial was conducted to compare the efficacy of and electrolyte changes caused by ramipril-chlorthalidone combination treatment (5 mg + 25 mg) and chlorthalidone monotherapy (25 mg daily) in patients with hypertension." | 5.08 | Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. ( Ljutic, D; Rumboldt, Z; Sardelic, S; Simunic, M, 1995) |
| " Therefore, the triad of metabolic neutrality with antihypertensive and antiproteinuric efficacy supports combined verapamil-trandolapril as a potentially valuable therapy for hypertension accompanying diabetes mellitus." | 5.08 | Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. ( Boehlen, L; Buechel, P; Lerch, M; Papiri, M; Risen, W; Schneider, M; Shaw, S; Weidmann, P, 1996) |
| "To assess the effect of the angiotensin-converting enzyme inhibitor ceronapril on cerebral blood flow (CBF) in patients with moderate hypertension." | 5.08 | Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients. ( Brass, EP; Brennan, JJ; Cutler, NR; Kurtz, NM; Luna, A; Mena, I; Sramek, JJ, 1996) |
| "In a double-blind, partial cross-over study of 141 patients with mild to moderate hypertension, chlorthalidone 50 mg was compared with chlorthalidone 50 mg/triamterene 50 mg combination treatment." | 5.08 | Double-blind parallel study of a combination of chlorthalidone 50 mg and triamterene 50 mg in patients with mild and moderate hypertension. ( Spiers, DR; Wade, RC, 1996) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 5.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "5 mg lisinopril/hydrochlorothiazide and placebo in patients with essential hypertension." | 5.08 | Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. ( de Leeuw, PW; Notter, T; Zilles, P, 1997) |
| "In older persons with isolated systolic hypertension, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in preventing heart failure." | 5.08 | Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. ( Applegate, WB; Berge, KG; Berkson, DM; Black, HR; Blaufox, MD; Cohen, JD; Curb, JD; Cutler, J; Davis, BR; Grimm, RH; Kostis, JB; Lacy, CR; McDonald, R; Perry, HM; Schron, E; Smith, WM; Wassertheil-Smoller, S, 1997) |
| "The Verapamil in Hypertension and Atherosclerosis Study (VHAS) is a prospective randomized study the objective of which was to compare the long-term effects of verapamil and chlorthalidone on the blood pressure, clinical safety, and the progression/regression of carotid wall lesions in members of a large population of hypertensive patients." | 5.08 | Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1997) |
| "Antihypertensive therapy with low-dose chlorthalidone (supplemented if necessary) for isolated systolic hypertension lowers blood pressure and its cardiovascular disease complications and has relatively mild effects on other cardiovascular disease risk factor levels." | 5.08 | Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Re ( Applegate, WB; Black, HR; Cohen, J; Curb, JD; Davis, BR; Frost, P; Gonzalez, N; Guthrie, GP; Oberman, A; Pressel, SL; Probstfield, JL; Rutan, G; Savage, PJ; Schron, EB; Smith, W; Stamler, J, 1998) |
| " The present paper reports the principal results of the ultrasound substudy of the randomized, prospective, controlled, Verapamil in Hypertension and Atherosclerosis Study (VHAS)." | 5.08 | The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. ( Dal Palù, C; Leonetti, G; Magnani, B; Pessina, A; Rosei, EA; Zanchetti, A, 1998) |
| "This study assessed the effectivity of the association between a diuretic, chlorthalidone, and retard nifedipine in the treatment of patients above 50 years of age with Arterial Hypertension refractory to retard nifedipine." | 5.07 | [Evaluation of a combination of a diuretic and nifedipine retard for the treatment of hypertensive patients refractory to nifedipine retard]. ( Florenciano Sánchez, R; Gómez Márquez, M; Martínez López, JJ; Molina Boix, M; Ortega González, G; Rúiz López, FJ, 1993) |
| "5 mg and atenolol 50 mg (C-A) in adult black patients with mild to moderate hypertension (a resting supine diastolic blood pressure (DBP) between 95 and 115 mmHg after a two week placebo washout period)." | 5.07 | Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. ( Maharaj, B; van der Byl, K, 1993) |
| " They were randomized to a usual diet (n = 296) or to a weight loss diet (n = 291) and within each diet group to placebo, chlorthalidone, 25 mg/d, or atenolol, 50 mg/d." | 5.07 | Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. ( Blaufox, MD; Cutler, JA; Davis, BR; Kirchner, K; Langford, HG; Oberman, A; Wassertheil-Smoller, S; Zimbaldi, N, 1993) |
| " To assess whether chlorthalidone affected levels of putatively atherogenic small, dense LDL (LDL 3), we conducted a 12 week double blind randomized, placebo controlled clinical trial in 34 nonsmoking men aged 35 to 57 years with mild hypertension (DBP 90 to 104 mm Hg)." | 5.07 | Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. ( Belcher, J; Bradley, K; Elmer, P; Flack, JM; Grimm, R; Miller, P, 1993) |
| " The Verapamil in Hypertension Atherosclerosis Study is an ongoing multicentre randomised double-blind parallel group trial comparing the antihypertensive efficacy of verapamil SR 240 mg/day with that of chlorthalidone 25 mg/day in 1464 patients with essential hypertension aged 40 to 65 years." | 5.07 | Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators. ( Dal Palù, C; Magnani, B; Zanchetti, A, 1992) |
| "Subjects were randomly assigned to usual, weight loss, or low sodium/high potassium diet and then randomly assigned to receive placebo, chlorthalidone, or atenolol." | 5.07 | Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. ( Blaufox, MD; Davis, B; Langford, H; Lee, HB; Oberman, A; Wassertheil-Smoller, S, 1992) |
| " The Trial of Antihypertensive Interventions and Management studied 878 mildly hypertensive individuals randomly assigned, in a 3 x 3 design, to no diet change, weight loss, or a low sodium-high potassium diet and to placebo, 25 mg chlorthalidone, or 50 mg atenolol." | 5.07 | Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. ( Blaufox, MD; Cutler, JA; Davis, BR; Hawkins, CM; Langford, HG; Oberman, A; Wassertheil-Smoller, S; Zimbaldi, N, 1992) |
| "In a double-blind, crossover study, five white men with mild-to-moderate hypertension received placebo and fixed doses of atenolol, metoprolol, chlorthalidone, verapamil, and the combination of atenolol and chlorthalidone in a quasi-random order." | 5.07 | Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. ( Durel, LA; Hayashi, PJ; Schneiderman, N; Weidler, DJ, 1992) |
| "In the majority of hypertensive patients, treatment with 50 mg/d of hydrochlorothiazide does not cause marked hypokalemia or ventricular arrhythmias." | 5.07 | Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. ( Black, DM; Cheitlin, MD; Fine, R; Hearst, N; Hulley, SB; Sebastian, A; Seeley, DG; Siegel, D, 1992) |
| "A controlled study was carried out in patients with mild to moderate hypertension to compare the efficacy and tolerability of chlorthalidone alone and chlorthalidone combined with the potassium-sparing diuretic triamterene." | 5.07 | Changes in blood pressure, serum potassium and electrolytes with a combination of triamterene and a low dose of chlorthalidone. ( Hort, JF; Wilkins, HM, 1991) |
| "Sixteen patients with severe hypertension were treated for 1 year with extended release nifedipine, during which time serial changes in left ventricular mass index and associated alterations in left ventricular systolic function, left ventricular filling, plasma renin activity, atrial natriuretic peptide and catecholamines were evaluated." | 5.07 | Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. ( Ardeljan, M; Eison, HB; Garbowit, DL; Goldman, ME; Krakoff, LR; Phillips, RA; Shimabukuro, S, 1991) |
| "Guanfacine, an alpha-2 adrenoceptor agonist, was compared with methyldopa as step-2 therapy for patients with mild-to-moderate essential hypertension in a 12-week, double-blind, randomized, parallel evaluation of efficacy and safety." | 5.07 | Antihypertensive efficacy of guanfacine and methyldopa in patients with mild to moderate essential hypertension. ( Blackshear, J; Lovallo, WR; Mathur, P; Parsons, OA; Wilson, MF, 1991) |
| "In persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%, with 5-year absolute benefit of 30 events per 1000 participants." | 5.07 | Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. ( , 1991) |
| "The effectiveness and safety of sustained action nifedipine (NF) were compared to those of chlorthalidone (CL) in two groups of 35 and 37 patients with mild to moderate hypertension followed up for 4 months." | 5.06 | [Comparison of chlorthalidone and sustained-action nifedipine in the treatment of mild to moderate arterial hypertension]. ( Calderón de la Barca Gázquez, JM; de Diego Cabrera, MS; González Santos, C; Iribarren Marín, MA; Martínez de la Iglesia, J; Pérula Torres, L, 1990) |
| "Sixty two black patients who had confirmed but untreated hypertension participated in a double blind clinical trial of the efficacy and tolerability of slow-release oxprenolol in a daily dose of 160 mg initially and 320 mg subsequently versus chlorthalidone 50 mg daily." | 5.06 | Efficacy and tolerability of long term oxprenolol and chlorthalidone singly and in combination in hypertensive blacks. ( Obel, AO, 1990) |
| "The aim of the study was to compare the effect of slow-release (SR) nicardipine, placebo and chlorthalidone on hypertension-related arrhythmias evaluating 24-h ambulatory ECG." | 5.06 | Hypertension and arrhythmias: effects of slow-release nicardipine vs chlorthalidone: a double-blind crossover study. ( Celentano, A; de Divitiis, O; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1990) |
| "The antihypertensive effect of slow-release (SR) nicardipine (40 mg twice a day) and chlorthalidone (25 mg once a day), was evaluated in 36 patients with mild to moderate hypertension by casual and 24-h BP monitoring." | 5.06 | Effects on casual and 24-h ambulatory blood pressure of slow-release nicardipine and chlorthalidone in arterial essential hypertension: double-blind, crossover study. ( Celentano, A; de Divitiis, O; Galderisi, M; Garofalo, M; Mureddu, GF; Tammaro, P, 1990) |
| " Twenty-one patients with mild to moderate hypertension were randomly assigned to nitrendipine (n = 10) and to verapamil treatment for 4 weeks." | 5.06 | Short- and long-term cerebrovascular effects of nitrendipine in hypertensive patients. ( Conen, D; Müller, J; Noll, G; Rüttimann, S; Schneider, K, 1988) |
| "One hundred twenty black patients with mild to moderate essential hypertension participated in a double-blind placebo-controlled crossover study of the efficacy and tolerability of slow release oxprenolol versus chlorthalidone singly and in combination." | 5.06 | Effects of chlorthalidone, oxprenolol, and their combination in hypertensive blacks: a randomized double-blind crossover study. ( Obel, AO, 1989) |
| "A close comparative study of the hypotensive effects of verapamil and chlorthalidone was carried out on 60 patients affected with mild essential hypertension showing systemic." | 5.06 | [Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension]. ( Hergueta García de Guadiana, G; Paumard Fraguas, A, 1989) |
| "In this multicenter, double-blind, parallel study, the antihypertensive effects of betaxolol (20 mg once daily) and/or chlorthalidone (25 mg once daily) were analyzed in 186 patients with essential hypertension." | 5.06 | Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination. ( Burris, JF; Davidov, ME; Ginsberg, D; Jain, AK; Jenkins, P; Mroczek, WJ; Rofman, B; Rosenbaum, R; Ryan, JR, 1989) |
| "The effect of adding placebo, a calcium antagonist, nicardipine and a thiazide diuretic, chlorthalidone, each for 2 weeks, to ongoing treatment with the ACE inhibitor, enalapril was evaluated in seven patients with essential hypertension." | 5.06 | Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone. ( Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987) |
| "5 mg chlorthalidone on uric acid and electrolyte metabolism was investigated in 22 hypertensive patients with gout in a randomized trial." | 5.06 | [Uricosuric action of a new beta receptor blocker-diuretic drug combination]. ( Brandstetter, G; Eslaminejad, S; Hoffmann, H; Maderbacher, H, 1986) |
| "Sixty patients were treated for 1 year for essential uncomplicated hypertension, 30 with beta-blockers alone (BB) and 30 with BB and chlorthalidone (CTD)." | 5.06 | Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. ( Baumeler, HR; Cesana, B; Cocco, G; Iselin, HU; Strozzi, C, 1987) |
| "Two hundred and one patients with essential hypertension, whose supine diastolic blood pressure (SDBP) was greater than or equal to 95 mmHg following 2 weeks of treatment with the optimal dose of a beta blocker-diuretic combination (Phase 1), were randomly assigned to the addition of either 25 or 50 mg captopril BID for 6 weeks (Phase 2)." | 5.06 | A multicenter trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker-diuretic treatment. ( Agabiti-Rosei, E; Alicandri, C; Buoninconti, R; Cagli, V; Carotti, A; Corea, L; Dal Palù, C; Innocenti, PF; Muiesan, G; Paciaroni, E, 1987) |
| "Previous studies have shown that single dose or short-term administration of celiprolol does not impair pulmonary function in patients with asthma." | 5.06 | Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. ( Clauzel, AM; Etienne, R; Jean, T; Michel, F; Visier, S, 1988) |
| "In a randomized, double-blind, parallel-group study of 31 patients with mild to moderate hypertension, we compared a placebo regimen with a regimen of atenolol and chlorthalidone (Tenoretic)." | 5.06 | Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. ( Curry, RC; Schwartz, KM; Urban, PL, 1988) |
| "We evaluated the safety and efficacy of transdermal clonidine (TC) in 23 patients with essential hypertension over a two-year period." | 5.06 | Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. ( Horning, JR; McNulty, R; Simmons, JL; Williams, L; Zawada, ET, 1988) |
| "To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of essential hypertension in elderly patients, we studied 54 patients, mean age 67." | 5.06 | [Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. ( Achilli, L; D'Amico, F; Latini, R; Lombi, V; Pierandrei, G, 1987) |
| " To investigate this, 75 out-patients with essential hypertension were treated with chlorthalidone 12." | 5.06 | Plasma renin activity does not predict the antihypertensive efficacy of chlorthalidone. ( Bartolomei, G; Cagianelli, MA; Cinotti, G; Innocenti, P; Loni, C; Papi, L; Pedrinelli, R; Saba, G; Saba, P; Salvetti, A, 1987) |
| "One hundred seventy-one patients, 60 years of age or older with isolated systolic hypertension, were randomly assigned to receive chlorthalidone 12." | 5.06 | Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. ( Aranda, J; Barra, P; Davidov, M; Ettinger, B; Gorwit, J; McBarron, F; Morledge, JH, 1986) |
| "Guanfacine, an alpha-adrenoceptor agonist, may exhibit distinct dose-related curves for efficacy and adverse effects in the step-2 therapy of essential hypertension." | 5.06 | A multicenter, randomized, double-blind dose-response evaluation of step-2 guanfacine versus placebo in mild to moderate hypertension. ( Alderman, MH; Canosa, FL; Finnerty, FA; Kessler, WB; Marlon, AM; Materson, BJ; McMillen, JI; Savran, SV, 1986) |
| "After a run-in period on placebo, 26 patients with essential hypertension were prescribed single-blind tibalosine, 150 mg daily." | 5.06 | Chronic treatment with tibalosine in essential hypertension. ( Amery, A; Fagard, R; Fiocchi, R; Lijnen, P; M'Buyamba-Kabangu, JR; Staessen, J, 1986) |
| " Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study." | 5.06 | Diuretics, potassium and arrhythmias in hypertensive coronary disease. ( Espiner, EA; Ikram, H; Nicholls, MG, 1986) |
| "Men and women with isolated systolic hypertension who were at least 60 years of age were treated for 1 year with chlorthalidone (25-50 mg daily) or matching placebo as the step I drug." | 5.06 | Use of diuretics in treatment of hypertension in the elderly. ( Feigal, DW; Furberg, CD; Greenlick, M; Kuller, L; Perry, HM; Schnaper, HW; Schoenberger, JA; Smith, WM, 1986) |
| "A systematic review of literature published from 1990 to 2018 was performed by using the following key words: Edarbyclor, azilsartan, chlorthalidone, pharmacokinetic, and hypertension." | 5.05 | Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review. ( Kim, GH; Kwon, A, 2020) |
| "eu in July 2020 to identify studies that investigate the effect of the combination of angiotensin receptor blocker with chlorthalidone or hydrochlorothiazide on the systolic and diastolic blood pressure in patients with hypertension." | 5.05 | Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2020) |
| "Twenty patients (mean age 49 +/- 4 (SEM) yr) with mild to moderate essential hypertension were studied during placebo conditions, following 6 weeks of chlorthalidone monotherapy and 6 to 28 weeks of combined beta-blocker-chlorthalidone treatment, or vice versa." | 5.05 | Responses of catecholamines and blood pressure to beta-blockade in diuretic-treated patients with essential hypertension. ( Meier, A; Weidmann, P; Ziegler, WH, 1982) |
| "Nineteen patients with uncomplicated essential hypertension and low activity of plasma renin in response to a change from recumbency to an upright posture along with furosemide administration were given spironolactone, 400 mg/d, or chlorthalidone, 100mg/d, in a double-blind, random-sequence, crossover trial." | 5.05 | Comparison of chlorthalidone and spironolactone in low--renin essential hypertension. ( Kreeft, JH; Larochelle, P; Ogilvie, RI, 1983) |
| "A single-blind trial was carried out in 36 people with mild to moderate hypertension to compare the efficacy and tolerance of long-term treatment with furosemide and chlorthalidone." | 5.05 | Long-acting and short-acting diuretics in the treatment of hypertension. ( Ansuini, R; Belogi, M; Campolucci, G; Pupita, F, 1983) |
| "A prospective study of propranolol versus chlorthalidone has been performed in eleven patients with renal hypertension and one with essential hypertension." | 5.05 | Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension. ( Bachmann, H, 1984) |
| "Thirty-two patients with moderate to severe essential hypertension whose supine diastolic blood pressure (SDBP) was greater than or equal to 95 mm Hg following 2 weeks' treatment with the optimal dosage of beta blocker-diuretic combination were randomly assigned to the addition of either captopril 25 mg or 50 mg b." | 5.05 | Efficacy of low-dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic. ( Agabiti-Rosei, E; Alicandri, C; Boni, E; Cinquegrana, A; Fariello, R; Montini, E; Muiesan, G; Muiesan, ML; Zaninelli, A, 1984) |
| "The acute and chronic effects of fixed dosages of clonidine and prazosin on supine and upright blood pressure, the renin-angiotensin-aldosterone system, and plasma catecholamines were compared in 24 patients with essential hypertension." | 5.05 | Comparative antihypertensive and endocrinologic effects of clonidine and prazosin in patients with essential hypertension. ( Drayer, JI; Hubbell, FA; Rose, DE; Weber, MA, 1984) |
| "A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension." | 5.05 | A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients. ( Born, A; Emanueli, A; Lavezzari, M, 1984) |
| "Thirty patients with essential hypertension participated in a double blind crossover trial in which they were randomly allocated to treatment with either once daily slow release metoprolol (200 mg) with placebo or once daily slow release metoprolol (200 mg) with chlorthalidone (25 mg)." | 5.05 | Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone. ( Altman, DG; Gould, BA; Hornung, RS; Kieso, HA; Mann, S; Raftery, EB, 1983) |
| "Exchangeable sodium, blood volume, plasma norepinephrine, epinephrine, renin levels, and pressor responses to infused norepinephrine or angiotensin II were assessed in 10 patients with essential hypertension on placebo, following six to eight weeks of monotherapy with nifedipine, 3 X 10-20 mg/day, and after six to eight weeks on nifedipine combined with the diuretic chlorthalidone, 25 to 50 mg/day." | 5.05 | Pressor factors and cardiovascular pressor responsiveness after short-term antihypertensive therapy with the calcium antagonist nifedipine alone or combined with a diuretic. ( Beretta-Piccoli, C; Bianchetti, MG; Bomio, F; Luisoli, S; Marone, C; Weidmann, P, 1984) |
| " They had simultaneously started therapy with, or increased the dosage of, chlorthalidone or hydrochlorothiazide for the treatment of hypertension." | 5.05 | Serum cholesterol during treatment of hypertension with diuretic drugs. ( Ames, RP; Peacock, PB, 1984) |
| "A randomised, placebo-controlled, double-blind crossover study was conducted in 14 patients with mild essential hypertension comparing different regimens of administration of the "short-acting" diuretic, chlorothiazide and the "long-acting" diuretic, chlorthalidone." | 5.05 | Long-acting and short-acting diuretics in mild essential hypertension. ( Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1982) |
| "Reserpine in different doses was assigned in random, double-blind fashion to 329 patients with mild to moderate hypertension who had not achieved normotension with chlorthalidone therapy alone." | 5.05 | Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone. ( , 1982) |
| "Patients over 60 years of age (M = 70 years) with the predominant systolic form of essential hypertension (systolic blood pressure greater than 160 mm Hg; diastolic blood pressure less than 100 mm Hg) were treated with a combination of low doses of the diuretic chlorthalidone and the centrally-acting sympatholytic agent clonidine." | 5.05 | Effects of low-dose antihypertensive therapy in elderly patients with predominant systolic hypertension. ( Drayer, JI; Gray, DR; Weber, MA, 1983) |
| "In an open two-period crossover study hydrochlorothiazide/amiloride and chlorthalidone were compared with regard to their anti-hypertensive and biochemical properties in ambulatory patients with mild to moderate hypertension." | 5.05 | The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone. ( van Soeren, F, 1980) |
| "A single evening dose of a clonidine-chlorthalidone combination (Combipres) was compared with the usual twice-daily schedule in 11 patients with essential hypertension." | 5.05 | Blood pressure response to a single daily dose of a clonidine-chlorthalidone combination. ( Grossman, SH; Gunnells, JC, 1980) |
| "Twenty-four black patients (Zulus) with hypertension participated in a double-blind, placebo-controlled cross-over trial of the efficacy of a beta-blocking agent (atenolol) 100 mg once daily as compared with chlorthalidone 25 mg once daily." | 5.05 | Trial of atenolol and chlorthalidone for hypertension in black South Africans. ( Seedat, YK, 1980) |
| "The Authors have examined, by statistical analysis of the variance for a three-period cross-over design, the effects of fenquizone, furosemide and chlorthalidone on 24 in-patients affected by hypertension, edematous cardiac, renal and liver diseases." | 5.05 | [Clinical trial of the activity and therapeutic effectiveness of 3 drugs with diuretic and antihypertensive action]. ( Corinaldesi, G; Tiberi, F, 1981) |
| "A double-blind, within-patient study was carried out in 23 newly diagnosed patients with mild to moderate hypertension (diastolic blood pressure of at least 100 mmHg) to compare the antihypertensive effects of atenolol (100 mg) and chlorthalidone (25 mg) given in free and fixed combination." | 5.05 | Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone. ( Nissinen, A; Tuomilehto, J, 1980) |
| "The effectiveness of a new potent diuretic, xipamide, was evaluated in the treatment of patients with mild to moderate essential hypertension." | 5.05 | Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial. ( Bonaduce, D; Canonico, V; Ferrara, N; Petretta, M; Rengo, F; Romango, E, 1981) |
| "Seventy-one patients with mild-to-moderate essential hypertension completed 14 weeks' treatment with a single daily dose of fixed combination of metoprolol tartrate 100 mg and chlorthalidone 25 mg (Logroton; Geigy)." | 5.05 | A fixed combination of metoprolol and chlorthalidone in hypertension. A clinical trial in general practice. ( Govind, U; Munro, BF; Robertson, LI, 1981) |
| "Pulmonary function was measured serially in two separate randomized trials of pindolol in the treatment of essential hypertension." | 5.05 | Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. ( Hamilton, BP; Hamilton, J; Kirkendall, WM, 1982) |
| "More than 1200 patients who received pindolol for the treatment of hypertension, angina pectoris, and various arrhythmias in studies conducted in the United States were included in the New Drug Application submitted to the FDA." | 5.05 | Adverse reactions to pindolol administration. ( Gonasun, LM; Langrall, H, 1982) |
| "The dose response curve for 25, 50, 75 and 100 mg doses of chlorthalidone was studied in double blind fashion over an 8 week period in patients who presented with untreated mild hypertension." | 5.05 | Chlorthalidone in mild hypertension - dose response relationship. ( Humphries, IS; Mayhew, SR; Russell, JG, 1981) |
| "In a multicenter, single-blind, interpatient study, 103 outpatients with mild to moderate hypertension were given, after 2 weeks of placebo wash-out, 160 mg oxprenolol slow-release in fixed combination with chlorthalidone (20 mg per tablet) (SROC 160) once daily or conventional oxprenolol (80 mg) in fixed combination with chlorthalidone (10 mg per tablet) (COC 80) twice daily for 8 weeks." | 5.05 | A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension. ( Agabiti-Rosei, E; Buoninconti, R; Carotti, A; Fariello, R; Innocenti, P; Motolese, M; Muiesan, G; Toso, M; Valori, C, 1981) |
| "A double-blind crossover study was designed to compare the antihypertensive and hypokalaemic effects of chlorthalidone administered at 10h00 and 22h00 to sixteen patients with primary hypertension." | 5.05 | Influence of the administration time on the antihypertensive and hypokalaemic effects of chlorthalidone in patients with primary hypertension. ( Carpentiere, G; Castello, F; Marino, S, 1985) |
| "In 20 patients with long-standing essential hypertension, a comparison was made in a randomized cross-over study of the effect of once and twice daily prazosin administration on blood pressure levels." | 5.05 | Prazosin once or twice daily? ( Hengeveld, WL; Schouten, JA; Westerman, RF, 1985) |
| " placebo was carried out in a series of twenty-three patients with mild or moderate essential hypertension who were receiving chlorthalidone (25 mg daily) as their basic treatment." | 5.04 | A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone. ( Jäättelä, A; Pyörälä, K, 1976) |
| "Five male subjects with essential hypertension received chlorthalidone at each of four dose levels (25, 50, 100, and 200 mg/day) for eight week periods each preceded by an eight week placebo period." | 5.04 | Cardiovascular response to exercise under increasing doses of chlorthalidone. ( Ogilvie, RI, 1976) |
| " The antihypertensive effect of a new beta-adrenoceptor blocking agent, trimepranol (10--14 mg/twice daily), chlorthalidone (50 mg every second day) and their combination was studied in eighteen patients with mild to moderate essential hypertension." | 5.04 | Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. ( Jounela, AJ; Neuvonen, PJ; Pentikäinen, PJ, 1978) |
| "The effect of diuretics on serum lipids and lipoproteins was evaluated in 23 patients with essential hypertension treated with chlorthalidone for six weeks." | 5.04 | [The effect of diuretic therapy on serum lipoproteins: an undesirable effect?]. ( Bachmann, C; Glück, Z; Keusch, G; Mordasini, R; Peheim, E; Riesen, W; Weidmann, P, 1979) |
| "The effectiveness of 5 sets of acupuncture loci in decreasing systemic blood pressure was compared with chlorthalidone and propranolol in patients with essential hypertension." | 5.04 | An unsuccessful attempt to treat hypertension with acupuncture. ( Mao, W; Mueller, RA; Sugioka, K; Woods, J, 1977) |
| "After a control period on a placebo, 45 patients with mild to moderate hypertension were treated with metoprolol, 100 mg twice daily alone and in free combination with chlorthalidone 50 mg daily using a double-blind crossover technique." | 5.04 | Metoprolol with and without chlorthalidone in hypertension. ( Ebbutt, A; John, V; Kendall, M; Kubik, M, 1979) |
| "The antihypertensive effect of atenolol, with and without chlorthalidone, on hypertension was assessed in an outpatient as well as in an inpatient study." | 5.04 | Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Teeuw, AH, 1979) |
| "The antihypertensive effects of atenolol and propranolol were compared in a double-blind crossover study of 19 patients with essential hypertension (World Health Organization, I and II) who were receiving long-term diuretic treatment (chlorthalidone, 50 mg daily) during the study." | 5.04 | Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Rooijen, GJ, 1979) |
| "A double blind cross-over trial of fixed doses of propranolol (640 mg/day) and the cardioselective drug practolol (1600 mg/day) was performed in 28 patients with essential hypertension whose blood pressure was not adequately controlled by chlorthalidone (100 mg 3 times weekly) alone." | 5.04 | Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone. ( Boer, P; Geyskes, GG; Mees, EJ; Stutterheim, A, 1975) |
| "In essential hypertension, 25 mg and 100 mg of chlorthalidone per day reduced blood pressure to a similar extent." | 5.04 | Optimal dose of a thiazide diuretic. ( Carney, S; Gillies, AI; Morgan, T, 1976) |
| " A double-blind cross-over evaluation of the anti-hypertensive effect of metoprolol vs placebo was carried out in a series of twenty-three patients with mild or moderate essential hypertension who were receiving 25 mg of chlorthalidone daily as their basic treatment." | 5.04 | A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone. ( Jäättelä, A; Pyörälä, K, 1976) |
| " Group A: In 14 patients with essential hypertension on chlorthalidone treatment, an additional daily dose of 640 mg propranolol for two months led to a significant reduction of the MAP (from 124 to 105 mm Hg) and PRA (from 5." | 5.04 | Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension. ( Boer, P; Geyskes, GG; Leenen, FH; Mees, EJ; Vos, J, 1975) |
| " From evidence regarding potency, cardiovascular events, and electrolytes, we hypothesized a priori that 'CHIP' diuretics [CHlorthalidone, Indapamide and Potassium-sparing Diuretic/hydrochlorothiazide (PSD/HCTZ)] would rival RASIs for reducing LVM." | 4.98 | Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. ( Abdelfattah, R; Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Song, S, 2018) |
| " The MEDLINE and EMBASE search included both medical subject headings (MeSHs) and keywords including azilsartan or azilsartan medoxomil or angiotensin receptor blockers or renin angiotensin system or chlorthalidone and hypertension." | 4.89 | Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? ( Barrios, V; Escobar, C, 2013) |
| "Chlorthalidone's safety and efficacy in the management of hypertension has been demonstrated in landmark trials." | 4.88 | Chlorthalidone: the forgotten diuretic. ( Ezer, M; Goldman, A; Kountz, DS; Mikhail, J, 2012) |
| "Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys." | 4.88 | Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. ( Guddati, AK; Holford, TR; Roush, GC, 2012) |
| "Thiazide and thiazide-like diuretics are widely used in the management of hypertension, but recently the equivalence of hydrochlorothiazide and chlorthalidone for blood pressure (BP) lowering and prevention of cardiovascular disease has been questioned." | 4.88 | Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. ( Chaturvedi, N; Hardy, R; Hughes, AD; Peterzan, MA, 2012) |
| "Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension." | 4.88 | Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. ( Bleske, BE; Dorsch, MP; Shuster, JE, 2012) |
| "Amlodipine lowered long-term gout risk compared with lisinopril or chlorthalidone." | 3.96 | The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Beach, JL; Davis, BR; Ishak, A; Juraschek, SP; Mukamal, KJ; Shmerling, RH; Simpson, LM, 2020) |
| "Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits." | 3.96 | Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. ( Chen, R; Hripcsak, G; Krumholz, HM; Madigan, D; Pratt, N; Ryan, PB; Schuemie, MJ; Shea, S; Suchard, MA; You, SC, 2020) |
| "Refractory hypertension is a recently described phenotype of antihypertensive treatment failure defined as uncontrolled blood pressure (BP) despite the use of ≥5 different antihypertensive agents, including chlorthalidone and spironolactone." | 3.85 | White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. ( Calhoun, DA; Judd, EK; Oparil, S; Siddiqui, M, 2017) |
| "To study effects of a fixed azilsartan medoxomil/chlorthalidone combination (Edarbi Clo) on clinical, ambulatory and central blood pressure (BP) in patients with uncontrolled arterial hypertension (AH))." | 3.85 | [Antihypertensive Efficacy of Fixed Combination Azilsartan Medoxomil / Chlorthalidone in Patients With Uncontrolled Arterial Hypertension]. ( Kobalava, ZD; Kulakov, VV; Villevalde, SV, 2017) |
| "Patients with hypertension were given diet and exercise recommendations and 25 mg of chlorthalidone per day were prescribed; Hemoglobin/hematocrit, viscosity, and basal nitric oxide (ON) were determined at 15 and 45 days and compared with healthy subjects." | 3.85 | Hemorrheologic effect of diuretics in the control of blood pressure in the hypertensive patient ( Chávez-Negrete, AJ; Gallardo-Montoya, JM; Intaglietta, M; Rojas-Uribe, M, 2017) |
| "To report a novel case of acute bilateral uveal effusions, angle closure, and acute myopia induced by administration of chlorthalidone." | 3.81 | Uveal effusion as a mechanism of bilateral angle-closure glaucoma induced by chlorthalidone. ( Pearce, ZD; Siebert, KJ; Singer, JR; Westhouse, SJ, 2015) |
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 3.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| "This study assessed the risk of new-onset gout following prescribing of hydrochlorothiazide (HCTZ) compared with chlorthalidone (CTD)." | 3.80 | Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. ( Nair, KV; Saseen, JJ; Wilson, L, 2014) |
| "Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide for the treatment of hypertension." | 3.79 | Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. ( Dhalla, IA; Gomes, T; Hellings, C; Juurlink, DN; Mamdani, MM; Nagge, J; Persaud, N; Yao, Z, 2013) |
| "To evaluate the efficacy, safety, and clinical utility of the combination product azilsartan medoxomil/chlorthalidone for the treatment of hypertension." | 3.79 | Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive. ( Anderson, KV; Pierini, D, 2013) |
| "In patients with hypertension already taking HCTZ, switching to chlorthalidone seems to further reduce systolic and diastolic blood pressures without any clinically significant changes in renal function or electrolyte levels." | 3.79 | Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. ( Brenner, AC; Brenner, MJ; Matthews, KA, 2013) |
| "There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
| "Celiprolol hydrochloride is a highly cardioselective beta1-adrenergic antagonist with a unique pharmacologic profile." | 3.76 | Safety profile of celiprolol. ( Lamon, KD, 1988) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "The contributions of arterial baroreceptor and Bezold-Jarisch reflexes, and atrial natriuretic factor (ANF) to the anti-hypertensive effect of the diuretic chlorthalidone were investigated in rats with deoxycorticosterone acetate (DOCA)-salt-induced hypertension." | 3.70 | The diuretic chlorthalidone normalizes baroreceptor and Bezold-Jarisch reflexes in DOCA-salt hypertensive rats. ( Bissoli, NS; Cabral, AM; Cicilini, MA; Vasquez, EC, 2000) |
| "To evaluate the hemodynamic effects of low doses of chlorthalidone (CHT) in patients with systemic arterial hypertension (SAH)." | 3.68 | [Hemodynamic effects of low doses of chlorthalidone in patients with mild systemic arterial hypertension]. ( da Luz, PL; Hueb, W; Mansur, Ade P; Pileggi, F; Ramires, JA; Rati, M; Solimene, MC, 1993) |
| "To evaluate the effects of the use of chlorthalidone on left ventricular mass of patients with mild and moderate systemic arterial hypertension (SAH)." | 3.68 | [Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension]. ( César, LA; da Luz, PL; Francischetti, E; Mansur, Ade P; Marcondes, M; Oigman, W; Pileggi, F; Ramires, JA, 1993) |
| "A 52-year-old woman developed severe hyponatremia following treatment for hypertension with chlorthalidone." | 3.68 | Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis. ( Goldhammer, Y; Sadeh, M, 1993) |
| "In the present work the clinical, biological, radiological, electrocardiographic and hormonal characteristics are analyzed in 51 patients suffering mild essential hypertension, in whom treatment with captopril in monotherapy or associated to chlortalidone managed to normalize arterial pressure and maintained the pressure control during a period of one year." | 3.68 | [Do clinical parameters exist that permit predicting the need to combine a diuretic with captopril in the initial treatment of essential arterial hypertension?]. ( Aguilera, MT; Closas, J; Coca, A; de la Sierra, A; Sánchez, M; Sobrino, J; Urbano-Márquez, A, 1990) |
| "The effect of the angiotensin converting enzyme (ACE) inhibitor fosinopril sodium on regional cerebral blood flow (rCBF) was investigated in 8 patients with moderate essential hypertension." | 3.68 | The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension. ( Andersen, AR; Ibsen, H; Paulson, OB; Rasmussen, S; Strandgaard, S; Waldemar, G, 1990) |
| "5 mg chlorthalidone (Tenoretic Mite, TM) was studied in 37 patients with arterial hypertension, aged 61-80 years (mean, 70." | 3.67 | Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients. ( Fogari, R; Zoppi, A, 1984) |
| "In ten patients with essential hypertension, 6 weeks of treatment with a clonidine/diuretic combination (1 retard capsule/day, 75 micrograms or 150 micrograms clonidine, and 15 mg chlortalidon) was suddenly discontinued." | 3.67 | [Clonidine-diuretic combination in patients with essential hypertension. Modification of sympathetic activity and blood pressure as well as the reaction following sudden withdrawal]. ( Beckenbauer, UE; Planz, G, 1984) |
| "The authors conducted a clinical investigation in twenty-five patients affected with essential hypertension of mild or moderate grade associated with type II diabetes mellitus, the purpose being to assess the effect of 8 weeks of combined treatment with atenolol (100 mg) and chlorthalidone (25 mg) on arterial blood pressure, heart rate, and glycaemia." | 3.67 | Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics. ( Coltorti, M; Gentile, S, 1984) |
| "Intrarenal sodium handling was studied in 8 patients with essential hypertension before spironolactone treatment (200 mg/day), on the 4th day of treatment, and after 3 months of treatment." | 3.67 | Intrarenal sodium handling during chronic spironolactone treatment. ( Boer, P; Dorhout Mees, EJ; Koomans, HA; Roos, JC, 1984) |
| "The effects of chlorthalidone and metoprolol on fasting plasma lipids and lipoprotein levels were compared in two similar nonrandomized groups of patients with mild hypertension." | 3.67 | Different effects of metoprolol and chlorthalidone on serum lipoprotein levels in mild hypertension. Possible implications for coronary heart disease risk status. ( Goldbourt, U; Holtzman, E; Rosenthal, T; Segal, P, 1984) |
| "Intra-arterial 24 hour blood pressure (BP) recording (OXFORD MEDILOG) was carried out in 10 patients with essential hypertension, 6 males and 4 females, aged between 41 and 58 years, 3 at WHO stage 1 and 7 at stage 2, in basal conditions and after 6 weeks of treatment with a fixed combination of 160 mg of slow-release oxprenolol and 20 mg of chlorthalidone per tablet (tb)." | 3.67 | [Continuous 24-hour registration of intra-arterial pressure in basal states and during therapy with a fixed slow-release oxprenolol-chlorthalidone combination, administered once a day]. ( Agabiti-Rosei, E; Alicandri, C; Boni, E; Fariello, R; Montini, E; Motolese, M; Muiesan, G; Zaninelli, A, 1984) |
| " The effects of chlorthalidone and metoprolol on fasting plasma lipids and lipoprotein levels were compared in two similar nonrandomized groups of patients with mild hypertension." | 3.67 | Do beta-blockers alter lipids and what are the consequences? ( Goldbourt, U; Holtzman, E; Rosenthal, T; Segal, P, 1987) |
| "In 13 patients, affected by hypertrophic obstructive cardiomyopathy (HOCM) and essential hypertension, antihypertensive-efficacy and effects of a new calcium-channel blocker (gallopamil) associated with a diuretic agent (chlorthalidone) on left ventricular systolic and diastolic performance assessed by phonocardiographic methods." | 3.67 | [Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle ( Brandini, V; Chieppa, S; De Simone, R; Giuliani, F; Iarussi, D; Langella, S; Lobascio, C, 1989) |
| "During chronic chlorthalidone treatment of patients with essential hypertension, distal tubular sodium reabsorption is continuously inhibited." | 3.67 | The effect of converting enzyme inhibition on the enhanced proximal sodium reabsorption induced by chronic diuretic treatment in patients with essential hypertension. ( Dorhout Mees, EJ; Geyskes, GG; van Schaik, BA, 1987) |
| "The aim of this study was a comparison between the hypotensive effects of two fixed combinations (atenolol + chlorthalidone and labetalol + chlorthalidone) in patients suffering from untreated mild to moderate hypertension." | 3.67 | Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone. ( Cumetti, C; De Cristofaro, A; Montanari, C; Roja, M; Vergani, A, 1985) |
| "To assess whether and how the activation of the renin-angiotensin system that occurs in response to changes in posture contributes to the maintenance of blood pressure, we measured blood pressure, heart rate, plasma noradrenaline and plasma active and inactive renin in patients with essential hypertension in the supine, sitting and standing positions, (each sustained for 30 min), before and after administration of captopril." | 3.67 | Participation of the renin-angiotensin system in the maintenance of blood pressure during changes in posture in patients with essential hypertension. ( Morganti, A; Palermo, A; Sala, C; Turolo, L; Zanchetti, A, 1985) |
| "We evaluated the effect of additional chlorthalidone therapy on blood pressure and body fluid volumes in 10 patients with essential hypertension who did not respond to chronic converting enzyme inhibition with enalapril." | 3.67 | Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril. ( Geyskes, GG; Mees, EJ; Roos, JC; van Schaik, BA, 1986) |
| "In 12 patients with essential hypertension who remained hypertensive despite chronic chlorthalidone treatment, the effect of 2 weeks of additional therapy with the converting enzyme inhibitor (CEI) enalapril on blood pressure and body fluid volumes has been evaluated." | 3.67 | Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Schaik, BA, 1986) |
| "The effect of a maximal dose of a commonly used diuretic, chlorthalidone, on renal function was assessed in 6 patients with untreated essential hypertension." | 3.67 | Diuretic-induced hypokalemia and altered renal function. ( Carney, SL; Morgan, TO, 1986) |
| "Interaction of thiazide diuretics and the serum uric acid and creatinine levels was studied in 3693 stepped care participants in the Hypertension Detection and Follow-up Program not receiving treatment at baseline." | 3.67 | Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. ( Blaufox, MD; Borhani, NO; Curb, JD; Langford, HG; Molteni, A; Pressel, S; Schneider, KA, 1987) |
| " Using a simple and convenient once-a-day regimen of minoxidil, nadolol, and chlorthalidone, we treated successfully 30 patients with moderate to severe hypertension." | 3.67 | Minoxidil in a once-a-day step-3 antihypertensive program. ( Alveranga, D; Bazilinski, N; Carroll, HJ; Lazar, I; Oh, MS; Uribarri, J, 1985) |
| "Exchangeable sodium, blood volume, plasma norepinephrine (NE), epinephrine, renin and aldosterone levels, and pressor responses to infused NE or angiotensin II (AII) were assessed in ten patients with essential hypertension on placebo, following 6 to 8 weeks of calcium-antagonist nifedipine (NIF), 3 X 10 to 20 mg/day, and after 6 to 8 weeks on NIF combined with the diuretic chlorthalidone (CHLOR), 25 to 50 mg/day." | 3.67 | Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine. ( Beretta-Piccoli, C; Bianchetti, MG; Bomio, F; Luisoli, S; Marone, C; Weidmann, P, 1985) |
| " In six patients with Bartter's syndrome, four with pseudo-Bartter's syndrome, and twenty with essential hypertension (EH) chronically treated with chlorthalidone, serum potassium (serum K+) and extracellular fluid volume (ECFV) were decreased, while plasma volume (PV) and blood volume (BV) were normal (see Table 1 for means, standard deviations, and levels of significance)." | 3.67 | Blood to interstitial fluid volume ratio in chronic hypokalaemic states. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; Hené, RJ; Koomans, HA; Roos, JC; Van Shaik, BA, 1985) |
| "The forearm resistance vessels of men with primary hypertension respond to verapamil with a greater than normal dilatation relative to that induced by sodium nitroprusside." | 3.66 | Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension. ( Dobbs, RJ; Phillips, RJ; Robinson, BF, 1983) |
| "The role of the renin-aldosterone axis in mediating responses to antihypertensive treatment was examined in patients with essential hypertension treated with propranolol (n=50) or chlorthalidone (n=50)." | 3.66 | The role of aldosterone in the response to treatment of primary hypertension. ( Drayer, JI; Laragh, JH; Purdy, RE; Weber, MA, 1982) |
| "A fixed combination of metoprolol slow-release 200 mg and chlorthalidone 25 mg was given once daily over a 3 months period in forty out-patients with mild-to-moderate arterial hypertension stage I or II WHO." | 3.66 | A fixed combination of metoprolol slow-release and chlorthalidone, given once daily, in the long-term treatment of arterial hypertension. ( Bichisao, E; Floris, B; Franchetta, G; Palestini, N; Sonaglioni, G; Verdecchia, P, 1982) |
| "The effect of 50 mg chlorthalidone on blood pressure, body fluid volumes and renal functional parameters was determined in 8 patients with essential hypertension." | 3.66 | Changes in intrarenal sodium handling during saluretic treatment in patients with essential hypertension. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; Koomans, HA; Roos, JC, 1981) |
| "Two studies of systolic time intervals (STIs) in patients with mild to moderate hypertension (HBP) revealed that no mean change in systolic intervals occurred with pindolol therapy, although some patients had significant alterations in their STIs." | 3.66 | Pindolol and systolic time intervals in patients with hypertension. ( Carliner, NH; Fisher, ML; Hamilton, BP; Hamilton, JH; Hammond, JJ; Jacks-Nagle, VL; Janoski, AH; Kirkendall, WM; Plotnick, GD; Robinson, M, 1982) |
| "Minoxidil is a potent antihypertensive drug widely used in severe arterial hypertension and in that refractory to treatment." | 3.66 | Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone. ( Cotorruelo, JG; Flórez, J; Llamazares, C, 1982) |
| "Intrarenal handling of uric acid was studied in 12 patients with essential hypertension under spironolactone treatment (200 mg/day)." | 3.66 | Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension. ( Boer, P; Dorhout Mees, EJ; Peuker, KH; Roos, JC, 1982) |
| "The short- and long-term effects of diuretic treatment with chlorthalidone 50 mg/day on haemodynamic and hormonal parameters in patients with essential hypertension (WHO grade I) were investigated." | 3.66 | Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; Koomans, HA; Roos, JC, 1981) |
| "Eleven patients suffering from WHO stage II essential arterial hypertension were treated with the combination of labetalol plus chlorthalidone in the reciprocal ratio of 10:1 in the form of once-a-day administration in the morning." | 3.66 | Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy. ( Rossi, AG, 1981) |
| "Two fixed-combination drugs commonly used in the step 2 treatment of hypertension, chlorthalidone plus reserpine and hydrochlorothiazide plus methyldopa, were compared in an evaluation of efficacy and adverse reactions." | 3.66 | A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension. ( Adlin, EV; Channick, BJ; Kessler, WB; Marks, AD, 1981) |
| "A retrospective survey using chart review was conducted to determine the incidence of clinically significant hypokalemia resulting from therapy with chlorthalidone (CTLD) or hydrochlorothiazide (HCTZ)." | 3.66 | Potassium loss associated with hydrochlorothiazide versus chlorthalidone. ( Frisof, KB; Podany, EC; Sumiye, L; Vivian, AS, 1981) |
| "The long-term antihypertensive efficacy and tolerability of a fixed combination of oxprenolol 160 mg slow-release + chlortalidone 20 mg was studied in 40 out-patients with mild to moderate essential hypertension followed during one year with monthly clinical visits." | 3.66 | One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension. ( Ambroso, G; Lazzaretto, R; Masoni, A; Pirani, R; Tomasi, AM, 1981) |
| "In 26 patients with essential hypertension who were on continuous chlorthalidone therapy, 1 and 3 daily doses of propranolol were compared in a crossover study." | 3.66 | One and three doses of propranolol a day in hypertension. ( Boer, P; Dorhout Mees, EJ; Geyskes, GG; van Asten, P; van den Brink, G, 1980) |
| "In a multicentre double-blind study, 92 out-patients with mild to moderate hypertension who had a resting blood pressure greater than or equal to 160/100 mmHg after a two-weeks' placebo wash-out were treated for 6 weeks with a fixed combination of oxprenolol 80 mg + chlorthalidone 10 mg per tablet or chlorthalidone alone (1 tablet = 10 mg)." | 3.66 | Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension. ( Agabiti-Rosei, E; Carotti, A; Innocenti, P; Montervino, C; Motolese, M; Muiesan, G; Solinas, E; Toso, M, 1980) |
| " The pressor role of renin stimulated by chronic diuretic therapy has been assessed in 31 patients with essential hypertension by infusing the angiotensin II antagonist, saralasin, immediately before and at the end of 2 weeks' treatment with the diuretic, chlorthalidone." | 3.66 | Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients. ( Bianchini, C; Leonetti, G; Sala, C; Sernesi, L; Terzoli, L; Zanchetti, A, 1978) |
| "A regimen consisting of chlorthalidone, hydralazine and propranolol would be useful in some hypertensive patients with coronary artery disease or aortic dissection if it could be shown that reflex cardiac stimulation induced by hydralazine is completely neutralized by propranolol." | 3.66 | Echocardiographic assessment of the effect of an antihypertensive regimen on left ventricular performance. ( Belasco, RN; Moyer, JP; Pittman, AW; Woods, JW, 1979) |
| "Twenty-four patients with hypertension were treated with chlorothiazide, chlorthalidone, and frusemide." | 3.66 | Duration of effect of different diuretics. ( Adam, WR; Hodgson, N; Morgan, TO; Myers, J, 1979) |
| "Twenty-five women were treated with propranolol during 26 pregnancies complicated by hypertension." | 3.66 | Propranolol for the treatment of hypertension in pregnancy. ( Eliahou, HE; Mashiach, S; Reisin, E; Romem, I; Serr, DM; Silverberg, DS, 1978) |
| "A 60-year-old woman who had been instructed to increase her water intake because of nephrolithiasis developed the syndrome of inappropriate secretion of antidiuretic hormone when treated with chlorthalidone for mild hypertension." | 3.66 | Chlorthalidone-induced syndrome of inappropriate secretion of antidiuretic hormone. ( Barzilai, D; Luboshitzky, R; Tal-Or, Z, 1978) |
| "The analysis of variance and Student's "t" test were applied in an assessment of the hypotensive effectiveness of three hypotensive protocols: a) diazepam + amitryptiline; b) reserpine + chlorthalidone; c) all drugs in 57 and 32 patients with stabilised essential hypertension." | 3.66 | [Clinical and statistical evaluation of the hypotensive effectiveness of 3 therapeutic plans in essential hypertension]. ( D'Amelio, G; Menozzi, L; Piccoli, A, 1978) |
| "Minoxidil-induced sequential changes in plasma renin activity, urinary aldosterone and norepinephrine excretion were assessed in 11 patients with severe hypertension receiving propranolol or oxprenolol, chlorthalidone and spironolactone." | 3.66 | [Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. ( Brunner, HR; Ferguson, RK; Gavras, H; Jaeger, P; Jéquier, E; Turini, GA, 1978) |
| "In 79 patients with essential hypertension, treatment with propranolol hydrochloride and chlorthalidone together produced significantly greater falls in both systolic and diastolic blood pressures than were obtained with either drug alone." | 3.65 | Renin reactivity as a determinant of responsiveness to antihypertensive treatment. ( Case, DB; Drayer, JI; Laragh, JH; Lopez-Ovejero, JA; Weber, MA, 1977) |
| "In 50 patients with essential hypertension treated with chlorthalidone, 100 mg daily for 6 weeks, treatment responders (fall in mean pressure, greater than or equal to 10%) and nonresponders experienced similar weight and electrolyte changes." | 3.65 | Disparate patterns of aldosterone response during diuretic treatment of hypertension. ( Drayer, JI; Laragh, JH; Rev, A; Weber, MA, 1977) |
| "The antihypertensive effect and the tolerance of the association of spironolactone and chlorthalidone were evaluated clinically and by numerous laboratory examinations in a group of 18 patients affected with non-complicated essential hypertension." | 3.65 | [Spironolactone combined with chlorthalidone in the treatment of essential arterial hypertension]. ( Favilli, R; Gragnoli, G; Nami, R; Puccetti, F; Tanganelli, I, 1975) |
| " Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension." | 3.30 | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. ( Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 3.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| "Hypertension is a leading risk factor for cardiovascular disease mortality." | 3.11 | Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study. ( Armstrong, ND; Arnett, DK; Chekka, LMS; Claas, SA; Cooper-DeHoff, RM; Gong, Y; Hidalgo, BA; Irvin, MR; Johnson, JA; Jones, AC; Limdi, NA; McDonough, CW; Nahid, NA; Nguyen, NHK; Srinivasasainagendra, V; Tanner, RM; Tiwari, HK, 2022) |
| "For patients with treatment-resistant hypertension, guidelines recommend the addition of spironolactone to the baseline antihypertensive regimen." | 3.01 | Hypertension in chronic kidney disease-treatment standard 2023. ( Agarwal, R; Georgianos, PI, 2023) |
| "Arterial hypertension is associated with increased morbidity and mortality and research in the field is highly dynamic." | 3.01 | Arterial Hypertension-clinical trials update 2023. ( Böhm, M; Götzinger, F; Kunz, M; Lauder, L; Mahfoud, F, 2023) |
| "Orthostatic hypertension is associated with future mortality risk, is easily detected, and can be used in refining cardiovascular risk assessment." | 2.90 | Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. ( Cabrera, J; Cosgrove, NM; Cushman, WC; Davis, BR; Kostis, JB; Kostis, WJ; Mekkaoui, C; Moreyra, AE; Pantazopoulos, JS; Pressel, SL; Sargsyan, D; Sedjro, JE, 2019) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| " AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ." | 2.87 | Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. ( Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018) |
| "Poorly controlled hypertension is a leading global public health problem requiring new treatment strategies." | 2.87 | Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. ( Amarasekara, S; Amarasena, N; Billot, L; de Silva, AP; de Silva, HA; Fernando, M; Guggilla, R; Jan, S; Jayawardena, J; Maulik, PK; Mendis, S; Munasinghe, J; Naik, N; Patel, A; Prabhakaran, D; Rajapakse, S; Ranasinghe, G; Rodgers, A; Salam, A; Selak, V; Senaratne, V; Stepien, S; Thom, S; Tisserra, N; Webster, R; Wijekoon, S; Wijeyasingam, S, 2018) |
| "Population pharmacokinetic and exposure-response models for azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) were developed using data from an 8-week placebo-controlled phase 3, factorial study of 20, 40, and 80 mg AZL-M every day (QD) and 12." | 2.82 | Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. ( Kupfer, S; Tsai, MC; Vakilynejad, M; Wu, J, 2016) |
| " Adverse events (AEs) were reported in 75." | 2.82 | Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. ( Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016) |
| " The most common adverse events, irrespective of treatment, were dizziness (8." | 2.80 | Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. ( Barger, B; Handley, A; Kipnes, MS; Lloyd, E; Roberts, A, 2015) |
| "Hypertension is a major risk factor for peripheral artery disease (PAD)." | 2.79 | Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. ( Baraniuk, S; Basile, JN; Dart, RA; Davis, BR; Ellsworth, AJ; Fendley, H; Habib, GB; Piller, LB; Probstfield, JL; Rahman, M; Simpson, LM; Whelton, PK, 2014) |
| "Hyperkalemia was associated with increased risk of combined cardiovascular disease (hazard ratio, 1." | 2.77 | Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. ( Alderman, MH; Calhoun, DA; Cushman, WC; Davis, BR; Eckfeldt, JH; Einhorn, PT; Ford, CE; Franklin, SS; Furberg, CD; Ong, ST; Oparil, S; Papademetriou, V; Piller, LB; Probstfield, JL, 2012) |
| "chlorthalidone treatment with fasting glucose (P < 0." | 2.75 | Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. ( Arnett, DK; Barzilay, JI; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Kabagambe, EK; Lynch, AI; Tiwari, HK, 2010) |
| "High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality." | 2.74 | Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension. ( Chandurkar, NB; Karnik, ND; Pareek, A; Salagre, SB; Zawar, SD, 2009) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Incident stroke was significantly decreased by treatment in the Systolic Hypertension in Elderly Program (SHEP) Trial, but the reduction in fatal events was not statistically significant." | 2.73 | Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. ( Davis, BR; Kostis, JB; Patel, AB; Pressel, SL; Shea, ML; Wilson, AC, 2008) |
| "Hypertension is a chronic condition leading to increased stress on the heart and blood vessels, a critical risk factor for clinically significant events such as myocardial infarction heart failure, stroke and death." | 2.72 | Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2021) |
| " The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection." | 2.72 | Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review. ( Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021) |
| "Unless convincing studies on treatment of hypertension after renal transplantation are available, the ESC/ESH Guidelines 2018 should apply for these patients." | 2.72 | Update on Treatment of Hypertension After Renal Transplantation. ( Chatzikyrkou, C; Schiffer, M; Schmieder, RE, 2021) |
| "Chlorthalidone has significantly reduced stroke and cardiovascular end points in several landmark trials; however, hydrochlorothiazide remains favored in practice." | 2.72 | Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. ( Bergus, GR; Carter, BL; Ernst, ME; Goerdt, CJ; Phillips, BB; Steffensmeier, JJ; Zimmerman, MB, 2006) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s." | 2.72 | Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Black, HR; Davis, BR; Ford, CE; Nwachuku, C; Oparil, S; Piller, LB; Probstfield, JL; Retta, TM, 2006) |
| "Chlorthalidone was at least equivalent to amlodipine and lisinopril in all of the outcomes measured, and was better in some, notably heart failure." | 2.71 | The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure. ( Vidt, DG, 2003) |
| " Drug dosage was determined in an initial stepped-care titration phase lasting six weeks." | 2.69 | Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension. ( De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999) |
| "If atenolol was contraindicated, 0." | 2.67 | Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. ( Applegate, WB; Camel, GH; Greenlick, MR; Hadley, E; Luhr, J; Moye, L; Perry, HM; Pressel, S; Shekelle, RB; Wittes, J, 1994) |
| " After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached." | 2.67 | Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. ( Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994) |
| "The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials." | 2.67 | Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. ( , 1993) |
| "This report examines the effect of weight loss, alone and in combination with drugs, on diastolic blood pressure change in the Trial of Antihypertensive Interventions and Management (TAIM), which is a randomized, multicenter, placebo-controlled clinical trial of drug and diet combinations in the treatment of mild hypertension among 787 patients." | 2.67 | The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. ( Blaufox, MD; Davis, BR; Langford, HG; Oberman, AS; Wassertheil-Smoller, S; Wylie-Rosett, J, 1992) |
| "To evaluate treatment of mild hypertension using combinations of diet and low-dose pharmacologic therapies." | 2.67 | Effect of antihypertensives on sexual function and quality of life: the TAIM Study. ( Blaufox, MD; Davis, BR; Hawkins, CM; Knerr, MO; Langford, HG; Oberman, A; Swencionis, C; Wassertheil-Smoller, S, 1991) |
| " Clonidine-related side effects are still evident, but the overall tolerance profile for this reduced dosage of the drug appears to be favorable." | 2.67 | Low-dose clonidine administration in the treatment of mild or moderate essential hypertension: results from a double-blind placebo-controlled study (Clobass). The Clobass Study Group. ( , 1990) |
| "Resistant hypertension is diagnosed if the blood pressure (BP) is not controlled despite optimum doses of 3 first-line classes of antihypertensive drugs including a thiazide diuretic or if adequate BP control needs 4 or more antihypertensive drugs from different classes." | 2.66 | Approaches for the Management of Resistant Hypertension in 2020. ( Aronow, WS, 2020) |
| "Celiprolol was compared with chlorthalidone, an antihypertensive drug without known effect on bronchial tone." | 2.66 | A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. ( Capone, P; Clauzel, AM; Dorow, P; Mathieu, M; Mayol, R, 1986) |
| "Enalapril treatment (5 mg/day for 5 days and 10 mg thereafter) was added to the diuretic therapy and after 2 months a further decrease in blood pressure was observed (to 158 +/- 5." | 2.66 | Effects of the angiotensin converting enzyme inhibitor enalapril compared with diuretic therapy in elderly hypertensive patients. ( Arpino, G; Cacciapuoti, F; D'Avino, M; D'Errico, S; Sepe, J; Spiezia, R; Varricchio, M; Verza, M, 1988) |
| "Treatment with labetalol, on the other hand, led to an improvement in respiratory function." | 2.66 | Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease. ( Dal Negro, RW; Pomari, C; Trevisan, F; Turco, P; Zoccatelli, O, 1986) |
| "Atenolol was significantly more effective than relaxation in reducing both systolic and diastolic pressure." | 2.66 | Relaxation therapy for hypertension. Comparison of effects with concomitant placebo, diuretic, and beta-blocker. ( Coburn, PC; Jacob, RG; Johnsen, AM; McDonald, RH; Reeves, RA; Shapiro, AP, 1986) |
| "Celiprolol was compared with chlorthalidone in a double-blind randomized placebo-controlled study of 30 hypertensive or anginal patients with reversible bronchial obstruction." | 2.66 | Celiprolol--review of airways studies. ( Dorow, P, 1988) |
| "5 mg/day of metolazone or 25 mg/day of chlorthalidone are effective antihypertensive agents but that blood pressure lowering may be inconsistent at these dosage levels." | 2.66 | Low-dose diuretic therapy for hypertension. ( Moser, M, 1986) |
| "The purpose of this study was to determine the effects on blood pressure and selected biochemical measures of reducing the dosage of chlorthalidone from 100 mg to 50 mg." | 2.66 | Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: a randomized study within a clinical trial. ( Allen, R; Bailey-Hoffman, G; Case, J; Childs, J; Grimm, RH; Hulley, SB; Kousch, D; McDonald, M; McGill, E; Neaton, JD, 1985) |
| " Dosage was a single tablet per day given in the morning." | 2.66 | Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial. ( Backhouse, CI; Edwards, KG; Hosie, J; Tweed, JA, 1985) |
| " The double regimen caused a drop in pressure of 16/11 mm Hg after one month (daily doses 25 mg chlorthalidone, 103 +/- 25 mg propranolol), and this reduction did not change at the third month in spite of dosage increases (daily doses 25 mg chlorthalidone, 222 +/- 77 mg propranolol)." | 2.65 | A crossover trial of oxdralazine in hypertension. ( Criscuolo, D; Galli, F; Salvadeo, A; Segagni, S; Villa, G, 1983) |
| " Pindolol and propranolol lowered PRA comparably at equivalent dosages, although this effect was not consistently observed in all studies or at all dosage levels." | 2.65 | Pindolol: effects on blood pressure and plasma renin activity. ( Bennett, CM; Glassock, RJ; Gonasun, L; Hamilton, B; Kirkendall, W; Maxwell, M; Weitzman, RE; Winer, N, 1982) |
| "1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients." | 2.65 | Atenolol and chlorthalidone in combination for hypertension. ( Bateman, DN; Bulpitt, CJ; Dean, CR; Dollery, CT; Mucklow, JC, 1979) |
| " However, patient compliance might be considerably improved with the once-daily dosage schedule of the fixed combination." | 2.65 | Antihypertensive effect of oxprenolol and chlorthalidone in fixed combination, given once daily. ( Buoninconti, R; Motolese, M; Rubegni, M, 1979) |
| "Prazosin was better tolerated, with side effects tending to diminish with time." | 2.64 | Prazosin and clonidine for moderately severe hypertension. ( Hammond, JJ; Kirkendall, WM; Overturf, ML; Thomas, JC; Zama, A, 1978) |
| " A reduction in dosage from 50 mg daily to 50 mg three times a week produced no significant changes in the diastolic or mean blood pressures though the systolic blood pressure was moderately increased." | 2.64 | Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. ( Bengtsson, C; Johnsson, G; Sannerstedt, R; Werkö, L, 1975) |
| "Treatment with propranolol resulted in marked suppression of the plasma renin activity (1." | 2.64 | Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. ( Benraad, TJ; Drayer, JI; Festen, J; Kloppenborg, PW; van't Laar, A, 1975) |
| " Triamterene seemed ineffective in the dosage used (50 mg twice daily)." | 2.64 | Potassium-sparing agents during diuretic therapy in hypertension. ( Brien, TG; Canning, BS; Donohoe, JF; Healy, JJ; McKenna, TJ; Muldowney, FP, 1971) |
| "The goals of treatment in hypertension are to optimally control high blood pressure and to reduce associated cardiovascular morbidity and mortality using the most suitable therapy available." | 2.61 | Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. ( Dineva, S; Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2019) |
| "Arterial hypertension is a disease that still affects a major part of the population worldwide, and leads to fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions." | 2.58 | Azilsartan and Chlorthalidone-new Powerful Fixed dose Antihypertensive Combination. ( Athanasiadi, E; Katsi, V; Tousoulis, D; Tsioufis, C, 2018) |
| "For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically significant for cardiovascular disease outcomes (RR = 0." | 2.55 | Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication. ( Arroll, B; Wallace, H, 2017) |
| "Hydrochlorothiazide has less effect on blood pressure, a high risk of metabolic side effects, and may not have pleiotropic effects." | 2.55 | [All diuretics used in the treatment of hypertension are not the same]. ( Asil, S; Atalar, E, 2017) |
| "Hypertension is a powerful risk factor strongly linked to adverse cardiovascular outcomes." | 2.52 | Misconceptions and facts about treating hypertension. ( Argulian, E; Grossman, E; Messerli, FH, 2015) |
| "Hydrochlorothiazide (HCTZ) has often been contrasted with chlorthalidone, but relatively little is known about HCTZ versus indapamide (INDAP)." | 2.52 | Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. ( Ernst, ME; Kostis, JB; Roush, GC; Sica, DA; Tandon, S, 2015) |
| "Hypertension is a modifiable cardiovascular risk factor." | 2.50 | Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. ( Bassett, K; Musini, VM; Nazer, M; Wright, JM, 2014) |
| "Hypertension is a major risk factor for cardiovascular disease, but control of hypertension remains inadequate, often because of poor patient adherence to prescribed medical regimens that are viewed as poorly tolerated and expensive." | 2.47 | Older blood pressure medications-do they still have a place? ( Black, HR; Slim, HB; Thompson, PD, 2011) |
| " We sought to describe their comparative dose-response relationships for changes in systolic blood pressure (SBP) and potassium." | 2.46 | Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. ( Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010) |
| "One of the current challenges in the treatment of hypertension is the variation in the incidence and morbidity among ethnic populations." | 2.42 | Recommendations for the management of special populations: racial and ethnic populations. ( Ferdinand, KC, 2003) |
| "The optimal first-line treatment of hypertension has been a contentious issue." | 2.42 | Diuretics: drugs of choice for the initial management of patients with hypertension. ( Fuchs, FD, 2003) |
| "Blood pressure and proteinuria are important determinants of progressive renal failure in patients with renal diseases." | 2.41 | [Intensive treatment of blood pressure in patients with kidney disease and proteinuria]. ( Huysmans, FT; Wetzels, JF, 2000) |
| " In addition, combination therapy enhances tolerability because one drug of fixed combination can antagonize some of the adverse effects of the second drug." | 2.40 | [Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy]. ( Gómez Guindal, JA; González Lama, I; González Maqueda, I, 1999) |
| "Thiazide diuretics are commonly used to treat hypertension because of their demonstrated efficacy, favorable safety profile, low acquisition cost, and their proven ability to reduce blood pressure-related morbidity and mortality." | 2.39 | Evidence for the efficacy of low-dose diuretic monotherapy. ( Cushman, WC; Flack, JM, 1996) |
| "Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs." | 1.91 | Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. ( Cazabon, D; Hering, D; Krishna, A; Moran, AE; Pathni, AK; Sahoo, SK; Sharma, B, 2023) |
| " The combination of AZ and CLT had greater BP lowering effect compared to AZ or CLT alone, despite of no pharmacokinetic interaction between two drugs." | 1.46 | Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. ( Bhateria, M; Bhatta, RS; Hanif, K; Jain, M; Kumar Puttrevu, S; Ramakrishna, R, 2017) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| "Chlorthalidone, 12." | 1.39 | Obesity and hypertension: It's about more than the numbers. ( Ferdinand, KC, 2013) |
| "Chlorthalidone has been used sparingly in clinical practice in large measure because it is not readily available in many fixed-dose combination products." | 1.35 | Chlorthalidone - a renaissance in use? ( Sica, DA, 2009) |
| "Resistant hypertension is an important clinical problem that is poorly studied and not well managed." | 1.34 | Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic. ( Beck, GR; Bisognano, JD; Filippone, JD; Fong, MW; Katz, MG, 2007) |
| "Type 2 diabetes is increasing in prevalence and is predominantly managed in general practice." | 1.30 | A cautionary tale. ( Phillips, PJ; Popplewell, PY; Tallis, GA, 1997) |
| "Chlorthalidone was given to one group during all 20 days of DOCA administration (preventive regimen) and to another group 20 days after DOCA treatment was initiated until the 40th day (therapeutic regimen)." | 1.29 | Effects of chlorthalidone on ventricular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. ( Cabral, AM; Carvalhinho, FB; Cicilini, MA; Vasquez, EC, 1994) |
| "Chlorthalidone treatment reduced the high plasma sodium content observed in DOCA-salt rats to the same levels observed in normotensive control groups." | 1.28 | Chlorthalidone reduces vascular hyperresponsiveness in DOCA-salt hypertensive rats. ( Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1992) |
| "Chlorthalidone treatment reduced arterial hypertension in DOC-salt treated rats (from 160 +/- 7 to 127 +/- 5 mmHg)." | 1.28 | Chlorthalidone alters the vascular reactivity of DOC-salt hypertensive rats to norepinephrine. ( Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1990) |
| "Captopril was applied the first two weeks in a dose of 25 mg 3 times daily." | 1.28 | [Captopril from Pharmachem in the treatment of arterial hypertension]. ( Belovezhdov, N; Monova, D, 1989) |
| "When prazosin was added to a beta-blocker/diuretic regimen, there was a further and statistically significant (p less than 0." | 1.27 | Effect of prazosin on blood pressure and plasma lipids in patients receiving a beta-blocker and diuretic regimen. ( Mauersberger, H, 1984) |
| "Chlorthalidone therapy was discontinued in 36 of the 67 patients." | 1.27 | Step-down treatment of mild systemic hypertension. ( Finnerty, FA, 1984) |
| "To evaluate the effects of the chronic administration of the fixed combination slow-release, oxprenolol 160 mg and chlorthalidone 20 mg on left ventricular hypertrophy, ten hypertensive out-patients, with left ventricular hypertrophy documented by left ventricular mass index (LVMI) greater than 130 g/m2, were studied." | 1.27 | Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. Echocardiographic study. ( Alberti, D; Bertoni, T; De Ambroggi, L; Francucci, BM; Peloso, A, 1988) |
| "Prazosin has been reported to reduce the hypotensive and/or bradycardic effect of clonidine in various animal models." | 1.27 | Prazosin partly blocks clonidine-induced hypotension in patients with essential hypertension. ( Farsang, C; Kapocsi, J; Vizi, ES, 1987) |
| " After 3 and 6 months of maintenance therapy, blood pressures were measured 24 hours after the previous day's dosing to evaluate the persistence of the antihypertensive effect." | 1.27 | The management of severe hypertension with minoxidil in a once-a-day treatment regimen. ( Bayley, A; Fraser, HS; Hassell, TA; Nicholson, GD, 1985) |
| " Results obtained show that the fixed combination oxprenolol 80 mg plus chlorthalidone 10 mg can be safely administered also in the elderly hypertensive patients, without risk of cardiovascular complications, allowing satisfactory blood pressure control, with a simple dosage schedule, thus improving patient compliance to the therapy." | 1.26 | [Effectiveness of treatment with beta-blocking agents and diuretics in fixed combination, in aged hypertensive patients]. ( Andreoni, A; Paciaroni, E; Quattrini, L; Saccomanno, G, 1980) |
| "Chlorthalidone caused an increase in total serum and low density lipoprotein (LDL) cholesterol, but not in high density lipoprotein (HDL) cholesterol." | 1.26 | The effect of chlorthalidone on serum lipids and lipoproteins. ( Holtzman, E; Rosenthal, T; Segal, P, 1980) |
| " This difference may be because chronic administration of the drug caused saturation of red cell binding." | 1.26 | Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone. ( Bastain, W; Farina, PL; McAinsh, J; Riva, E; Sega, R; Tognoni, G, 1980) |
| "Chlorthalidone (50 mg daily) was given for 14 days." | 1.26 | Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction. ( Landmann-Suter, R; Struyvenberg, A, 1978) |
| "When chlorthalidone was prescribed in addition to diet, serum cholesterol rose by 12 mg/dl and triglyceride by 36 mg/dl (P less than 0-005 vs pretreatment value for both)." | 1.26 | Increase in serum-lipids during treatment of hypertension with chlorthalidone. ( Ames, RP; Hill, P, 1976) |
| "Three different regimens of drug treatment for hypertension were compared with regard to the development of undesirable side-effects in a group of 53 patients attending a hypertension clinic." | 1.26 | Some side-effects of alpha-methyldopa. ( Pillay, VK, 1976) |
| "Indapamide has a prolonged saluretic action which in combination with the direct vascular effects may well account for its antihypertensive activity." | 1.25 | Antihypertensive action of indapamide. Comparative studies in several experimental models. ( Kyncl, J; Oheim, K; Seki, T; Solles, A, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 537 (55.08) | 18.7374 |
| 1990's | 105 (10.77) | 18.2507 |
| 2000's | 114 (11.69) | 29.6817 |
| 2010's | 152 (15.59) | 24.3611 |
| 2020's | 67 (6.87) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, R | 9 |
| Sinha, AD | 4 |
| Cramer, AE | 2 |
| Balmes-Fenwick, M | 2 |
| Dickinson, JH | 1 |
| Ouyang, F | 2 |
| Tu, W | 4 |
| Du, XL | 1 |
| Simpson, LM | 9 |
| Tandy, BC | 1 |
| Bettencourt, JL | 1 |
| Davis, BR | 60 |
| Allison, SJ | 1 |
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Crews, DC | 1 |
| Lindner, G | 2 |
| Ravioli, S | 2 |
| Elias, R | 1 |
| Zatz, R | 1 |
| Afsar, B | 1 |
| Kanbay, M | 1 |
| Elsurer Afsar, R | 1 |
| Ishani, A | 4 |
| Leatherman, SM | 4 |
| Woods, P | 3 |
| Hau, C | 3 |
| Klint, A | 3 |
| Lew, RA | 3 |
| Taylor, AA | 3 |
| Glassman, PA | 3 |
| Brophy, MT | 4 |
| Fiore, LD | 3 |
| Ferguson, RE | 4 |
| Cushman, WC | 26 |
| Ernst, ME | 15 |
| Fravel, MA | 2 |
| Gnanenthiran, SR | 2 |
| Wang, N | 2 |
| Di Tanna, GL | 1 |
| Salam, A | 4 |
| Webster, R | 5 |
| de Silva, HA | 2 |
| Guggilla, R | 3 |
| Jan, S | 3 |
| Maulik, PK | 4 |
| Naik, N | 3 |
| Selak, V | 4 |
| Thom, S | 3 |
| Prabhakaran, D | 3 |
| Schutte, AE | 2 |
| Patel, A | 5 |
| Rodgers, A | 5 |
| Furgeson, SB | 1 |
| Linas, S | 1 |
| Georgianos, PI | 2 |
| Armstrong, ND | 1 |
| Srinivasasainagendra, V | 1 |
| Chekka, LMS | 2 |
| Nguyen, NHK | 1 |
| Nahid, NA | 1 |
| Jones, AC | 1 |
| Tanner, RM | 2 |
| Hidalgo, BA | 1 |
| Limdi, NA | 1 |
| Claas, SA | 1 |
| Gong, Y | 3 |
| McDonough, CW | 3 |
| Cooper-DeHoff, RM | 4 |
| Johnson, JA | 4 |
| Tiwari, HK | 2 |
| Arnett, DK | 8 |
| Irvin, MR | 2 |
| Ali, S | 1 |
| Navaneethan, SD | 1 |
| Virani, SS | 1 |
| Gregg, LP | 1 |
| Wang, SY | 1 |
| Hanna, JM | 1 |
| Gongal, P | 1 |
| Onuma, OK | 1 |
| Nanna, MG | 1 |
| Bashir, K | 1 |
| Burns, T | 1 |
| Pirruccello, SJ | 1 |
| Aurit, SJ | 1 |
| Hilleman, DE | 1 |
| Sung, KC | 3 |
| Sung, JH | 1 |
| Cho, EJ | 3 |
| Ahn, JC | 1 |
| Han, SH | 2 |
| Kim, W | 3 |
| Kim, KH | 1 |
| Sohn, IS | 1 |
| Shin, J | 5 |
| Kim, SY | 3 |
| Kim, KI | 1 |
| Kang, SM | 2 |
| Park, SJ | 2 |
| Kim, YJ | 1 |
| Shin, JH | 3 |
| Park, SM | 1 |
| Park, CG | 2 |
| Solis-Jimenez, F | 1 |
| Perez-Navarro, LM | 1 |
| Cabrera-Barron, R | 1 |
| Chida-Romero, JA | 1 |
| Martin-Alemañy, G | 1 |
| Dehesa-López, E | 1 |
| Madero, M | 1 |
| Valdez-Ortiz, R | 1 |
| Mansbart, F | 1 |
| Kienberger, G | 1 |
| Sönnichsen, A | 1 |
| Mann, E | 1 |
| Silva, A | 1 |
| Guggilla, RK | 1 |
| Sahoo, SK | 1 |
| Pathni, AK | 1 |
| Krishna, A | 1 |
| Sharma, B | 1 |
| Cazabon, D | 1 |
| Moran, AE | 2 |
| Hering, D | 1 |
| Gums, JG | 3 |
| Chapman, AB | 3 |
| Huang, GD | 2 |
| Volpe, M | 1 |
| Liuzzo, G | 1 |
| van der Giet, M | 1 |
| Nitschmann, S | 1 |
| Bavishi, C | 1 |
| Krämer, BK | 1 |
| Hausberg, M | 1 |
| Kreutz, R | 1 |
| Wenzel, U | 1 |
| Messerli, FH | 7 |
| Hong, SJ | 4 |
| Rhee, MY | 3 |
| Jeong, MH | 2 |
| Kim, DH | 1 |
| Lim, SW | 3 |
| Park, K | 1 |
| Lee, JB | 1 |
| Cho, JM | 1 |
| Cho, GY | 1 |
| Heo, JH | 2 |
| Kim, SH | 3 |
| Lee, HY | 1 |
| Cho, DK | 1 |
| Park, S | 2 |
| Pyun, WB | 1 |
| Kwon, K | 2 |
| Rha, SW | 1 |
| Jung, JA | 1 |
| Götzinger, F | 1 |
| Kunz, M | 1 |
| Lauder, L | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Lucca, MB | 1 |
| Jorge, JA | 1 |
| Cichelero, FT | 2 |
| Martinez, D | 2 |
| Borges, RB | 1 |
| Hirakata, VN | 1 |
| Fuchs, FD | 10 |
| Fuchs, SC | 9 |
| Kim, MH | 1 |
| Kim, YH | 1 |
| Chang, K | 1 |
| Choi, DJ | 2 |
| Kang, WC | 1 |
| Lee, N | 1 |
| Son, JW | 1 |
| Doh, JH | 1 |
| Kim, WS | 2 |
| Ahn, Y | 1 |
| Hong, SP | 1 |
| Choi, SY | 1 |
| Hyon, MS | 1 |
| Hwang, JY | 1 |
| Cha, KS | 1 |
| Ihm, SH | 2 |
| Lee, JH | 1 |
| Yoo, BS | 1 |
| Kim, HS | 1 |
| Ebell, MH | 1 |
| Steurer, J | 1 |
| Juraschek, SP | 2 |
| Beach, JL | 2 |
| Ishak, A | 2 |
| Mukamal, KJ | 2 |
| Dineva, S | 3 |
| Uzunova, K | 3 |
| Pavlova, V | 3 |
| Filipova, E | 3 |
| Kalinov, K | 3 |
| Vekov, T | 3 |
| Singh, S | 2 |
| Bailey, KR | 1 |
| Boerwinkle, E | 7 |
| Turner, ST | 2 |
| Martins, VM | 1 |
| Helal, L | 1 |
| Ferrari, F | 1 |
| Bottino, LG | 1 |
| Aronow, WS | 1 |
| Shmerling, RH | 1 |
| Pareek, A | 3 |
| Ram, CVS | 1 |
| Mehta, RT | 1 |
| Dharmadhikari, S | 1 |
| Lung, T | 1 |
| Laba, TL | 1 |
| Hripcsak, G | 2 |
| Suchard, MA | 1 |
| Shea, S | 2 |
| Chen, R | 1 |
| You, SC | 1 |
| Pratt, N | 1 |
| Madigan, D | 1 |
| Krumholz, HM | 2 |
| Ryan, PB | 1 |
| Schuemie, MJ | 2 |
| Goldenberg, R | 2 |
| Bell, A | 2 |
| Cheng, W | 2 |
| Paron, E | 1 |
| Fils-Aimé, N | 2 |
| Burrows, M | 2 |
| Blavignac, J | 2 |
| Barakat, M | 2 |
| Roush, GC | 9 |
| Oparil, S | 15 |
| Whelton, PK | 19 |
| Frieden, TR | 1 |
| Kwon, A | 1 |
| Kim, GH | 1 |
| de Silva, A | 1 |
| Stepien, S | 2 |
| Mysore, J | 1 |
| Billot, L | 2 |
| Parron, E | 1 |
| Scala, LCN | 1 |
| Vilela-Martin, JF | 6 |
| Poli-de-Figueiredo, CE | 5 |
| Pereira E Silva, R | 3 |
| Gus, M | 6 |
| Bortolotto, LA | 2 |
| Consolim-Colombo, FM | 2 |
| Schlatter, RP | 1 |
| Cesarino, JE | 1 |
| Castro, I | 5 |
| Figueiredo Neto, JA | 3 |
| Chaves, H | 5 |
| Steffens, AA | 5 |
| Alves, JG | 5 |
| Brandão, AA | 5 |
| de Sousa, MR | 5 |
| Jardim, PC | 5 |
| Moreira, LB | 6 |
| Franco, RS | 3 |
| Gomes, MM | 2 |
| Afiune Neto, A | 2 |
| Fuchs, FC | 3 |
| Sobral Filho, DC | 3 |
| Nóbrega, AC | 5 |
| Nobre, F | 5 |
| Berwanger, O | 5 |
| Kim, HY | 1 |
| Katsi, V | 2 |
| Michalakeas, C | 1 |
| Soulaidopoulos, S | 1 |
| Antonopoulos, AS | 1 |
| Vlachopoulos, C | 1 |
| Tousoulis, D | 2 |
| Tsioufis, K | 1 |
| Chrysant, SG | 1 |
| Chrysant, GS | 1 |
| Chatzikyrkou, C | 1 |
| Schmieder, RE | 1 |
| Schiffer, M | 1 |
| Bahmad, S | 1 |
| Funk, GC | 1 |
| Schwarz, C | 1 |
| Exadaktylos, A | 1 |
| Vakil, D | 1 |
| Zinonos, S | 1 |
| Kostis, JB | 17 |
| Dobrzynski, JM | 1 |
| Cosgrove, NM | 7 |
| Moreyra, AE | 2 |
| Kostis, WJ | 4 |
| Trujillo, H | 1 |
| Caravaca-Fontán, F | 1 |
| Caro, J | 1 |
| Morales, E | 1 |
| Praga, M | 1 |
| Bang, CN | 1 |
| Soliman, EZ | 5 |
| Devereux, RB | 2 |
| Okin, PM | 3 |
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 16 |
| Pressel, SL | 15 |
| Coifman, RR | 1 |
| Liang, W | 1 |
| Ma, H | 1 |
| Cao, L | 1 |
| Yan, W | 1 |
| Yang, J | 1 |
| Siddiqui, M | 1 |
| Judd, EK | 1 |
| Calhoun, DA | 5 |
| Jeong, HS | 1 |
| Chang, KY | 1 |
| Hong, BK | 1 |
| Lee, BK | 1 |
| Chae, SC | 1 |
| Lee, SU | 1 |
| Kim, YD | 1 |
| Kim, KS | 1 |
| Choi, JH | 1 |
| Kang, HJ | 1 |
| Kim, JJ | 1 |
| Choi, YJ | 2 |
| Chun, KJ | 1 |
| Shin, DG | 1 |
| Park, SH | 2 |
| Kwan, J | 1 |
| Chae, JK | 1 |
| Kim, DW | 1 |
| Cho, JR | 1 |
| Han, KR | 2 |
| Won, KH | 1 |
| Lee, SK | 1 |
| Jung, J | 1 |
| Kim, CH | 1 |
| Mehanna, M | 1 |
| Beitelshees, AL | 1 |
| Schwartz, GL | 1 |
| Bertoluci, C | 1 |
| Foppa, M | 1 |
| Santos, ABS | 1 |
| Branchi, TV | 1 |
| Thomopoulos, C | 2 |
| Yugar, LBT | 1 |
| Moreno, B | 1 |
| Moreno, H | 3 |
| Yugar-Toledo, JC | 1 |
| Dewland, TA | 1 |
| Yamal, JM | 4 |
| Alonso, A | 1 |
| Albert, CM | 1 |
| Haywood, LJ | 6 |
| Marcus, GM | 1 |
| Kobalava, ZD | 1 |
| Villevalde, SV | 1 |
| Kulakov, VV | 1 |
| Bakris, GL | 8 |
| White, WB | 6 |
| Weber, MA | 11 |
| Sica, D | 4 |
| Roberts, A | 5 |
| Lloyd, E | 6 |
| Kupfer, S | 6 |
| Abdelfattah, R | 2 |
| Song, S | 2 |
| Sica, DA | 7 |
| van der Merwe, WM | 1 |
| Zhao, L | 1 |
| Juhasz, A | 1 |
| Hisada, M | 1 |
| Goodyear-Smith, F | 1 |
| Arroll, B | 2 |
| Wallace, H | 1 |
| de la Sierra, A | 2 |
| Armario, P | 1 |
| Oliveras, A | 1 |
| Banegas, JR | 1 |
| Gorostidi, M | 1 |
| Vinyoles, E | 1 |
| de la Cruz, JJ | 1 |
| Segura, J | 1 |
| Ruilope, LM | 1 |
| Athanasiadi, E | 1 |
| Tsioufis, C | 1 |
| Chávez-Negrete, AJ | 1 |
| Rojas-Uribe, M | 1 |
| Gallardo-Montoya, JM | 1 |
| Intaglietta, M | 1 |
| Jo, SH | 1 |
| Kim, EJ | 1 |
| Kim, SJ | 1 |
| Cho, HJ | 1 |
| Song, JM | 1 |
| Park, JJ | 1 |
| Mukhtar, O | 1 |
| Cheriyan, J | 1 |
| Cockcroft, JR | 1 |
| Collier, D | 1 |
| Coulson, JM | 1 |
| Dasgupta, I | 1 |
| Faconti, L | 1 |
| Glover, M | 1 |
| Heagerty, AM | 1 |
| Khong, TK | 1 |
| Lip, GYH | 1 |
| Mander, AP | 1 |
| Marchong, MN | 1 |
| Martin, U | 1 |
| McDonnell, BJ | 1 |
| McEniery, CM | 1 |
| Padmanabhan, S | 1 |
| Saxena, M | 1 |
| Sever, PJ | 1 |
| Shiel, JI | 1 |
| Wych, J | 1 |
| Chowienczyk, PJ | 1 |
| Wilkinson, IB | 1 |
| Rajapakse, S | 1 |
| Amarasekara, S | 1 |
| Amarasena, N | 1 |
| de Silva, AP | 1 |
| Fernando, M | 1 |
| Jayawardena, J | 1 |
| Mendis, S | 2 |
| Munasinghe, J | 1 |
| Ranasinghe, G | 1 |
| Tisserra, N | 1 |
| Senaratne, V | 1 |
| Wijekoon, S | 1 |
| Wijeyasingam, S | 1 |
| Piller, LB | 9 |
| Ghosh, A | 2 |
| Einhorn, PT | 11 |
| Ford, CE | 18 |
| Probstfield, JL | 13 |
| Wright, JT | 13 |
| Ferdinand, KC | 3 |
| Wu, J | 2 |
| Tadic, M | 1 |
| Cuspidi, C | 1 |
| Meadows, C | 1 |
| Khitan, ZJ | 1 |
| Kuusela, PJ | 1 |
| Barzilay, JI | 7 |
| Lai, D | 1 |
| Pressel, S | 8 |
| Previn, HE | 1 |
| Kjeldsen, SE | 1 |
| Sargsyan, D | 1 |
| Mekkaoui, C | 1 |
| Cabrera, J | 4 |
| Sedjro, JE | 3 |
| Pantazopoulos, JS | 2 |
| Carmel, AS | 1 |
| Cornelius-Schecter, A | 1 |
| Frankel, B | 1 |
| Jannat-Khah, D | 1 |
| Sinha, S | 1 |
| Pelzman, F | 1 |
| Safford, MM | 1 |
| Johnson, K | 1 |
| Tereshchenko, LG | 1 |
| Turtle, EJ | 2 |
| Sule, AA | 1 |
| Bath, LE | 1 |
| Denvir, MA | 1 |
| Gebbie, A | 1 |
| Mirsadraee, S | 1 |
| Webb, DJ | 2 |
| Habib, GB | 4 |
| Margolis, K | 1 |
| Dhalla, IA | 2 |
| Gomes, T | 1 |
| Yao, Z | 1 |
| Nagge, J | 1 |
| Persaud, N | 1 |
| Hellings, C | 1 |
| Mamdani, MM | 2 |
| Juurlink, DN | 2 |
| Pierini, D | 1 |
| Anderson, KV | 1 |
| Morrison, EE | 1 |
| Buddharaju, V | 1 |
| Holford, TR | 2 |
| Guddati, AK | 2 |
| DiNicolantonio, JJ | 2 |
| O'Keefe, JH | 2 |
| Lavie, CJ | 2 |
| Badgett, RG | 1 |
| Donzelli, A | 1 |
| Matthews, KA | 1 |
| Brenner, MJ | 1 |
| Brenner, AC | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Phillips, W | 1 |
| Williamson, JD | 3 |
| Whittle, J | 4 |
| Jafri, SZ | 2 |
| Grimm, RH | 12 |
| Alderman, MH | 5 |
| Lederle, FA | 2 |
| Cheng, JQ | 2 |
| Swerdel, JN | 1 |
| Deng, Y | 2 |
| Cirillo, M | 2 |
| Marcarelli, F | 1 |
| Mele, AA | 1 |
| Romano, M | 2 |
| Lombardi, C | 1 |
| Bilancio, G | 1 |
| Singer, JR | 1 |
| Pearce, ZD | 1 |
| Westhouse, SJ | 1 |
| Siebert, KJ | 1 |
| Wang, JG | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Crist, LW | 1 |
| Dixon, DL | 1 |
| Muntner, P | 2 |
| Levitan, EB | 1 |
| Lynch, AI | 7 |
| Reisin, E | 3 |
| Graves, JW | 1 |
| Dart, RA | 3 |
| Retta, TM | 3 |
| Saklayen, MG | 2 |
| Musini, VM | 1 |
| Nazer, M | 1 |
| Bassett, K | 1 |
| Wright, JM | 1 |
| Baker, WL | 1 |
| Nigro, SC | 1 |
| Kildare, L | 1 |
| Jones, T | 1 |
| Neher, JO | 1 |
| St Anna, L | 1 |
| Trimarco, V | 1 |
| Izzo, R | 1 |
| Migliore, T | 1 |
| Rozza, F | 1 |
| Marino, M | 1 |
| Manzi, MV | 1 |
| De Marco, M | 1 |
| de Simone, G | 2 |
| De Luca, N | 1 |
| Baraniuk, S | 1 |
| Rahman, M | 8 |
| Basile, JN | 5 |
| Ellsworth, AJ | 1 |
| Fendley, H | 1 |
| Jin, C | 1 |
| Jeon, Y | 1 |
| Kleven, DT | 1 |
| Pollock, JS | 1 |
| White, JJ | 1 |
| Pollock, DM | 1 |
| Wilson, L | 1 |
| Nair, KV | 2 |
| Saseen, JJ | 2 |
| Fendley, HF | 1 |
| Franklin, SS | 3 |
| Sastrasinh, S | 1 |
| Parati, G | 2 |
| Zanchetti, A | 10 |
| Argulian, E | 1 |
| Grossman, E | 1 |
| Ghushchyan, V | 1 |
| Kipnes, MS | 1 |
| Handley, A | 3 |
| Barger, B | 2 |
| Kithas, PA | 1 |
| Supiano, MA | 1 |
| Kaplan, NM | 6 |
| Tandon, S | 1 |
| Bhutani, J | 1 |
| Zaremba, IeKh | 1 |
| Bula, MS | 1 |
| Zaremba-Fedchyshyn, OV | 1 |
| Zaremba, OV | 1 |
| Virna, MM | 1 |
| Kaur, R | 1 |
| Segal, MS | 1 |
| Srinivas, TR | 1 |
| Mohandas, R | 1 |
| Shuster, JJ | 1 |
| Wen, X | 1 |
| Whidden, E | 1 |
| Tantravahi, J | 1 |
| Johnson, RJ | 2 |
| Cooney, D | 1 |
| Milfred-LaForest, S | 1 |
| Castro-Torres, Y | 1 |
| Fleites-Pérez, A | 1 |
| Carmona-Puerta, R | 1 |
| Jiménez-Garrido, RG | 1 |
| Tsai, MC | 1 |
| Vakilynejad, M | 1 |
| Springer, K | 1 |
| Pareek, AK | 2 |
| Chandurkar, NB | 3 |
| Dharmadhikari, SK | 1 |
| Godbole, AV | 1 |
| Kshirsagar, PP | 1 |
| Agarwal, MA | 1 |
| Sharma, KH | 1 |
| Mathur, SL | 1 |
| Kumbla, MM | 1 |
| Sternlicht, H | 1 |
| Scala, LC | 4 |
| de Mello, RB | 4 |
| Mosele, F | 4 |
| de Alencastro, PR | 2 |
| E Silva, RP | 1 |
| Schlatter, R | 4 |
| Cesarino, EJ | 4 |
| Neto, JA | 2 |
| Neto, AA | 3 |
| Filho, DC | 2 |
| Holzgreve, H | 2 |
| Beard, BL | 1 |
| Marginean, H | 2 |
| Hamilton, BP | 5 |
| Suhan, PS | 1 |
| Tschanz, MP | 1 |
| McBee, EC | 1 |
| Harrell, TE | 1 |
| Spalding, BM | 1 |
| Fiore Md, LD | 1 |
| Dargad, RR | 2 |
| Parekh, JD | 1 |
| Kukrety, S | 1 |
| Hwang, AY | 1 |
| Dave, C | 1 |
| Smith, SM | 1 |
| Olson, NJ | 1 |
| Cervinski, MA | 1 |
| Ornstein, DL | 1 |
| Prineas, RJ | 4 |
| Mota Gomes, M | 1 |
| Silva, RP | 1 |
| Bordignon, A | 1 |
| Bangalore, S | 1 |
| Muntner, PM | 1 |
| Black, HR | 8 |
| Asil, S | 1 |
| Atalar, E | 1 |
| Kumar Puttrevu, S | 1 |
| Ramakrishna, R | 1 |
| Bhateria, M | 1 |
| Jain, M | 1 |
| Hanif, K | 1 |
| Bhatta, RS | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| van den Meiracker, AH | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Düsing, R | 2 |
| Taler, SJ | 1 |
| Kenealy, T | 1 |
| Elley, CR | 1 |
| Shafi, T | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Klag, MJ | 1 |
| Parekh, RS | 1 |
| Preston, RA | 2 |
| Weiss, RJ | 1 |
| Bastien, A | 1 |
| Courtney, DL | 1 |
| Kirchner, K | 3 |
| Louis, GT | 4 |
| Vidt, DG | 3 |
| Chen, H | 1 |
| Yang, LQ | 1 |
| Yu, L | 1 |
| Wu, XY | 1 |
| Lu, LH | 1 |
| Gui, W | 1 |
| Carter, BL | 5 |
| Elliott, WJ | 3 |
| Menon, DV | 1 |
| Arbique, D | 2 |
| Wang, Z | 2 |
| Adams-Huet, B | 2 |
| Auchus, RJ | 2 |
| Vongpatanasin, W | 2 |
| Parra, D | 1 |
| Rosenstein, R | 1 |
| Eckfeldt, JH | 9 |
| Leiendecker-Foster, C | 5 |
| Zawar, SD | 2 |
| Salagre, SB | 2 |
| Karnik, ND | 1 |
| Massie, BM | 1 |
| Pitt, B | 1 |
| Yamanari, H | 1 |
| Nakamura, K | 1 |
| Miura, D | 1 |
| Yamanari, S | 1 |
| Ohe, T | 1 |
| Czarina Acelajado, M | 1 |
| Armanini, D | 1 |
| Fiore, C | 1 |
| Zheng, S | 1 |
| Kooter, AJ | 1 |
| Smulders, YM | 1 |
| Kabagambe, EK | 1 |
| Nakagawa, T | 1 |
| Lund, BC | 2 |
| Sato, K | 1 |
| Dohi, Y | 1 |
| Kojima, M | 1 |
| Takase, H | 1 |
| Suzuki, S | 1 |
| Ito, S | 1 |
| Mion, D | 2 |
| Bortolotto, L | 1 |
| Consolim-Colombo, F | 2 |
| Coelho, EB | 2 |
| Franco, R | 2 |
| Ribeiro, AL | 2 |
| Mota, M | 2 |
| Irigoyen, MC | 2 |
| Ghizzoni, F | 2 |
| Bortoloto, L | 1 |
| Flack, JM | 5 |
| Nesbitt, S | 1 |
| Dorsch, MP | 2 |
| Gillespie, BW | 1 |
| Erickson, SR | 1 |
| Bleske, BE | 2 |
| Weder, AB | 1 |
| Slim, HB | 1 |
| Thompson, PD | 1 |
| Handler, J | 2 |
| Neaton, JD | 3 |
| Collins, G | 1 |
| Thomas, W | 1 |
| Jäättelä, A | 4 |
| Pyörälä, K | 2 |
| Kaski, JC | 1 |
| Kountz, DS | 1 |
| Goldman, A | 2 |
| Mikhail, J | 1 |
| Ezer, M | 1 |
| Cutler, JA | 14 |
| Margolis, KL | 5 |
| Moloo, J | 1 |
| Simmons, DL | 2 |
| Sweeney, ME | 1 |
| Wong, ND | 3 |
| Papademetriou, V | 4 |
| Ong, ST | 2 |
| Zhang, X | 1 |
| Coca, S | 1 |
| Brown, CD | 1 |
| Colon, PJ | 2 |
| Fine, LJ | 1 |
| Gupta, AK | 2 |
| Baimbridge, C | 3 |
| Henriquez, MA | 2 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Huang, P | 1 |
| Peterzan, MA | 1 |
| Hardy, R | 1 |
| Chaturvedi, N | 1 |
| Hughes, AD | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Leenen, FH | 5 |
| Ruzicka, M | 1 |
| Floras, JS | 1 |
| Raheja, P | 1 |
| Price, A | 1 |
| Shuster, JE | 1 |
| Allan, GM | 1 |
| Ivers, N | 1 |
| Padwal, RS | 1 |
| Karadsheh, F | 1 |
| Weir, MR | 1 |
| Germino, FW | 1 |
| Song, E | 1 |
| Proschan, M | 2 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Gordon, D | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Kwon, BJ | 1 |
| Jang, SW | 1 |
| Choi, KY | 1 |
| Kim, DB | 1 |
| Youn, HJ | 1 |
| Kim, JH | 1 |
| Kapoor, S | 1 |
| Tziomalos, K | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Karagiannis, A | 1 |
| Farber, MA | 2 |
| Felicetta, JV | 1 |
| Stokes, JD | 1 |
| Rakić, D | 2 |
| Rumboldt, Z | 4 |
| Bagatin, J | 3 |
| Polić, S | 2 |
| Nilsson, P | 1 |
| Hernborg, A | 1 |
| Håkansson, J | 1 |
| Werkö, L | 3 |
| Berglund, G | 1 |
| Traynor, K | 1 |
| Wepner, U | 1 |
| Vetter, W | 1 |
| Salam, AM | 1 |
| Slany, J | 1 |
| Nakov, R | 1 |
| Beck, K | 1 |
| Janka, HU | 1 |
| Mancia, G | 3 |
| Rollins, G | 1 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Siragy, HM | 1 |
| Reese, AM | 1 |
| Talbert, RL | 1 |
| Bussey, HI | 1 |
| Malacco, E | 2 |
| Rappelli, A | 3 |
| Menotti, A | 1 |
| Zuccaro, MS | 1 |
| Coppini, A | 2 |
| Diener, HC | 1 |
| Liakishev, AA | 1 |
| HANGAARD, G | 1 |
| HOLEN, N | 1 |
| MATHISEN, HS | 3 |
| DOUGLAS, A | 1 |
| HALL, R | 1 |
| HORN, DB | 1 |
| KERR, DN | 1 |
| PEARSON, DT | 1 |
| RICHARDSON, H | 1 |
| WEHLE, B | 1 |
| COTTIER, P | 1 |
| GLOOR, R | 1 |
| PUGATSCH, I | 1 |
| BRYANT, JM | 3 |
| SCHVARTZ, N | 3 |
| TOROSDAG, S | 2 |
| FLETCHER, L | 3 |
| FERTIG, H | 2 |
| SCHWARTZ, MS | 2 |
| McDERMOTT, JJ | 1 |
| SPENCER, TB | 1 |
| YU, TF | 1 |
| BERGER, L | 1 |
| QUAN, RB | 2 |
| CRANSTON, WI | 3 |
| JUEL-JENSEN, BE | 2 |
| DYRDA, I | 1 |
| DUFAULT, C | 1 |
| HERBERT, JG | 1 |
| TREMBLAY, G | 1 |
| GENEST, J | 1 |
| LEMBACH, K | 1 |
| LUTTRUP, K | 1 |
| GESSLER, U | 1 |
| GOODMAN, RM | 1 |
| COMINGS, DE | 1 |
| STEIGMANN, F | 1 |
| KAKAVIATOS, N | 3 |
| FINNERTY, FA | 12 |
| STOKKE, H | 1 |
| TOLKSDORF, A | 1 |
| BREST, AN | 2 |
| ONESTI, G | 4 |
| SEKINE, G | 1 |
| SELLER, R | 1 |
| MOYER, JH | 2 |
| CAPDEVILA MIRABET, JM | 1 |
| KOCAK, N | 1 |
| TELAFERLI, A | 1 |
| SEMMENCE, AM | 2 |
| JONES, RP | 1 |
| FORBES, JA | 1 |
| MUTCH, LM | 1 |
| ROOTH, G | 2 |
| BERGSTROEM, J | 1 |
| FREIS, ED | 3 |
| THURAU, H | 1 |
| SCHUPPIUS, A | 1 |
| MONTANDON, A | 1 |
| JOHNSTON, LC | 4 |
| GRIEBLE, HG | 3 |
| SCHOENBERGER, JA | 6 |
| FULLER, JB | 1 |
| SEBRANJOBRIZ, F | 1 |
| BOETTIGER, LE | 1 |
| MALMBORG, RO | 1 |
| MICHAELI, EW | 1 |
| KLAPPER, MS | 1 |
| CHAZAN, JA | 1 |
| RICHARD, LS | 1 |
| ANDREUKERN, F | 1 |
| HOYUELAJIMENEZ, JM | 1 |
| CARNEADO, J | 1 |
| JUNKERSDORF, J | 1 |
| MURUKAS, J | 1 |
| SCHMIDT-BENTELE, R | 1 |
| BENOT, E | 1 |
| CAPOTEBENOT, R | 1 |
| RODRIGUEZALVAREZ, J | 1 |
| TORRESGOMEZ, M | 1 |
| QUEROCABRERA, C | 1 |
| VAZQUEZGUZMAN, D | 1 |
| TEUSCHER, A | 1 |
| LUGINBUEHL, H | 1 |
| BROMMER, W | 1 |
| MAIDHOF, E | 1 |
| MEES, EJ | 6 |
| GEYSKES, GG | 12 |
| CHRISTENSSON, B | 1 |
| GUSTAFSON, A | 1 |
| WESTLING, H | 1 |
| LIUM, O | 1 |
| TVETER, KJ | 1 |
| OBROWSKY, L | 1 |
| JENNINGS, RC | 1 |
| SHAIKH, VA | 1 |
| ALLEN, WM | 1 |
| MILLIEZ, P | 2 |
| FRITEL, D | 1 |
| REY, LP | 1 |
| FUERST, C | 1 |
| LYON, AF | 1 |
| DEGRAFF, AC | 1 |
| KOBAYASHI, K | 1 |
| SHIBATA, M | 1 |
| FUJII, R | 1 |
| KATO, K | 1 |
| IWAZU, A | 1 |
| CASTELLETTA, L | 1 |
| ARNOLD, OH | 1 |
| STRATA, A | 2 |
| SALVATORE, V | 2 |
| CARLINER, NH | 2 |
| SCHELLING, JL | 1 |
| RUSSELL, RP | 1 |
| OKUN, R | 1 |
| DAVIS, M | 1 |
| GRIJO, FC | 1 |
| ESQUENAZI, R | 1 |
| SCHAEFFER, S | 1 |
| SAMSON, WE | 1 |
| HOWARD, BE | 1 |
| MIZGALA, HF | 1 |
| HUTCHEON, DE | 1 |
| LEONARD, GB | 1 |
| SCHWARTZ, ML | 1 |
| HECKENBERGER, S | 1 |
| MOKRY, H | 1 |
| BONTE, D | 1 |
| CHUPKOVICH, V | 1 |
| MARRIOTT, HJ | 1 |
| LEMMERT, WA | 1 |
| SANDLER, IA | 1 |
| CATSAROS, D | 1 |
| WICKE, BS | 1 |
| REUTTER, F | 1 |
| SCHAUB, F | 1 |
| Cassinello Ogea, C | 1 |
| Girón Nombiela, JA | 1 |
| Ruiz Tramazaygues, J | 1 |
| Izquierdo Villarroya, B | 1 |
| Sánchez Tirado, JA | 1 |
| Almajano Domínguez, RM | 1 |
| Oro Fraile, J | 1 |
| Cohen, JD | 5 |
| Siebenhofer, A | 1 |
| Horvath, K | 1 |
| Kraly, B | 1 |
| Plank, J | 1 |
| Rahn, KH | 1 |
| Bettencourt, J | 1 |
| Goff, DC | 2 |
| Black, H | 4 |
| Habib, G | 1 |
| Ellsworth, A | 2 |
| Force, RW | 1 |
| Wiegmann, T | 3 |
| Ciocon, JO | 1 |
| Os, I | 1 |
| Landmark, K | 1 |
| Toft, I | 1 |
| Kuwajima, I | 1 |
| Psaty, BM | 1 |
| Lumley, T | 1 |
| Choi, KL | 1 |
| Chua, D | 1 |
| Caruso, D | 1 |
| D'Avino, M | 2 |
| Acampora, C | 1 |
| Romano, L | 1 |
| Bevilacqua, N | 1 |
| Caruso, G | 1 |
| Esposti, DD | 1 |
| Borghi, C | 4 |
| Wilson, AC | 4 |
| Freudenberger, RS | 1 |
| Stergiou, GS | 3 |
| Makris, T | 1 |
| Papavasiliou, M | 1 |
| Efstathiou, S | 1 |
| Manolis, A | 1 |
| Dunn, JK | 1 |
| Nwachuku, C | 5 |
| Barzilay, J | 4 |
| Batuman, V | 2 |
| Farber, M | 1 |
| Henriquez, M | 2 |
| Kopyt, N | 2 |
| Saklayen, M | 2 |
| Stanford, C | 3 |
| Walworth, C | 2 |
| Ward, H | 2 |
| Khosla, N | 1 |
| Chua, DY | 1 |
| Krakoff, LR | 3 |
| Al Khaja, KA | 1 |
| Sequeira, RP | 1 |
| Fomin, VV | 1 |
| Moiseev, SV | 1 |
| Dell'Omo, G | 1 |
| Penno, G | 1 |
| Del Prato, S | 1 |
| Pedrinelli, R | 2 |
| Goerdt, CJ | 1 |
| Steffensmeier, JJ | 1 |
| Phillips, BB | 1 |
| Zimmerman, MB | 1 |
| Bergus, GR | 1 |
| Franklin, S | 2 |
| Hollenberg, NK | 1 |
| Salvetti, A | 5 |
| Ghiadoni, L | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Yusuf, S | 1 |
| Miller, MB | 1 |
| Karotsis, AK | 1 |
| Symeonidis, A | 1 |
| Mastorantonakis, SE | 1 |
| Basile, J | 2 |
| Sadler, LS | 1 |
| Summerson, J | 1 |
| Varughese, GI | 1 |
| Tahrani, AA | 1 |
| Scarpello, JH | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Alberici, M | 1 |
| Christian, R | 1 |
| Davis, B | 3 |
| Whelton, P | 1 |
| Thadani, U | 1 |
| Fong, MW | 1 |
| Filippone, JD | 1 |
| Beck, GR | 1 |
| Katz, MG | 1 |
| Bisognano, JD | 1 |
| Harris-Haywood, S | 1 |
| Bareis, CJ | 1 |
| Dart, R | 1 |
| Scott, CL | 1 |
| Heidenreich, PA | 1 |
| Lairson, DR | 1 |
| Shlipak, MG | 1 |
| Goldman, L | 1 |
| Patel, AB | 1 |
| Shea, ML | 1 |
| Vagaonescu, TD | 1 |
| Karnik, N | 1 |
| Joglekar, VK | 1 |
| Chandurkar, N | 1 |
| Naik, GS | 1 |
| Davidov, M | 4 |
| Jahnecke, J | 1 |
| Bufalari, A | 1 |
| Meloni, G | 1 |
| Chiaverini, P | 1 |
| Dalli, G | 1 |
| Paciaroni, E | 3 |
| Quattrini, L | 1 |
| Saccomanno, G | 1 |
| Andreoni, A | 1 |
| Meier, A | 7 |
| Schiffl, H | 2 |
| Weidmann, P | 13 |
| Mordasini, R | 4 |
| Riesen, W | 4 |
| Bachmann, C | 4 |
| Ziegler, WH | 5 |
| Glorioso, N | 2 |
| Madeddu, P | 2 |
| Dessì Fulgheri, P | 1 |
| Sanna, G | 1 |
| Fiori, C | 1 |
| Dettori, S | 1 |
| Cocco, F | 1 |
| Mayer, O | 3 |
| Cepelák, V | 3 |
| Cícha, Z | 2 |
| Kokaisl, V | 2 |
| Mádle, A | 2 |
| Mazanec, J | 2 |
| Moses, K | 2 |
| Vácha, J | 2 |
| Lowenstein, J | 1 |
| Velasco, M | 3 |
| Silva, H | 1 |
| Morillo, J | 3 |
| Pellicer, R | 1 |
| Urbina-Quintana, A | 3 |
| Hernández-Pieretti, O | 3 |
| Fletcher, R | 1 |
| Khatri, IM | 1 |
| Carpentiere, G | 2 |
| Castello, F | 2 |
| Marino, S | 2 |
| Zarcone, P | 1 |
| Castello, A | 1 |
| Piovana, U | 1 |
| Brandstetter, G | 2 |
| Hoffmann, H | 3 |
| Lombardo, M | 3 |
| Zaini, G | 1 |
| Pastori, F | 1 |
| Fusco, M | 1 |
| Pacini, S | 1 |
| Foppoli, C | 1 |
| Brunner, HR | 3 |
| Gavras, H | 3 |
| Waeber, B | 1 |
| Santucci, A | 1 |
| Aguglia, F | 1 |
| Ficara, C | 1 |
| Molle, D | 1 |
| Labeyrie, E | 1 |
| Daveloose, D | 1 |
| Salesse, R | 1 |
| Viret, J | 1 |
| Leterrier, F | 1 |
| Kreeft, JH | 1 |
| Larochelle, P | 1 |
| Ogilvie, RI | 2 |
| Beretta-Piccoli, C | 5 |
| Keusch, G | 4 |
| Glück, Z | 4 |
| Salvadeo, A | 2 |
| Villa, G | 2 |
| Segagni, S | 2 |
| Galli, F | 1 |
| Criscuolo, D | 2 |
| Gelman, A | 1 |
| de Albuquerque, EM | 1 |
| Reynaldo Stella, S | 1 |
| Draibe, SA | 1 |
| Ajzen, H | 1 |
| Krönig, B | 1 |
| Wendt, G | 1 |
| Del Nero Júnior, E | 1 |
| Lima, EV | 1 |
| Savioli, RM | 1 |
| de Rezende, MC | 1 |
| Pupita, F | 2 |
| Belogi, M | 2 |
| Ansuini, R | 2 |
| Campolucci, G | 2 |
| Suchová, H | 1 |
| Bachmann, H | 1 |
| Webb, EL | 2 |
| Godfrey, JC | 2 |
| Gertel, A | 2 |
| Costello, RJ | 2 |
| Applin, WJ | 1 |
| Zisblatt, M | 2 |
| Vukovich, RA | 2 |
| Neiss, ES | 2 |
| Cooper, WH | 1 |
| Pallavini, G | 1 |
| Comi, D | 2 |
| Grillo, G | 1 |
| Mantero, O | 2 |
| Minetti, L | 2 |
| Selvini, A | 2 |
| Suppa, G | 2 |
| Muiesan, G | 6 |
| Alicandri, C | 3 |
| Agabiti-Rosei, E | 6 |
| Fariello, R | 3 |
| Montini, E | 2 |
| Muiesan, ML | 1 |
| Boni, E | 2 |
| Cinquegrana, A | 1 |
| Zaninelli, A | 2 |
| Dessì-Fulgheri, P | 1 |
| Delle Gemme, E | 1 |
| Costa, FV | 2 |
| Ambrosioni, E | 3 |
| Cybulska, I | 1 |
| Sznajderman, M | 1 |
| Hubbell, FA | 1 |
| Drayer, JI | 8 |
| Rose, DE | 1 |
| Emanueli, A | 1 |
| Born, A | 1 |
| Lavezzari, M | 1 |
| Grell, GA | 3 |
| Forrester, TE | 1 |
| Alleyne, GA | 2 |
| Ferrara, LA | 4 |
| Mancini, M | 4 |
| Fasano, ML | 2 |
| Pasanisi, F | 3 |
| Vallone, G | 1 |
| Misra, NP | 1 |
| Bahadur, MM | 1 |
| Licht, JH | 1 |
| Haley, RJ | 1 |
| Pugh, B | 1 |
| Lewis, SB | 1 |
| Kieso, HA | 1 |
| Gould, BA | 1 |
| Mann, S | 1 |
| Hornung, RS | 1 |
| Altman, DG | 1 |
| Raftery, EB | 1 |
| Erwteman, TM | 1 |
| Nagelkerke, N | 1 |
| Lubsen, J | 1 |
| Koster, M | 1 |
| Dunning, AJ | 1 |
| Fogari, R | 2 |
| Zoppi, A | 1 |
| McChesney, JA | 1 |
| Beckenbauer, UE | 1 |
| Planz, G | 1 |
| Pollavini, G | 1 |
| Grillo, C | 1 |
| Gentile, S | 2 |
| Coltorti, M | 1 |
| Gillum, RF | 1 |
| Roos, JC | 6 |
| Dorhout Mees, EJ | 10 |
| Koomans, HA | 4 |
| Boer, P | 11 |
| Holtzman, E | 3 |
| Rosenthal, T | 4 |
| Goldbourt, U | 2 |
| Segal, P | 3 |
| Pomidossi, G | 1 |
| Motolese, M | 6 |
| Rossi, A | 1 |
| Ziacchi, V | 1 |
| Fracalossi, C | 1 |
| Marino, A | 1 |
| Lomanto, B | 1 |
| Zhao, GS | 1 |
| Torma, Z | 1 |
| Ferrier, C | 1 |
| Bianchetti, MG | 3 |
| Marone, C | 2 |
| Luisoli, S | 2 |
| Bomio, F | 2 |
| Robinson, BF | 2 |
| Dobbs, RJ | 2 |
| Phillips, RJ | 2 |
| Bhigjee, AI | 1 |
| Seedat, YK | 2 |
| Hoosen, S | 1 |
| Neerahoo, RM | 1 |
| Naidoo, K | 1 |
| Saldanha, RV | 1 |
| Macruz, R | 2 |
| Santana, PC | 1 |
| de Lima, JJ | 1 |
| Zalc, S | 1 |
| Pileggi, F | 5 |
| Karachalios, GN | 1 |
| Dolce, E | 1 |
| Misceo, N | 1 |
| Pirrelli, A | 1 |
| Mauersberger, H | 1 |
| Ames, RP | 2 |
| Peacock, PB | 1 |
| Caralis, PV | 1 |
| Materson, BJ | 3 |
| Perez-Stable, E | 1 |
| Shkhvatsabaia, IK | 1 |
| Musaev, ZM | 1 |
| Nekrasova, AA | 1 |
| Suvorov, IuI | 1 |
| Pöch, G | 1 |
| Wing, LM | 1 |
| West, MJ | 1 |
| Graham, JR | 1 |
| Chalmers, JP | 1 |
| Hilgert, A | 1 |
| Horch, G | 1 |
| Candau, LA | 1 |
| Pereira, LS | 1 |
| Scherr, C | 1 |
| Purdy, RE | 1 |
| Laragh, JH | 6 |
| Carotti, A | 4 |
| Corea, L | 3 |
| Innocenti, P | 6 |
| Montervino, C | 2 |
| Prezioso, R | 1 |
| Romanelli, G | 1 |
| Toso, M | 3 |
| Wajngarten, M | 4 |
| Solorzano, J | 1 |
| Godoy, M | 2 |
| Barretto, AC | 3 |
| Blazek, M | 1 |
| Cerný, J | 1 |
| Niebauer, R | 1 |
| Koznarová, M | 1 |
| Munzarová, A | 1 |
| Burke, T | 1 |
| Hausen, T | 1 |
| Floris, B | 1 |
| Franchetta, G | 1 |
| Palestini, N | 1 |
| Sonaglioni, G | 1 |
| Verdecchia, P | 4 |
| Bichisao, E | 3 |
| Bibracher, C | 1 |
| Podzich, M | 1 |
| Thananopavarn, C | 1 |
| Golub, MS | 1 |
| Sambhi, MP | 1 |
| Gray, DR | 2 |
| Bayley, S | 1 |
| Chiodini, P | 1 |
| Wilson, P | 1 |
| van Kalmthout, PM | 1 |
| Vree, TB | 1 |
| Thien, T | 3 |
| Struyker-Boudier, HA | 1 |
| Smits, JF | 1 |
| Kleinjans, JC | 1 |
| van Essen, H | 1 |
| Rodríguez Rodríguez, FJ | 1 |
| Petersen Guitarte, G | 1 |
| Paumard Fraguas, A | 2 |
| López-Vidriero, E | 1 |
| Franco Manera, R | 1 |
| Liusov, VA | 3 |
| Kharchenko, VI | 3 |
| Istomina, IA | 2 |
| Rifai, MA | 1 |
| Evsikov, EM | 3 |
| Gray, JM | 1 |
| Lawson, DH | 1 |
| Boddy, K | 1 |
| East, W | 1 |
| Bellini, G | 2 |
| Battilana, G | 2 |
| Rigoni, A | 1 |
| Puppis, E | 1 |
| Cosenzi, A | 1 |
| Carretta, R | 2 |
| Fabris, B | 2 |
| Tonutti, L | 1 |
| van Soeren, F | 1 |
| Grossman, SH | 1 |
| Gunnells, JC | 1 |
| Guevara, J | 2 |
| Ramírez, A | 2 |
| Goldman, AI | 1 |
| Steele, BW | 1 |
| Schnaper, HW | 4 |
| Fitz, AE | 1 |
| Frohlich, ED | 1 |
| Perry, HM | 9 |
| Wester, PO | 3 |
| Gruppillo, P | 1 |
| Tomasi, AM | 2 |
| Masoni, A | 2 |
| Finzi, C | 1 |
| Albanesi Filho, FM | 2 |
| Benchimol, AB | 2 |
| Tiberi, F | 1 |
| Corinaldesi, G | 1 |
| Nissinen, A | 1 |
| Tuomilehto, J | 2 |
| Falch, DK | 1 |
| Schreiner, AM | 1 |
| Asbury, MJ | 1 |
| Wells, FO | 1 |
| Barker, NP | 2 |
| Bonaduce, D | 1 |
| Ferrara, N | 1 |
| Petretta, M | 1 |
| Canonico, V | 1 |
| Romango, E | 1 |
| Rengo, F | 1 |
| Del Guercio, R | 1 |
| Baronchelli, A | 1 |
| Agosta, R | 2 |
| Pasotti, C | 2 |
| Rossi, R | 1 |
| Gandolfi, P | 1 |
| Govind, U | 1 |
| Munro, BF | 1 |
| Robertson, LI | 1 |
| Guidi, G | 1 |
| Giuntoli, F | 3 |
| Galeone, F | 2 |
| Checchi, M | 1 |
| Locci, P | 1 |
| Saba, GC | 1 |
| Saba, P | 5 |
| Blum, M | 1 |
| Algueti, A | 1 |
| Bauminger, S | 1 |
| Aviram, A | 1 |
| Ayalon, D | 1 |
| Rylski, M | 1 |
| Rawczyńska-Englert, I | 1 |
| Hoffman, M | 1 |
| Fischer, RG | 1 |
| Glassock, RJ | 1 |
| Weitzman, RE | 1 |
| Bennett, CM | 1 |
| Maxwell, M | 1 |
| Hamilton, B | 1 |
| Winer, N | 1 |
| Kirkendall, W | 1 |
| Gonasun, L | 1 |
| Hamilton, J | 1 |
| Kirkendall, WM | 3 |
| Gonasun, LM | 1 |
| Langrall, H | 1 |
| Lechi, A | 1 |
| Pomari, S | 1 |
| Berto, R | 1 |
| Buniotto, P | 1 |
| Parrinello, A | 1 |
| Marini, F | 1 |
| Cogo, L | 1 |
| Tomasi, A | 1 |
| Baretta, G | 1 |
| Houtzagers, JJ | 1 |
| Chadha, DR | 1 |
| Otter, HP | 1 |
| Hammond, JJ | 2 |
| Jacks-Nagle, VL | 1 |
| Plotnick, GD | 1 |
| Fisher, ML | 1 |
| Hamilton, JH | 1 |
| Robinson, M | 1 |
| Janoski, AH | 1 |
| De Giorgio, LA | 1 |
| Innocenti, F | 1 |
| Pettinà, G | 1 |
| Seghieri, G | 1 |
| Cotorruelo, JG | 1 |
| Llamazares, C | 1 |
| Flórez, J | 1 |
| Peuker, KH | 1 |
| Sau, F | 5 |
| Raffo, M | 2 |
| Seguro, C | 5 |
| Pisano, MR | 2 |
| Pirisi, R | 2 |
| Cherchi, A | 5 |
| Netto, MP | 2 |
| Solórzano, JA | 1 |
| Mady, C | 2 |
| Zampaglione, G | 1 |
| Ferrari, O | 1 |
| Bianchi, C | 1 |
| Bonifazi, C | 1 |
| Coppetti, S | 1 |
| Costanza, G | 1 |
| Lanzarini, L | 1 |
| Ricevuti, A | 1 |
| Rinaldo, R | 1 |
| Rizzi, GM | 1 |
| Tavecchi, L | 1 |
| Ziletti, G | 1 |
| Distante, S | 1 |
| Bacci, D | 1 |
| Menchini, U | 1 |
| Ram, CV | 1 |
| Garrett, BN | 2 |
| Rossi, AG | 1 |
| Gotzen, R | 1 |
| Hiemstra, S | 1 |
| Borba, P | 1 |
| Tenório, J | 1 |
| Didier, M | 1 |
| França, P | 1 |
| Santos, A | 1 |
| Centritto, V | 1 |
| Russell, JG | 1 |
| Mayhew, SR | 1 |
| Humphries, IS | 1 |
| Metz, P | 1 |
| Robinson, HM | 1 |
| Anderson, M | 1 |
| Channick, BJ | 1 |
| Kessler, WB | 2 |
| Marks, AD | 1 |
| Adlin, EV | 1 |
| Buoninconti, R | 3 |
| Valori, C | 2 |
| Talberg, J | 2 |
| Fernandes, EO | 1 |
| Chequer, CV | 1 |
| Latreca, CE | 1 |
| Reis, NB | 1 |
| Marchesi, E | 1 |
| Bernardi, L | 1 |
| Finardi, G | 1 |
| Sumiye, L | 1 |
| Vivian, AS | 1 |
| Frisof, KB | 1 |
| Podany, EC | 1 |
| Pirani, R | 1 |
| Lazzaretto, R | 2 |
| Ambroso, G | 1 |
| Brandão, AP | 1 |
| Oigman, W | 3 |
| Matteoli, S | 1 |
| De Martino, A | 1 |
| Filabozzi, P | 1 |
| Greco, V | 1 |
| Manzi, M | 1 |
| Simonetti, BM | 1 |
| Cinotti, GA | 1 |
| Stirati, G | 1 |
| van den Brink, G | 1 |
| van Asten, P | 1 |
| Borhani, NO | 5 |
| Peheim, E | 2 |
| Morgan, DB | 1 |
| Davidson, C | 1 |
| Solinas, E | 1 |
| Riva, E | 1 |
| Farina, PL | 1 |
| Sega, R | 1 |
| Tognoni, G | 2 |
| Bastain, W | 1 |
| McAinsh, J | 1 |
| Stessman, J | 1 |
| Ben-Ishay, D | 1 |
| Mhlongo, SW | 1 |
| Noveck, RJ | 1 |
| McMahon, FG | 1 |
| Jain, AK | 2 |
| Ryan, JR | 2 |
| Deibert, K | 1 |
| Leon, AS | 1 |
| Hunninghake, DB | 1 |
| Lenz, K | 1 |
| Hannan, P | 1 |
| Blackburn, H | 1 |
| de Moraes, AV | 1 |
| Martnelli Filho, M | 1 |
| Dauar, D | 1 |
| Ebaid, M | 1 |
| Décourt, LV | 1 |
| Lacy, CR | 2 |
| Hall, WD | 1 |
| Krieger, SD | 1 |
| Gnemmi, AE | 1 |
| Romagnoli, A | 1 |
| Cugurra, F | 1 |
| González-Juanatey, JR | 2 |
| Pose Reino, A | 1 |
| Amaro Cendón, A | 2 |
| García Acuña, JM | 2 |
| Castelo Fuentes, V | 1 |
| Calvo Gómez, C | 2 |
| de la Peña, MG | 1 |
| De Lima, MD | 1 |
| Kohlmann, NE | 2 |
| Neves, FA | 1 |
| Zanella, MT | 3 |
| Ribeiro, AB | 4 |
| Kohlmann, O | 1 |
| Oberman, A | 10 |
| Blaufox, MD | 10 |
| Wassertheil-Smoller, S | 9 |
| Zimbaldi, N | 4 |
| Wylie-Rosett, J | 3 |
| Langford, HG | 9 |
| Casiglia, E | 1 |
| Spolaore, P | 1 |
| Mazza, A | 1 |
| Ginocchio, G | 1 |
| Colangeli, G | 1 |
| Onesto, C | 1 |
| Di Menza, G | 1 |
| Pegoraro, L | 1 |
| Ambrosio, GB | 1 |
| Fenichel, RR | 1 |
| Lipicky, RJ | 1 |
| Applegate, WB | 11 |
| Wittes, J | 1 |
| Luhr, J | 1 |
| Shekelle, RB | 1 |
| Camel, GH | 1 |
| Greenlick, MR | 2 |
| Hadley, E | 1 |
| Moye, L | 1 |
| Avanzini, F | 1 |
| Alli, C | 1 |
| Bettelli, G | 1 |
| Corso, R | 1 |
| Colombo, F | 1 |
| Mariotti, G | 1 |
| Radice, M | 1 |
| Torri, V | 1 |
| Antonicelli, R | 1 |
| Savonitto, S | 1 |
| Tomassini, PF | 1 |
| Gambini, C | 1 |
| Sardina, M | 1 |
| Ranieri, G | 3 |
| Taddei, S | 1 |
| Filitti, V | 1 |
| Andriani, A | 1 |
| Bonfantino, MV | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 3 |
| Siegel, D | 2 |
| Saliba, P | 1 |
| Haffner, S | 1 |
| Martínez López, JJ | 1 |
| Rúiz López, FJ | 1 |
| Gómez Márquez, M | 1 |
| Ortega González, G | 1 |
| Molina Boix, M | 1 |
| Florenciano Sánchez, R | 1 |
| Mansur, Ade P | 2 |
| Ramires, JA | 3 |
| Rati, M | 1 |
| Solimene, MC | 1 |
| Hueb, W | 1 |
| da Luz, PL | 2 |
| Maharaj, B | 1 |
| van der Byl, K | 1 |
| Francischetti, E | 1 |
| César, LA | 1 |
| Marcondes, M | 1 |
| Cabral, AM | 6 |
| Carvalhinho, FB | 3 |
| Vasquez, EC | 5 |
| Cicilini, MA | 3 |
| Leiva, F | 1 |
| Bosch, M | 1 |
| Delgadillo, J | 1 |
| Stamler, J | 5 |
| Grandits, GA | 2 |
| Elmer, PJ | 3 |
| McDonald, R | 4 |
| Bradley, K | 1 |
| Belcher, J | 1 |
| Elmer, P | 1 |
| Miller, P | 1 |
| Grimm, R | 1 |
| Sadeh, M | 1 |
| Goldhammer, Y | 1 |
| Jennings, S | 1 |
| Hataway, H | 1 |
| Stern, J | 1 |
| Lewis, CE | 2 |
| Grandits, A | 1 |
| Flack, J | 1 |
| Fortini, A | 1 |
| Nenci, G | 1 |
| Laureano, R | 1 |
| Cappelletti, C | 1 |
| Widimský, J | 1 |
| Lánská, V | 1 |
| Hulínský, V | 1 |
| Balazovjech, I | 1 |
| Havlík, V | 1 |
| Havránek, P | 1 |
| Kroupa, E | 1 |
| Nikodýmová, L | 1 |
| Pátek, F | 1 |
| Svítil, F | 1 |
| Svihovcová, P | 1 |
| Simunic, M | 1 |
| Ljutic, D | 2 |
| Sardelic, S | 3 |
| Schneider, M | 1 |
| Lerch, M | 1 |
| Papiri, M | 1 |
| Buechel, P | 1 |
| Boehlen, L | 1 |
| Shaw, S | 1 |
| Risen, W | 1 |
| Cutler, NR | 1 |
| Sramek, JJ | 1 |
| Luna, A | 1 |
| Mena, I | 1 |
| Brass, EP | 1 |
| Kurtz, NM | 1 |
| Brennan, JJ | 1 |
| Bissoli, NS | 5 |
| Pavlicević, I | 1 |
| Pivac, N | 2 |
| Spiers, DR | 1 |
| Wade, RC | 1 |
| Curb, JD | 6 |
| Savage, PJ | 2 |
| Camel, G | 1 |
| Frost, PH | 2 |
| Gonzalez, N | 2 |
| Guthrie, G | 1 |
| Rutan, GH | 1 |
| Berge, KG | 3 |
| Hawkins, CM | 4 |
| Probstfield, J | 1 |
| Baptista, M | 1 |
| Costa, CH | 1 |
| Kohlmann Júnior, O | 2 |
| McDonald, RH | 3 |
| Yunis, C | 1 |
| Svendsen, K | 1 |
| Liebson, PR | 1 |
| de Leeuw, PW | 1 |
| Notter, T | 1 |
| Zilles, P | 1 |
| Malakos, JS | 1 |
| Achimastos, AD | 1 |
| Mountokalakis, TD | 1 |
| Dernellis, JM | 1 |
| Vyssoulis, GP | 1 |
| Zacharoulis, AA | 1 |
| Toutouzas, PK | 1 |
| Santos-Costa, JL | 1 |
| Cutler, J | 1 |
| Schron, E | 1 |
| Berkson, DM | 1 |
| Smith, WM | 6 |
| Tallis, GA | 1 |
| Phillips, PJ | 1 |
| Popplewell, PY | 1 |
| Leonetti, G | 6 |
| Trimarco, B | 1 |
| Collatina, S | 1 |
| Tosetti, A | 1 |
| Rosei, EA | 2 |
| Dal Palù, C | 4 |
| Magnani, B | 4 |
| Pessina, A | 2 |
| Ofili, EO | 1 |
| St Vrain, JA | 1 |
| Pearson, A | 1 |
| Martin, TJ | 1 |
| Uy, ND | 1 |
| Castello, R | 1 |
| Labovitz, AJ | 1 |
| Schron, EB | 1 |
| Cohen, J | 2 |
| Frost, P | 1 |
| Smith, W | 1 |
| Guthrie, GP | 1 |
| Rutan, G | 1 |
| Vogt, T | 1 |
| Burlando, A | 1 |
| Wilson, A | 1 |
| Brass, LM | 1 |
| Frishman, W | 1 |
| Price, T | 1 |
| Naranca, M | 1 |
| Bojić, L | 1 |
| Kovacić, Z | 1 |
| Singer, RB | 1 |
| González Maqueda, I | 1 |
| Gómez Guindal, JA | 1 |
| González Lama, I | 1 |
| De Rosa, ML | 1 |
| Giordano, A | 1 |
| Della Guardia, D | 1 |
| Maddaluno, G | 1 |
| Lionetti, F | 1 |
| Marsicani, N | 1 |
| Vigorito, C | 1 |
| SoRelle, R | 1 |
| Einecke, D | 1 |
| Lasagna, L | 1 |
| Franse, LV | 3 |
| Pahor, M | 4 |
| Di Bari, M | 3 |
| Somes, GW | 3 |
| Price, TR | 1 |
| Fields, WS | 1 |
| Guralnik, JM | 2 |
| Kuller, L | 3 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Shorr, RI | 2 |
| Wan, JY | 2 |
| Chen, BH | 1 |
| Huysmans, FT | 2 |
| Wetzels, JF | 1 |
| Schillaci, G | 1 |
| Ferrucci, L | 2 |
| Serro-Azul, JB | 1 |
| de Paula, RS | 1 |
| Gruppi, C | 1 |
| Pinto, L | 1 |
| Pierri, H | 1 |
| Nussbacher, A | 1 |
| Gebara, O | 1 |
| Moffa, P | 1 |
| Pereira-Barreto, AC | 1 |
| Faulhaber, HD | 1 |
| Bueno, J | 1 |
| Amiguet, JA | 1 |
| Carasusan, J | 1 |
| Cebollada, J | 1 |
| Carretero, J | 1 |
| Penninx, BW | 1 |
| DiBari, M | 1 |
| Chen, JG | 1 |
| Rowen, R | 1 |
| Lewin, A | 1 |
| Shi, H | 1 |
| Ghadanfar, M | 1 |
| Serkova, VK | 2 |
| Sheverda, NV | 1 |
| Pyöräiä, K | 1 |
| Leemhuis, MP | 1 |
| van Damme, KJ | 1 |
| Struyvenberg, A | 2 |
| Webster, J | 1 |
| Jeffers, TA | 1 |
| Galloway, DB | 1 |
| Petrie, JC | 1 |
| Landmann-Suter, R | 1 |
| Neuvonen, PJ | 1 |
| Pentikäinen, PJ | 1 |
| Jounela, AJ | 1 |
| Gudbrandsson, T | 1 |
| Hansson, L | 2 |
| Angelino, PF | 2 |
| Lavezzaro, GC | 1 |
| Castaldo, D | 1 |
| Salerno, L | 1 |
| Licata, G | 1 |
| Sparacino, V | 1 |
| Custro, N | 1 |
| Indovina, I | 1 |
| Hill, P | 1 |
| Schnaper, H | 2 |
| Fitz, A | 2 |
| Frohlich, E | 1 |
| Steele, B | 1 |
| Atlas, SA | 1 |
| Sealey, JE | 1 |
| Moon, C | 1 |
| Mertz, DP | 1 |
| Patzschke, U | 2 |
| Manegold, C | 2 |
| Wolff, G | 1 |
| Terzoli, L | 2 |
| Sala, C | 3 |
| Bianchini, C | 2 |
| Sernesi, L | 2 |
| Sugioka, K | 1 |
| Mao, W | 1 |
| Woods, J | 1 |
| Mueller, RA | 1 |
| Delwiche, F | 1 |
| Staroukine, M | 1 |
| Telerman, M | 1 |
| Verniory, A | 1 |
| Sullivan, JM | 1 |
| De Chătel, R | 1 |
| Flammer, J | 1 |
| Reubi, F | 1 |
| Maus, Y | 1 |
| Rorive, G | 1 |
| de Pasquale, C | 1 |
| Currò, F | 1 |
| Amadeo, A | 1 |
| Oster, JR | 1 |
| Michael, UF | 1 |
| Bolton, SM | 1 |
| Burton, ZC | 1 |
| Stambaugh, JE | 1 |
| Morledge, J | 1 |
| Thomas, JC | 1 |
| Overturf, ML | 1 |
| Zama, A | 1 |
| Kubik, M | 1 |
| Kendall, M | 1 |
| Ebbutt, A | 1 |
| John, V | 1 |
| Teeuw, AH | 1 |
| Bateman, DN | 1 |
| Dean, CR | 1 |
| Mucklow, JC | 1 |
| Bulpitt, CJ | 1 |
| Dollery, CT | 1 |
| Clark, EC | 1 |
| Podolsky, S | 1 |
| Thompson, EJ | 1 |
| Rubegni, M | 2 |
| Luna, RL | 2 |
| Faerchtein, I | 1 |
| de Vasconcelos, EM | 1 |
| Arslanian, L | 1 |
| de La Nuez, SB | 1 |
| Pereira, WQ | 1 |
| Puppin, S | 1 |
| Campos, JC | 1 |
| Roque, AF | 1 |
| Kastansky, I | 1 |
| Moyer, JP | 1 |
| Pittman, AW | 2 |
| Belasco, RN | 1 |
| Woods, JW | 2 |
| Lawton, WJ | 1 |
| Grant, C | 2 |
| Witte, DL | 2 |
| Albanesi, FM | 1 |
| Albuquerque, DC | 1 |
| Rocha, PJ | 1 |
| Benchimol, CB | 1 |
| Schlesinger, P | 1 |
| Dirix, R | 1 |
| Savoye, D | 1 |
| Tyberghein, JM | 1 |
| van Rooijen, GJ | 1 |
| Mujagic, M | 1 |
| Grimm, M | 1 |
| Morgan, TO | 2 |
| Adam, WR | 1 |
| Hodgson, N | 1 |
| Myers, J | 1 |
| van Leeuwen, K | 1 |
| Tiggeler, RG | 1 |
| Rosier, JG | 1 |
| Koene, RA | 1 |
| Arena, G | 1 |
| Tedesco, V | 1 |
| Peskoe, ST | 1 |
| McMillan, JH | 1 |
| Lorch, A | 1 |
| Sussman, H | 1 |
| Ozawa, T | 1 |
| Palmer, FJ | 2 |
| Eliahou, HE | 1 |
| Silverberg, DS | 1 |
| Romem, I | 1 |
| Mashiach, S | 1 |
| Serr, DM | 1 |
| Luboshitzky, R | 1 |
| Tal-Or, Z | 1 |
| Barzilai, D | 1 |
| D'Amelio, G | 2 |
| Piccoli, A | 1 |
| Menozzi, L | 1 |
| Benge, W | 1 |
| White, CW | 1 |
| Franz, IW | 1 |
| Lohmann, FW | 1 |
| Bustamante, J | 1 |
| Laso, J | 1 |
| Jaeger, P | 1 |
| Turini, GA | 1 |
| Jéquier, E | 1 |
| Ferguson, RK | 1 |
| Kissin, E | 1 |
| Teicher, A | 1 |
| Stern, N | 1 |
| Takala, J | 1 |
| Niemelä, N | 1 |
| Rosti, J | 1 |
| Sievers, K | 1 |
| Pulliam, CC | 1 |
| Werk, EE | 1 |
| Waider, W | 1 |
| Allen, CA | 1 |
| Stutterheim, A | 1 |
| Carney, S | 1 |
| Gillies, AI | 1 |
| Morgan, T | 1 |
| Mroczek, WJ | 5 |
| Lee, WR | 1 |
| Davidov, ME | 2 |
| Eshelman, FN | 1 |
| Fitzloff, J | 1 |
| Esch, I | 1 |
| Placheta, P | 1 |
| Gaul, G | 1 |
| Lopez-Ovejero, JA | 1 |
| Case, DB | 1 |
| Fagard, R | 2 |
| Amery, A | 3 |
| Lijnen, P | 2 |
| Reybrouck, T | 1 |
| Rev, A | 1 |
| Antonello, A | 1 |
| Campanini, M | 1 |
| Glorioso, S | 1 |
| Borsatti, A | 1 |
| Todesco, S | 1 |
| Hoefnagels, WH | 1 |
| Canavese, JC | 1 |
| Fabre, J | 1 |
| Sunawala, JD | 1 |
| Noronha, JL | 1 |
| Gadgil, UG | 1 |
| Pinto, IJ | 1 |
| Provvedi, D | 1 |
| Bandinelli, C | 1 |
| Bellini, PG | 1 |
| De Mauro, G | 1 |
| Hunyor, SN | 1 |
| Zweifler, AJ | 1 |
| Schork, MA | 1 |
| Ellis, C | 1 |
| Racco, F | 1 |
| Bengtsson, C | 4 |
| Johnsson, G | 2 |
| Sannerstedt, R | 2 |
| Vos, J | 1 |
| Hatt, PY | 1 |
| Leblond, JB | 1 |
| Kloppenborg, PW | 2 |
| Festen, J | 1 |
| van't Laar, A | 1 |
| Benraad, TJ | 2 |
| Gragnoli, G | 1 |
| Puccetti, F | 1 |
| Tanganelli, I | 1 |
| Favilli, R | 1 |
| Nami, R | 1 |
| Wijdeveld, P | 1 |
| Koene, R | 1 |
| Rosenman, RH | 1 |
| Van Es, JC | 1 |
| Pillay, VK | 1 |
| Kyncl, J | 1 |
| Oheim, K | 1 |
| Seki, T | 1 |
| Solles, A | 1 |
| Caldwell, JR | 1 |
| Routh, JI | 1 |
| Lawton, W | 1 |
| Lovell, RR | 1 |
| Weed, SG | 1 |
| Alves, KB | 1 |
| Casarini, DE | 1 |
| da Costa, RH | 1 |
| Plavnik, FL | 2 |
| Portela, JE | 1 |
| Marson, O | 1 |
| Franco, RJ | 1 |
| Sampaio, M | 1 |
| Balbi, AL | 1 |
| Martin, LC | 1 |
| Ménard, J | 2 |
| Chatellier, G | 1 |
| Phillips, RA | 2 |
| Ardeljan, M | 2 |
| Shimabukuro, S | 2 |
| Goldman, ME | 2 |
| Garbowit, DL | 2 |
| Eison, HB | 2 |
| Vega Fernández, M | 1 |
| Virgós Lamela, A | 1 |
| Gil de la Peña, M | 1 |
| Lee, HB | 1 |
| Langford, H | 2 |
| Petrovitch, H | 1 |
| Vogt, TM | 3 |
| Musso, MN | 2 |
| Camaiti, A | 1 |
| Del Rosso, A | 1 |
| Federighi, G | 1 |
| Durel, LA | 1 |
| Hayashi, PJ | 1 |
| Weidler, DJ | 1 |
| Schneiderman, N | 1 |
| Magagna, A | 2 |
| Ponzanelli, F | 1 |
| Cagianelli, A | 2 |
| Cipriani, M | 2 |
| Gandolfi, E | 2 |
| Del Prato, C | 2 |
| Ballestra, AM | 2 |
| Oberman, AS | 1 |
| Plavinik, FL | 1 |
| Rodrigues, CI | 1 |
| Hulley, SB | 6 |
| Black, DM | 3 |
| Cheitlin, MD | 1 |
| Sebastian, A | 1 |
| Seeley, DG | 1 |
| Hearst, N | 1 |
| Fine, R | 1 |
| Hort, JF | 1 |
| Wilkins, HM | 1 |
| Ivashkin, VT | 2 |
| Grigor'ev, IuV | 2 |
| Sinopal'nikov, AI | 2 |
| Korneev, NV | 1 |
| Levitskiĭ, DN | 1 |
| Virs, EA | 1 |
| Anderson, RJ | 1 |
| Duchin, KL | 1 |
| Gore, RD | 1 |
| Herman, TS | 1 |
| Michaels, RS | 1 |
| Nichola, PS | 1 |
| Nolen, TM | 1 |
| Wolfson, P | 1 |
| Wombolt, DG | 1 |
| Zusman, R | 1 |
| Bielmann, P | 1 |
| Leduc, G | 1 |
| Thibault, G | 1 |
| Lepage, J | 1 |
| Davignon, J | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 1 |
| Schneider, KA | 3 |
| Swencionis, C | 1 |
| Knerr, MO | 1 |
| Wilson, MF | 1 |
| Blackshear, J | 1 |
| Parsons, OA | 1 |
| Lovallo, WR | 1 |
| Mathur, P | 1 |
| Winker, MA | 1 |
| Murphy, MB | 1 |
| Labiós, M | 1 |
| Romero, M | 1 |
| Gabriel, F | 1 |
| Fuster, E | 1 |
| Tatay, E | 1 |
| Vallés, R | 1 |
| Guillén Llera, F | 1 |
| Caballero, JC | 1 |
| Guijarro, JL | 1 |
| Reuss, JM | 1 |
| Rodríguez Mañas, L | 1 |
| Sagués, F | 1 |
| Sempere, R | 1 |
| Tobares, N | 1 |
| Vigueras, S | 1 |
| Coca, A | 1 |
| Sobrino, J | 1 |
| Aguilera, MT | 1 |
| Closas, J | 1 |
| Sánchez, M | 1 |
| Urbano-Márquez, A | 1 |
| Martínez de la Iglesia, J | 1 |
| de Diego Cabrera, MS | 1 |
| González Santos, C | 1 |
| Iribarren Marín, MA | 1 |
| Calderón de la Barca Gázquez, JM | 1 |
| Pérula Torres, L | 1 |
| Waldemar, G | 1 |
| Ibsen, H | 1 |
| Strandgaard, S | 1 |
| Andersen, AR | 1 |
| Rasmussen, S | 1 |
| Paulson, OB | 1 |
| Gerstenblith, G | 1 |
| Pili, G | 1 |
| Basciu, M | 1 |
| Siddi, PP | 1 |
| Tamponi, R | 1 |
| Pilgaard, S | 1 |
| Palmelund, VO | 1 |
| Svendsen, TL | 1 |
| Obel, AO | 2 |
| Galderisi, M | 2 |
| Celentano, A | 2 |
| Tammaro, P | 2 |
| Garofalo, M | 2 |
| Mureddu, GF | 2 |
| de Divitiis, O | 2 |
| Berenson, GS | 1 |
| Shear, CL | 1 |
| Chiang, YK | 1 |
| Webber, LS | 1 |
| Voors, AW | 1 |
| Vitols, AV | 1 |
| Skarda, IJ | 1 |
| Liepinia, DJ | 1 |
| Voita, DU | 1 |
| Skards, JV | 1 |
| Kuller, LH | 3 |
| Neaton, J | 1 |
| Dorow, P | 3 |
| Clauzel, AM | 2 |
| Capone, P | 2 |
| Mayol, R | 2 |
| Mathieu, M | 2 |
| Marotta, T | 2 |
| Rubba, P | 1 |
| Conen, D | 1 |
| Rüttimann, S | 1 |
| Noll, G | 1 |
| Schneider, K | 1 |
| Müller, J | 1 |
| Hergueta García de Guadiana, G | 1 |
| Otto, GL | 1 |
| de Carvalho, JG | 1 |
| Laffitte, A | 1 |
| Baroni, G | 1 |
| Chieppa, S | 1 |
| Lobascio, C | 1 |
| Brandini, V | 1 |
| Iarussi, D | 1 |
| Giuliani, F | 1 |
| Langella, S | 1 |
| De Simone, R | 1 |
| Monova, D | 1 |
| Belovezhdov, N | 1 |
| Lakatos, E | 1 |
| Page, LB | 1 |
| Zeller, KR | 1 |
| Von Kuhnert, L | 1 |
| Matthews, C | 1 |
| Burris, JF | 1 |
| Jenkins, P | 1 |
| Rofman, B | 1 |
| Ginsberg, D | 1 |
| Rosenbaum, R | 1 |
| Gabbani, S | 1 |
| Natali, A | 1 |
| Soro, S | 1 |
| Gómez Marino, MA | 1 |
| Alonso Rodríguez, C | 1 |
| Gayán Laviña, R | 1 |
| Jiménez Ramos, A | 1 |
| Fagan, TC | 1 |
| Van Schaik, BA | 4 |
| Donnelly, R | 1 |
| Elliott, HL | 1 |
| Meredith, PA | 1 |
| Reid, JL | 1 |
| Verza, M | 1 |
| Cacciapuoti, F | 1 |
| Spiezia, R | 1 |
| Arpino, G | 1 |
| D'Errico, S | 1 |
| Sepe, J | 1 |
| Varricchio, M | 1 |
| Hoffmann, W | 1 |
| Niarchos, AP | 1 |
| Resnick, LM | 1 |
| Weinstein, DL | 1 |
| Bentivoglio, M | 1 |
| Severin, E | 1 |
| Mladovan, G | 1 |
| Leviashvili, BI | 1 |
| Roja, M | 1 |
| Cumetti, C | 1 |
| Vergani, A | 1 |
| Montanari, C | 1 |
| De Cristofaro, A | 1 |
| Dal Negro, RW | 1 |
| Zoccatelli, O | 1 |
| Pomari, C | 1 |
| Trevisan, F | 1 |
| Turco, P | 1 |
| Maderbacher, H | 1 |
| Eslaminejad, S | 1 |
| Jacob, RG | 2 |
| Shapiro, AP | 2 |
| Reeves, RA | 1 |
| Johnsen, AM | 1 |
| Coburn, PC | 1 |
| Cocco, G | 1 |
| Iselin, HU | 1 |
| Strozzi, C | 1 |
| Cesana, B | 1 |
| Baumeler, HR | 1 |
| Cagli, V | 1 |
| Innocenti, PF | 1 |
| Lamon, KD | 1 |
| Maiorano, G | 2 |
| Contursi, V | 2 |
| Saracino, E | 1 |
| Ricapito, M | 2 |
| Di Lecce, G | 1 |
| Radó, J | 1 |
| Csányi, P | 1 |
| Alberti, D | 3 |
| Beltrami, M | 1 |
| Antiga, F | 1 |
| Bola, U | 1 |
| Caponi, S | 1 |
| De Ranieri, P | 1 |
| Galli, G | 1 |
| Gasparotti, G | 1 |
| Guidicelli, N | 1 |
| Natali, P | 1 |
| Panvini, F | 1 |
| Wolf, R | 1 |
| Dorfman, B | 1 |
| Krakowski, A | 1 |
| Mohallen, KL | 1 |
| do Patrocínio, LL | 1 |
| Célnik, D | 1 |
| Kruczan, DD | 1 |
| Pinheiro, L | 1 |
| Weitzel, LH | 1 |
| Bosco, J | 1 |
| Sekeff, JA | 1 |
| Azevedo, Ade C | 1 |
| Lehmann, P | 1 |
| Hölzle, E | 1 |
| Plewig, G | 1 |
| Bertoni, T | 1 |
| Peloso, A | 1 |
| Francucci, BM | 2 |
| De Ambroggi, L | 1 |
| Jean, T | 1 |
| Etienne, R | 1 |
| Visier, S | 1 |
| Michel, F | 1 |
| Morganti, A | 1 |
| Turolo, L | 1 |
| Palermo, A | 1 |
| Kapocsi, J | 1 |
| Farsang, C | 1 |
| Vizi, ES | 1 |
| Curry, RC | 1 |
| Schwartz, KM | 1 |
| Urban, PL | 1 |
| Maranhão, MF | 1 |
| Nusbaum, IM | 1 |
| Glezer, GA | 2 |
| Levinzon, AM | 2 |
| Armaganijan, D | 1 |
| Sbissa, AS | 1 |
| Savióli Neto, F | 1 |
| Sbissa, L | 1 |
| Batlouni, M | 1 |
| Mastranzo, P | 1 |
| Serrurier, D | 1 |
| Bautier, P | 1 |
| Plouin, PF | 1 |
| Corvol, P | 1 |
| Horning, JR | 1 |
| Zawada, ET | 1 |
| Simmons, JL | 1 |
| Williams, L | 1 |
| McNulty, R | 1 |
| Mikunis, RI | 1 |
| Kaminskaia, NA | 1 |
| Latini, R | 1 |
| Pierandrei, G | 1 |
| Achilli, L | 1 |
| Lombi, V | 1 |
| D'Amico, F | 1 |
| Bartolomei, G | 1 |
| Cagianelli, MA | 1 |
| Cinotti, G | 1 |
| Loni, C | 1 |
| Saba, G | 1 |
| Papi, L | 1 |
| Petrella, V | 1 |
| Marler, MR | 1 |
| Lehoczky, JP | 1 |
| Galletti, F | 1 |
| Strazzullo, P | 1 |
| Gagliardi, R | 1 |
| Siani, A | 1 |
| Iacone, R | 1 |
| Ramirez, JA | 1 |
| Sanjuliani, AF | 1 |
| Fagundes, VG | 1 |
| Bellotti, G | 1 |
| Francischeti, E | 1 |
| Pillegi, F | 1 |
| Feigal, D | 1 |
| Ireland, C | 1 |
| Morledge, JH | 2 |
| Ettinger, B | 1 |
| Aranda, J | 1 |
| McBarron, F | 1 |
| Barra, P | 1 |
| Gorwit, J | 1 |
| Canosa, FL | 1 |
| Savran, SV | 1 |
| McMillen, JI | 1 |
| Marlon, AM | 1 |
| Keenan, RE | 1 |
| Black, PL | 1 |
| Freudenburg, JC | 1 |
| Hill, JA | 1 |
| Holmburg, CE | 1 |
| Reitbrock, MJ | 1 |
| Sullivan, MJ | 1 |
| Thompson, MT | 1 |
| Wright, DL | 1 |
| Capra, A | 1 |
| Staessen, J | 1 |
| Fiocchi, R | 1 |
| M'Buyamba-Kabangu, JR | 1 |
| Chiarappa, R | 2 |
| Balestrazzi, M | 2 |
| Antoncecchi, E | 1 |
| Vitale, P | 1 |
| Agretto, A | 1 |
| De Stefano, R | 1 |
| Manzo, M | 1 |
| Villani, C | 1 |
| Russo, G | 1 |
| Libretti, A | 2 |
| Catalano, M | 2 |
| Franchi, F | 1 |
| Bisi, G | 1 |
| Fabbri, G | 1 |
| Pedenovi, P | 1 |
| Lo Sapio, P | 1 |
| Matassi, L | 1 |
| Righi, D | 1 |
| Galanti, G | 1 |
| Carney, SL | 1 |
| Novo, S | 2 |
| Giannola, A | 2 |
| Immordino, R | 2 |
| Strano, A | 2 |
| Mart'ianova, II | 1 |
| Shcheplikova, TM | 1 |
| Acquarone, N | 1 |
| Vinciguerra, G | 1 |
| Crisalli, MP | 1 |
| Maxwell, MH | 1 |
| Saunders, E | 1 |
| Brand, RJ | 1 |
| Greenlick, M | 2 |
| Hughes, G | 1 |
| Smith, J | 1 |
| Mussi, A | 1 |
| Petrelli, G | 1 |
| Loiacono, N | 1 |
| Bovenzi, F | 1 |
| Ikram, H | 2 |
| Espiner, EA | 2 |
| Nicholls, MG | 2 |
| Feigal, DW | 1 |
| Moser, M | 1 |
| Poulter, NR | 1 |
| Sanderson, JE | 1 |
| Caponnetto, S | 1 |
| Bafico, GL | 1 |
| Bertulla, A | 1 |
| Camerieri, A | 1 |
| Gatto, E | 1 |
| Gentile, A | 1 |
| Livi, S | 1 |
| Mereto, PE | 1 |
| Budriesi, N | 1 |
| Adalio, G | 1 |
| Zamboni, A | 1 |
| Turina, MC | 1 |
| Vincenzi, M | 1 |
| De Dominicis, E | 1 |
| Mattiello, M | 1 |
| Onza, I | 1 |
| Molteni, A | 1 |
| Oh, MS | 1 |
| Uribarri, J | 1 |
| Alveranga, D | 1 |
| Bazilinski, N | 1 |
| Lazar, I | 1 |
| Carroll, HJ | 1 |
| Nicholson, GD | 1 |
| Fraser, HS | 1 |
| Hassell, TA | 1 |
| Bayley, A | 1 |
| Grimaldi, A | 1 |
| Avantaggiato, F | 1 |
| McDonald, M | 1 |
| Case, J | 1 |
| McGill, E | 1 |
| Allen, R | 1 |
| Bailey-Hoffman, G | 1 |
| Kousch, D | 1 |
| Childs, J | 1 |
| Backhouse, CI | 1 |
| Hosie, J | 1 |
| Tweed, JA | 1 |
| Edwards, KG | 1 |
| Parini, J | 1 |
| Heyden, S | 1 |
| Tyroler, HA | 1 |
| Hames, CG | 1 |
| Hutchinson, R | 1 |
| Pagano, G | 1 |
| Dal Molin, V | 1 |
| Bozzo, C | 1 |
| Carta, Q | 1 |
| Ivanushkina, ZN | 1 |
| Delsignore, R | 1 |
| Baroni, MC | 1 |
| Mineo, F | 1 |
| Crotti, G | 1 |
| Butturini, U | 1 |
| Alvino-Demartino, A | 1 |
| Mappa, R | 1 |
| Donati, C | 1 |
| Conway, J | 1 |
| Campana, C | 1 |
| Ferrario, M | 1 |
| Tondi, C | 1 |
| Montemartini, C | 1 |
| Kale, PA | 1 |
| Soman, RN | 1 |
| Skerrett, FD | 1 |
| Hené, RJ | 1 |
| Van Shaik, BA | 1 |
| Schück, O | 1 |
| Nádvorníková, H | 1 |
| Westerman, RF | 1 |
| Schouten, JA | 1 |
| Hengeveld, WL | 1 |
| Leclercq, RM | 1 |
| Gullotti, D | 1 |
| Scali, G | 1 |
| Del Vita, M | 1 |
| Bompani, R | 1 |
| Consoli, G | 1 |
| Di Martino, G | 1 |
| Stewart, DE | 1 |
| Farrier, N | 1 |
| Caggiula, A | 1 |
| Borhani, N | 1 |
| Dunkle, S | 1 |
| Gurland, B | 1 |
| Pulido, M | 1 |
| Rotatori, P | 1 |
| Frausini, G | 1 |
| Barone, A | 1 |
| Gaggi, S | 1 |
| Greenwald, SE | 1 |
| Berry, CL | 1 |
| Ramsey, RE | 1 |
| Gustavsen, WR | 1 |
| Kuntzmann, F | 1 |
| Reville, P | 1 |
| Kurtz, T | 1 |
| Jahn, H | 1 |
| Stahl, J | 1 |
| Kilcoyne, MM | 1 |
| Thomson, GE | 1 |
| Branche, G | 1 |
| Williams, M | 1 |
| Garnier, C | 1 |
| Chiles, B | 1 |
| Soland, T | 1 |
| Berg, KJ | 1 |
| Gisholt, K | 1 |
| Wideroe, TE | 1 |
| Guazzi, M | 1 |
| Polese, A | 1 |
| Fiorentini, C | 1 |
| Magrini, F | 1 |
| Leibel, BA | 1 |
| Amery, AK | 1 |
| Bossaert, H | 2 |
| Fagard, RH | 1 |
| Verstraete, M | 2 |
| Castenfors, J | 1 |
| Johnsson, H | 1 |
| Orö, L | 1 |
| Garetto, G | 1 |
| Gyntelberg, F | 1 |
| Lung-Johansen, P | 1 |
| Comerford, MB | 1 |
| Pringle, A | 1 |
| Puska, P | 1 |
| Mustaniemi, H | 1 |
| Distler, A | 1 |
| Dalla Volta, S | 1 |
| De Longhi, B | 1 |
| Razzolini, R | 1 |
| Perrotta, P | 1 |
| Rawlins, MD | 1 |
| Curtis, J | 1 |
| Horrigan, F | 1 |
| Ahearn, D | 1 |
| Varney, R | 1 |
| Sandler, SG | 1 |
| Tashian, RE | 1 |
| Yu, YS | 1 |
| Dejaco, RM | 1 |
| Hartl, O | 1 |
| Carstens, E | 1 |
| Haller, J | 1 |
| Erina, EV | 1 |
| Shepeleva, OG | 1 |
| Louis, WJ | 1 |
| Doyle, AE | 1 |
| Dawborn, JK | 1 |
| Johnston, CI | 1 |
| Vaughan, ED | 1 |
| Gavras, I | 1 |
| Bühler, FR | 1 |
| Baer, L | 1 |
| du Burger, PD | 1 |
| Teodoresco, P | 1 |
| Câmpeanu, A | 1 |
| Kjaerulff, J | 1 |
| Lyngsoe, J | 1 |
| Dustan, HR | 1 |
| Tarazi, RC | 1 |
| Bravo, EL | 1 |
| Fagerberg, SE | 1 |
| Göransson, K | 1 |
| Fotiu, S | 1 |
| Richardson, DW | 2 |
| Freund, J | 1 |
| Gear, AS | 1 |
| Mauck, HP | 1 |
| Preston, LW | 1 |
| Froment, R | 1 |
| Froment, A | 1 |
| Zech, P | 1 |
| Schwartz, AB | 2 |
| Kim, KE | 2 |
| Swartz, C | 2 |
| Feltkamp, TE | 1 |
| Nieuwenhuis, MG | 1 |
| Ikeda, T | 1 |
| Verstreken, G | 1 |
| Hutchison, JC | 1 |
| Wilkinson, WH | 1 |
| Lintgen, AB | 1 |
| Sung, PK | 1 |
| Samet, P | 1 |
| Yeh, BK | 1 |
| Enger, E | 1 |
| Bartorelli, C | 1 |
| McKenna, TJ | 2 |
| Donohoe, JF | 1 |
| Brien, TG | 2 |
| Healy, JJ | 2 |
| Canning, BS | 2 |
| Muldowney, FP | 2 |
| Kishimoto, M | 1 |
| Risse, S | 1 |
| Barnett, CF | 1 |
| Gantt, CL | 1 |
| Abitbol, L | 1 |
| Pereira, AF | 1 |
| Villela, R | 1 |
| Abrantes, IB | 1 |
| Villela, AA | 1 |
| Johnson, P | 1 |
| Kitchin, AH | 1 |
| Lowther, CP | 1 |
| Turner, RW | 1 |
| Avanzi, G | 1 |
| Mathur, MN | 1 |
| Bedi, HK | 1 |
| Enk, B | 1 |
| Persson, I | 4 |
| Thomson, AE | 1 |
| Duffy, GJ | 1 |
| Juhl, F | 1 |
| Gastaldi, L | 1 |
| Buccianti, G | 1 |
| Rizzato, G | 1 |
| Marazzini, L | 1 |
| Lund-Johansen, P | 1 |
| Parsons, WB | 1 |
| Bergener, M | 1 |
| Mittelstaedt, A | 1 |
| Paz-Martinez, V | 1 |
| Cachin, JC | 1 |
| Grimaldi, MG | 2 |
| Scalabrino, R | 1 |
| Holtmeier, HJ | 1 |
| Steim, H | 1 |
| Danner, H | 1 |
| Marongiu, F | 1 |
| Königstein, RP | 1 |
| Andersen, OO | 2 |
| Blom van Assendelft, PM | 1 |
| Hart, PG | 1 |
| Pinacci, U | 1 |
| Guida, B | 1 |
| Forin, G | 1 |
| Permutti, B | 1 |
| Iser, H | 1 |
| Marburger, P | 1 |
| Tobian, L | 1 |
| Momose, M | 1 |
| Takasawa, A | 1 |
| Imamura, B | 1 |
| Hasegawa, M | 1 |
| Asano, T | 1 |
| Garde, K | 1 |
| Lindahl, A | 1 |
| Domart, A | 1 |
| Fillastre, JP | 1 |
| Heimsoth, V | 1 |
| Hartmann, F | 1 |
| Gómez Francisco, A | 1 |
| Eisenberg, R | 1 |
| Warembourg, H | 1 |
| Delomez, M | 1 |
| Fris, T | 1 |
| Lintrup, J | 1 |
| Nissen, NI | 1 |
| Remenchik, AP | 1 |
| Mutalik, GS | 1 |
| Angelo, TL | 1 |
| Sappington, RF | 1 |
| Hueber, EF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02841280] | Phase 2 | 160 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| CSP #597 - Diuretic Comparison Project[NCT02185417] | Phase 3 | 13,523 participants (Actual) | Interventional | 2016-06-15 | Completed | ||
| Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide[NCT02100462] | Phase 4 | 30 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension[NCT04218552] | Phase 2 | 176 participants (Actual) | Interventional | 2020-02-25 | Completed | ||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination With Amiloride in Multiple Doses on Blood Pressure in Patients With Primary Hypertension: a Factorial Randomized Controlled Trial.[NCT03928145] | Phase 3 | 84 participants (Anticipated) | Interventional | 2019-11-13 | Recruiting | ||
| A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study[NCT00971165] | Phase 3 | 655 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension[NCT03897868] | Phase 2 | 248 participants (Actual) | Interventional | 2019-03-21 | Completed | ||
| A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605[NCT02916602] | Phase 3 | 340 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension[NCT00846365] | Phase 3 | 1,085 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828] | Phase 3 | 153 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy[NCT03226340] | Phase 4 | 170 participants (Anticipated) | Interventional | 2015-12-02 | Recruiting | ||
| Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)[NCT02847338] | Phase 4 | 1,320 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| The Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making About Antihypertensive Medication: A Pilot Study[NCT03156634] | 118 participants (Actual) | Interventional | 2017-04-15 | Completed | |||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial[NCT01896661] | Phase 3 | 53 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.[NCT00408512] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension[NCT00696384] | Phase 3 | 418 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study[NCT00970931] | Phase 3 | 730 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)[NCT03764020] | Phase 3 | 320 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| MI-Plus: Web-enhanced Guideline Implementation for Post MI CBOC Patients[NCT00126750] | 847 participants (Actual) | Interventional | 2003-09-30 | Completed | |||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension[NCT01033071] | Phase 3 | 1,071 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Neural Mechanisms of Thiazide-induced Insulin Resistance[NCT00353652] | Phase 4 | 166 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension[NCT00818883] | Phase 3 | 609 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms[NCT00129909] | Phase 4 | 2,081 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Prospective Evaluation of Adrenal Function After Living Donor Nephrectomy With or Without Ligation of the Adrenal Vein[NCT00251836] | 30 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| [NCT00000525] | Phase 3 | 233 participants (Actual) | Interventional | 1986-07-31 | Completed | ||
| [NCT00000522] | Phase 2 | 0 participants | Interventional | 1985-08-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction[NCT00382161] | Phase 3 | 20 participants (Anticipated) | Interventional | 2006-10-31 | Withdrawn (stopped due to not enough patients meeting inclusion criteria) | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [NCT00005122] | 0 participants | Observational | 1958-07-31 | Completed | |||
| Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108] | 200 participants (Anticipated) | Observational | 2018-02-24 | Recruiting | |||
| Hypertension Prevalence, Treatment Patterns and Outcomes in Long-Term Care Facilities[NCT03046420] | 139 participants (Actual) | Observational | 2017-01-26 | Completed | |||
| The Bogalusa Heart Study[NCT00005129] | 11,737 participants (Actual) | Observational | 1972-06-30 | Active, not recruiting | |||
| [NCT00000487] | Phase 3 | 0 participants | Interventional | 1972-06-30 | Completed | ||
| Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial[NCT03015311] | 8,000 participants (Anticipated) | Interventional | 2017-01-15 | Active, not recruiting | |||
| [NCT00000499] | Phase 2 | 0 participants | Interventional | 1980-09-30 | Completed | ||
| [NCT00000485] | Phase 3 | 0 participants | Interventional | 1971-05-31 | Completed | ||
| Hemodynamic Effect of Intrathecal Clonidine in Hypertensive Subjects: A Pilot Study to Assess Its Effectiveness in Hypertensive Subjects With Poor Blood Pressure Control (Phase II)[NCT01297335] | Phase 2 | 10 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Chlorthalidone | -11.0 |
| Placebo | -0.5 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | Liters (Mean) | ||
|---|---|---|---|
| Change in body volume 4 weeks from baseline | Change in body volume 8 weeks from baseline | Change in body volume 12 weeks from baseline | |
| Chlorthalidone | -1.1 | -1.7 | -2 |
| Placebo | 0.2 | 0.3 | 0.3 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Percent change 4 weeks from baseline in aldosterone | Percent change 8 weeks from baseline in aldosterone | Percent change 12 weeks from baseline in aldosterone | Percent change 4 weeks from baseline in renin | Percent change 8 weeks from baseline in renin | Percent change 12 weeks from baseline in renin | |
| Chlorthalidone | 57 | 65 | 52 | 57 | 67 | 64 |
| Placebo | 16 | 12 | 8 | 14 | 5 | 15 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change in NTproBNP (Geometric Mean) | ||
|---|---|---|---|
| Percent change from 4 weeks from baseline in NTproBNP | Percent change from 8 weeks from baseline in NTproBNP | Percent change from 12 weeks from baseline in NTproBNP | |
| Chlorthalidone | -25 | -32 | -30 |
| Placebo | -14 | 5 | -11 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change in UACR (Mean) | ||
|---|---|---|---|
| Percent change in albuminuria 4 weeks from baseline in UACR | Percent change in albuminuria 8 weeks from baseline in UACR | Percent change in albuminuria 12 weeks from baseline in UACR | |
| Chlorthalidone | -41 | -45 | -52 |
| Placebo | -7 | -3 | -4 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 4.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -33.0 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -34.1 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -26.9 |
The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 8.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -37.6 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -38.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -31.5 |
The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -14.4 | -15.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.8 | -16.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.8 | -12.1 |
The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -25.0 | -27.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -25.5 | -28.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -19.2 | -21.1 |
The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.9 | -15.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.4 | -16.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.5 | -12.0 |
The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -24.1 | -26.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -24.4 | -27.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -18.4 | -20.7 |
The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -14.2 | -15.3 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.7 | -16.6 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.7 | -12.1 |
The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -24.5 | -26.7 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -25.1 | -28.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -18.9 | -21.0 |
The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.4 | -14.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -13.3 | -15.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -9.6 | -11.8 |
The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -22.3 | -25.2 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -21.9 | -26.3 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.6 | -19.7 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.4 | -14.6 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.6 | -15.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.9 | -12.0 |
The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=223; n=227; n=219) | Week 8 (n=290; n=278; n=281) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -22.4 | -24.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -23.6 | -26.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.4 | -19.6 |
The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=360; n=347; n=352) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | -13.6 | -16.1 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | -14.2 | -16.5 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -10.4 | -12.8 |
Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or <130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 51.3 | 58.1 | 68.8 | 69.4 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 48.5 | 61.4 | 65.4 | 68.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 35.9 | 44.6 | 55.5 | 54.7 |
Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as <90 mm Hg for participants without diabetes or CKD or <80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 63.6 | 71.4 | 77.9 | 79.9 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 66.2 | 73.8 | 76.9 | 79.1 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 47.8 | 58.2 | 66.9 | 66.0 |
Percentage of participants who achieve a clinic systolic blood pressure response, defined as <140 mm Hg for participants without diabetes or CKD or <130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 2 (n=343; n=334; n=345) | Week 4 (n=360; n=347; n=352) | Week 6 (n=362; n=350; n=353) | Week 8 (n=363; n=350; n=353) | |
| Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD | 60.3 | 66.1 | 76.8 | 76.0 |
| Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD | 57.2 | 68.9 | 73.4 | 76.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 44.9 | 52.3 | 64.9 | 64.6 |
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 69.3 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 78.4 |
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 58.7 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 73.0 |
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 80.0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 87.8 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Adverse Events | Adverse Events Leading to Discontinuation | Serious Adverse Events | Serious Adverse Events Leading to Discontinuation | Death | |
| Azilsartan Medoxomil + Chlorthalidone | 68 | 17 | 8 | 5 | 0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 58 | 15 | 9 | 4 | 1 |
The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase. (NCT00696384)
Timeframe: Double-blind Baseline (Week 26) and Week 32.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil QD - Double Blind Reversal Phase | 0.14 |
| Placebo QD - Double Blind Reversal Phase | 7.92 |
The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase. (NCT00696384)
Timeframe: Double-blind Baseline (Week 26) and Week 32.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil QD - Double Blind Reversal Phase | 0.59 |
| Placebo QD - Double Blind Reversal Phase | 12.97 |
The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26. (NCT00696384)
Timeframe: Baseline and Week 26.
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan Medoxomil QD - Open Label Phase | -15.76 |
The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26. (NCT00696384)
Timeframe: Baseline and Week 26.
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan Medoxomil QD - Open Label Phase | -23.01 |
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event. (NCT00696384)
Timeframe: Baseline to Week 26
| Intervention | participants (Number) | |
|---|---|---|
| Serious Adverse Events | Treatment Emergent Adverse Events | |
| Azilsartan Medoxomil QD - Open Label Phase | 8 | 226 |
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event. (NCT00696384)
Timeframe: Double-blind Baseline/Week 26 to Week 32
| Intervention | participants (Number) | |
|---|---|---|
| Serious Adverse Events | Treatment Emergent Adverse Events | |
| Azilsartan Medoxomil QD - Double Blind Reversal Phase | 0 | 42 |
| Placebo QD - Double Blind Reversal Phase | 1 | 38 |
The investigators used an intent-to-treat approach for our main analysis, basing our outcome measures on provider's eligible patient population in each of the clinics. Performance improvement was calculated at the change (before vs after the intervention) the percentage of provider's patients with each clinical indicator. 1) change in the percentage of patients with improvements in LDL. Improvement defined as LDL-C level < previous 18 mos; 2) Change in the percentage of patients with improvements in A1c. Improvement defined as HbA1c level < previous 18 mos; 3) Change in percentage of patients prescribed Beta Blockers; 4) Change in the percentage of patients prescribed Statins; 5) Change in the percentage of patients prescribed ACEI or ARB; 6) Change in percentage of patients reaching target goal for LDL-C (<100mg/dL); 7) Change in percentage of patients reaching target goal for HbA1c (<8%). (NCT00126750)
Timeframe: 1/1/02 - 12/31/08
| Intervention | percentage of provider's patients (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Change in % of patients w/ improvement in LDL | Change in % of patients w/ improvement in HbA1c | Change in % of patients prescribed B-Blockers | Change in % patients prescribed Statins | Change in % of patients prescribed ACEI or ARB | Change in % of patients reaching target LDL | Change in % of patients reaching target HbA1c | |
| Control | 2.1 | 9.5 | 12.1 | 7.5 | 2.9 | 15.2 | .7 |
| Intervention | 2.8 | 11.5 | 15.5 | 8.5 | 4.9 | 19.9 | 6 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -19.4 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.7 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.2 |
The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -33.9 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.3 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -27.5 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -20.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -21.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.0 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -35.3 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -37.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -28.8 |
The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -17.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -18.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -14.0 |
The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -29.6 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -31.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -23.9 |
The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -19.8 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -16.0 |
The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -32.9 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -34.9 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -25.9 |
The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -20.4 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -22.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -17.5 |
The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -36.2 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -38.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -29.7 |
The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -42.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -44.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -37.1 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | 1 to 2 Hour (n=232; n=214; n=238) | 2 to 3 Hour (n=232; n=214; n=238) | 3 to 4 Hour (n=232; n=214; n=238) | 4 to 5 Hour (n=232; n=214; n=238) | 5 to 6 Hour (n=232; n=214; n=238) | 6 to 7 Hour (n=232; n=214; n=238) | 7 to 8 Hour (n=232; n=214; n=238) | 8 to 9 Hour (n=232; n=214; n=238) | 9 to 10 Hour (n=232; n=214; n=238) | 10 to 11 Hour (n=232; n=214; n=238) | 11 to 12 Hour (n=232; n=214; n=238) | 12 to 13 Hour (n=232; n=214; n=238) | 13 to 14 Hour (n=232; n=214; n=238) | 14 to 15 Hour (n=232; n=214; n=238) | 15 to 16 Hour (n=232; n=214; n=238) | 16 to 17 Hour (n=232; n=214; n=238) | 17 to 18 Hour (n=231; n=214; n=238) | 18 to 19 Hour (n=232; n=214; n=238) | 19 to 20 Hour (n=232; n=214; n=238) | 20 to 21 Hour (n=232; n=214; n=238) | 21 to 22 Hour (n=232; n=214; n=238) | 22 to 23 Hour (n=232; n=214; n=238) | 23 to 24 Hour (n=232; n=214; n=238) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -18.2 | -18.8 | -21.2 | -20.8 | -21.7 | -20.9 | -20.8 | -20.5 | -20.7 | -21.0 | -19.7 | -19.3 | -19.2 | -19.6 | -18.9 | -17.8 | -17.2 | -16.6 | -17.4 | -17.8 | -16.7 | -17.8 | -19.5 | -20.2 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -20.4 | -20.9 | -23.4 | -23.7 | -23.7 | -23.6 | -22.0 | -21.9 | -21.5 | -21.9 | -20.7 | -21.2 | -20.3 | -19.5 | -19.7 | -18.6 | -16.9 | -17.1 | -18.1 | -18.5 | -18.4 | -18.5 | -19.6 | -21.0 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -15.2 | -15.9 | -17.7 | -18.2 | -17.9 | -19.0 | -18.0 | -17.7 | -17.9 | -18.3 | -16.7 | -17.0 | -16.0 | -15.3 | -15.4 | -14.5 | -13.9 | -13.2 | -14.3 | -13.8 | -13.9 | -14.7 | -15.6 | -16.4 |
The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.
| Intervention | mmHg (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 to 1 Hour (n=232; n=212; n=237) | 1 to 2 Hour (n=232; n=214; n=238) | 2 to 3 Hour (n=232; n=214; n=238) | 3 to 4 Hour (n=232; n=214; n=238) | 4 to 5 Hour (n=232; n=214; n=238) | 5 to 6 Hour (n=232; n=214; n=238) | 6 to 7 Hour (n=232; n=214; n=238) | 7 to 8 Hour (n=232; n=214; n=238) | 8 to 9 Hour (n=232; n=214; n=238) | 9 to 10 Hour (n=232; n=214; n=238) | 10 to 11 Hour (n=232; n=214; n=238) | 11 to 12 Hour (n=232; n=214; n=238) | 12 to 13 Hour (n=232; n=214; n=238) | 13 to 14 Hour (n=232; n=214; n=238) | 14 to 15 Hour (n=232; n=214; n=238) | 15 to 16 Hour (n=232; n=214; n=238) | 16 to 17 Hour (n=232; n=214; n=238) | 17 to 18 Hour (n=231; n=214; n=238) | 18 to 19 Hour (n=232; n=214; n=238) | 19 to 20 Hour (n=232; n=214; n=238) | 20 to 21 Hour (n=232; n=214; n=238) | 21 to 22 Hour (n=232; n=214; n=238) | 22 to 23 Hour (n=232; n=214; n=238) | 23 to 24 Hour (n=232; n=214; n=238) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -33.6 | -33.4 | -36.7 | -36.6 | -36.8 | -37.2 | -36.3 | -37.2 | -37.3 | -36.9 | -36.1 | -35.2 | -34.8 | -34.1 | -33.4 | -30.9 | -29.6 | -28.5 | -29.5 | -29.7 | -28.2 | -30.6 | -32.9 | -33.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.2 | -36.4 | -39.3 | -40.3 | -40.8 | -41.2 | -38.6 | -38.5 | -38.1 | -38.0 | -37.6 | -38.2 | -36.2 | -35.3 | -35.0 | -32.9 | -31.1 | -30.8 | -31.9 | -32.5 | -31.2 | -32.8 | -34.0 | -35.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -26.8 | -27.5 | -30.0 | -29.6 | -30.1 | -31.5 | -29.8 | -29.7 | -30.5 | -30.8 | -29.4 | -29.3 | -27.7 | -26.4 | -26.2 | -25.3 | -24.5 | -23.1 | -24.3 | -23.5 | -23.0 | -24.6 | -25.9 | -26.1 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -14.9 | -17.0 | -18.8 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -15.8 | -17.7 | -20.5 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -11.7 | -13.9 | -16.4 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4 and Week 8.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | -34.7 | -39.1 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | -36.7 | -39.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | -29.7 | -33.5 |
Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 81.3 | 88.1 | 91.3 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 84.8 | 87.3 | 92.4 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 74.4 | 81.0 | 84.7 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 89.2 | 90.7 | 94.5 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 89.7 | 90.9 | 95.8 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 85.2 | 87.8 | 91.5 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 4 (n=343; n=330; n=352) | Week 8 (n=344; n=330; n=353) | Week 12 (n=344; n=330; n=354) | |
| Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD | 87.8 | 93.3 | 93.0 |
| Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD | 90.0 | 92.4 | 94.2 |
| Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD | 79.8 | 85.6 | 89.3 |
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 127.4 |
| Study #1: Spironolactone (SP), Titrated Dose | 128.6 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 123.5 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 121.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 119.8 |
assessment of insulin resistance calculated by multiplying fasting plasma insulin (mU/l) with fasting plasma glucose (mmol/l) divided by 22.5. (NCT00353652)
Timeframe: 3 months
| Intervention | mU/l*mmol/l (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 1.91 |
| Study #1: Spironolactone (SP), Titrated Dose | 1.33 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 1.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 0.85 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 1.42 |
fasting plasma insulin (NCT00353652)
Timeframe: 3 months
| Intervention | mU/liter (Median) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 8.24 |
| Study #1: Spironolactone (SP), Titrated Dose | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d | 7.6 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 4.87 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 6.8 |
slope relating percent change in SNA (% change in total activity from baseline) to diastolic BP. (NCT00353652)
Timeframe: 3 months
| Intervention | % change from baseline per mmHg (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | -9.1 |
| Drug: Study #1: Spironolactone (SP), Titrated Dose | -15.2 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | -12.9 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | -11.3 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | -12.0 |
(NCT00353652)
Timeframe: Measured at 3 months
| Intervention | bursts/min (Mean) |
|---|---|
| Study#1: Chlorthalidone (CTD), Titrated Dose | 46 |
| Study #1: Spironolactone (SP), Titrated Dose | 40 |
| Study# 2 Chlorthalidone (CTD), Fixed Dose | 49 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose | 42 |
| Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose | 52 |
The change in 24-hour mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.9 | -12.6 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -14.7 | -15.2 |
The change in 24-hour mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179, n=162) | Week 10 (n=227, n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -19.9 | -22.4 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -25.7 | -26.6 |
The change in trough diastolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.6 | -12.7 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.2 | -15.1 |
The change in trough systolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179, n=162) | Week 10 (n=227, n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -18.4 | -21.4 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -25.7 | -25.6 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.1 | -12.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.4 | -15.8 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -20.2 | -22.8 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -27.0 | -27.5 |
The change in the 12-hour mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.1 | -12.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.7 | -16.0 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -10.3 | -11.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -12.8 | -13.8 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -18.8 | -21.1 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -21.8 | -23.8 |
The change in the 12-hour mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=179; n=162) | Week 10 (n=227; n=230) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -20.6 | -23.2 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -27.7 | -28.0 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated including final visit relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -11.2 | -13.7 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -15.0 | -16.4 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.
| Intervention | mmHg (Least Squares Mean) | |
|---|---|---|
| Week 6 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | -29.5 | -32.8 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | -35.1 | -37.8 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as <90 mm Hg for participants without diabetes or chronic kidney disease or <80 mm Hg for participants with diabetes or chronic kidney disease. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 41.3 | 57.4 | 59.2 | 72.3 | 75.0 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 49.1 | 71.9 | 76.6 | 81.4 | 82.7 |
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at each week indicated, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease or <130/80 mm Hg for participants with diabetes or chronic kidney disease[GFR <60 mL/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) >200 mg albumin/g creatinine at Screening.] Systolic/diastolic blood pressure is the average of the 3 serial trough sitting systolic/diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 24.6 | 45.3 | 45.9 | 59.2 | 62.3 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 27.2 | 58.6 | 64.1 | 72.5 | 71.5 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as <140mm Hg without diabetes or chronic kidney disease or <130/mm Hg with diabetes or chronic kidney disease. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (n=283; n=276) | Week 4 (n=292; n=289) | Week 6 (n=295; n=292) | Week 8 (n=295; n=292) | Week 10 (n=295; n=292) | |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | 34.1 | 54.7 | 58.2 | 65.4 | 69.9 |
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | 33.2 | 68.2 | 71.9 | 79.7 | 76.9 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -1.27 |
| Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.57 |
| Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.09 |
| Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.07 |
| Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 6.3 |
| Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -10.98 |
| Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.05 |
| Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.05 |
| Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.02 |
| Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.04 |
| Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.71 |
| Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 1.23 |
| Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.20 |
| Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.95 |
| Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -6.70 |
| Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -7.12 |
| Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -1.39 |
| Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.67 |
| Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.46 |
| Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -3 |
| Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.15 |
| Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 2.46 |
| Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Lidocaine | 87 |
| Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 1 year Change Work Activities | 1 year Change General health perception | |
| Lidocaine | -1.37 | -0.28 |
| Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 6-Week Change Work activities | 6-Week Change General health perception | |
| Lidocaine | 2.71 | -0.004 |
| Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
| Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
| Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
| Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
| Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
"Subjects baseline blood pressure (systolic blood pressure (SBP), and diastolic blood pressure (DBP)), and blood pressures after clonidine injection was compared against baseline to assess efficacy of clonidine in refractory hypertensive subjects. Subject's blood pressure was monitored continuously after intrathecal injection of clonidine until subjects blood pressure nadir and return to pre clonidine injection level. The mean value reported below are the average changes in blood pressure from baseline (pre clonidine injection) in both SBP and DBP during post clonidine injection blood pressure monitoring for 4 hours.~Blood pressure measurements were collected every 10 minutes for first hour after injection, and every 15 minutes after the first hour, up to 4 hours were averaged to report the change from baseline." (NCT01297335)
Timeframe: Baseline, Every 10 Minutes for first hour after clonidine injection, and every 15 minutes after first hour, until 4 hours after clonidine injection
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in mean SBP after clonidine injection | Change in DBP after clonidine injection | |
| Intrathecal Clonidine | 79 | 37 |
Subjects were asked to rate severity of two of the most common side effects of clonidine, sedation and sensation of dry mouth, at pre and post (1 hour after) intrathecal administration of clonidine. The mean changes between pre and post injection VAS ratings of sedation and sensation of dry mouth are reported below. The VAS scale ranges from 1 to 10 cm, with higher values indicating higher level of sedation and higher level of dry mouth. (NCT01297335)
Timeframe: Before clonidine injection (Baseline), and at 1 hour after clonidine injection.
| Intervention | cm (Mean) | |
|---|---|---|
| Change in level of sedation | Change in sensation of dry mouth | |
| Intrathecal Clonidine | 3.36 | 3.47 |
Likert scale is 11 point digital pain rating system that asks subjects to rate their pain from 0 to 10. Rating of 0 means no pain at all, and in increasing order, 10 would mean worst pain imaginable/ unbearable pain. (NCT01297335)
Timeframe: Pre-dose and 1 hour post injection.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Pre-injection average Likert score | Post-injection average Likert score | |
| Intrathecal Clonidine | 6.5 | 3.6 |
75 reviews available for chlorthalidone and Hypertension
| Article | Year |
|---|---|
Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indap | 2022 |
Management of hypertension in advanced kidney disease.
Topics: Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antag | 2022 |
Revisiting diuretic choice in chronic kidney disease.
Topics: Acute Kidney Injury; Chlorthalidone; Diuretics; Humans; Hypertension; Renal Insufficiency, Chronic; | 2022 |
Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents | 2022 |
[Which is better? Chlorthalidone or Hydrochlorothiazide].
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2023 |
Hypertension in chronic kidney disease-treatment standard 2023.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineral | 2023 |
Arterial Hypertension-clinical trials update 2023.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Humans; Hypertens | 2023 |
Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2019 |
Approaches for the Management of Resistant Hypertension in 2020.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Drug Therapy, Combination; Human | 2020 |
Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Dr | 2020 |
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2020 |
Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2021 |
Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Ch | 2021 |
Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2021 |
Superior antihypertensive and cardioprotective effects of chlorthalidone compared with hydrochlorothiazide.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2021 |
Update on Treatment of Hypertension After Renal Transplantation.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hypertension; Kidney Transpl | 2021 |
The Forgotten Antiproteinuric Properties of Diuretics.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Chlorthalidone; | 2021 |
Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Chlorthalidone; Cholesterol; Diuretics; Huma | 2017 |
Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Diuretics, Potassium Spari | 2018 |
Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication.
Topics: Antihypertensive Agents; Bendroflumethiazide; Chlorthalidone; Drug Substitution; Humans; Hypertensio | 2017 |
Azilsartan and Chlorthalidone-new Powerful Fixed dose Antihypertensive Combination.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Chlort | 2018 |
Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics, Potassium Sparing; Drug Therapy, | 2018 |
Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2013 |
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Chlorthal | 2013 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Essential Hypertension; Humans; Hydr | 2014 |
Efficacy of azilsartan medoxomil with chlorthalidone in hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Blood Pressure; Chlorthalidone; Diuretics; | 2014 |
Clinical inquiry: How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?
Topics: Antihypertensive Agents; Chlorthalidone; Evidence-Based Medicine; Humans; Hydrochlorothiazide; Hyper | 2014 |
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
Misconceptions and facts about treating hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2015 |
Hypertension in the geriatric population: a patient-centered approach.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Chlorthalidone; Comorbidity; Diuretics; Frail Elde | 2015 |
Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Topics: Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hypokalemia; I | 2015 |
Evidence-based diuretics: focus on chlorthalidone and indapamide.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indap | 2015 |
Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2015 |
Negative effects of chlorthalidone on sympathetic nervous system and insulin resistance in hypertensive patients may be avoided with spironolactone: further studies are still needed.
Topics: Blood Pressure; Chlorthalidone; Humans; Hypertension; Insulin Resistance; Spironolactone; Sympatheti | 2015 |
[All diuretics used in the treatment of hypertension are not the same].
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Indapamide | 2017 |
Should chlorthalidone be the diuretic of choice for antihypertensive therapy?
Topics: Chlorthalidone; Clinical Trials as Topic; Diuretics; Dose-Response Relationship, Drug; Half-Life; Hu | 2008 |
Treatment of resistant hypertension.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Ambulatory Care; Antihypertensive Agents; Black or African Ame | 2009 |
Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as | 2010 |
ALLHAT: still providing correct answers after 7 years.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bla | 2010 |
Older blood pressure medications-do they still have a place?
Topics: Antihypertensive Agents; Chlorthalidone; Clonidine; Diuretics; Ethacrynic Acid; Guanethidine; Humans | 2011 |
Chlorthalidone: the forgotten diuretic.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2012 |
Edarbyclor: an ARB/chlorthalidone combination for hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Chlorthalidone; Clinical Trials as | 2012 |
Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Humans; Hyd | 2012 |
Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.
Topics: Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Chlorthalidone; Dose-Response Relation | 2012 |
Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Ch | 2012 |
Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease.
Topics: Antihypertensive Agents; Chlorthalidone; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hy | 2012 |
Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Practice Guidelines as Topic; | 2012 |
Module 2: Rethinking the role of thiazide-type diuretics in the management of hypertension: which diuretic is best?
Topics: Antihypertensive Agents; Chlorthalidone; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hyp | 2012 |
Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; Humans; | 2013 |
What are the best first-line antihypertensives: answers and more questions from the ALLHAT study.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cal | 2003 |
NEWER DRUGS IN THE TREATMENT OF HYPERTENSION.
Topics: Antihypertensive Agents; Bretylium Compounds; Chlorothiazide; Chlorthalidone; Diuretics; Drug Therap | 1965 |
Recommendations for the management of special populations: racial and ethnic populations.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African Amer | 2003 |
Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Dose-Response Relation | 2004 |
[Diabetes and drug treatment of hypertension].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benz | 2003 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
Diuretics: drugs of choice for the initial management of patients with hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug T | 2003 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies.
Topics: Antihypertensive Agents; Chlorthalidone; Coronary Disease; Diuretics; Humans; Hypertension; Treatmen | 2004 |
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Evaluation; Humans; Hydroc | 2005 |
Diuretics for hypertension.
Topics: Aged; Antihypertensive Agents; Black or African American; Chlorthalidone; Diuretics; Female; Humans; | 2005 |
[Hypertension combined with atherosclerotic lesions in carotid arteries: should angiotensin converting enzyme inhibitors be prescribed?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Ant | 2005 |
Thiazide diuretics in the treatment of hypertension: an update.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as Topic; Glucose; | 2006 |
Managing diuretic-induced hypokalemia in ambulatory hypertensive patients.
Topics: Aged; Ambulatory Care; Chlorthalidone; Diuretics; Food; Humans; Hydrochlorothiazide; Hypertension; H | 1982 |
Evidence for the efficacy of low-dose diuretic monotherapy.
Topics: Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorot | 1996 |
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1999 |
[Intensive treatment of blood pressure in patients with kidney disease and proteinuria].
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Drug; Enalapril; Glom | 2000 |
Physiologic and biochemical profile of hypertension for rational clinical management.
Topics: Adrenal Gland Diseases; Angiotensins; Body Fluid Compartments; Chlorthalidone; Diuretics; Guanethidi | 1978 |
[Importance of the continuity of anti-hypertension treatment in prevention of ischemic cardiovascular diseases: preliminary note. Controlled study of hypertensive patients treated with amiloride associated with hydrochlorothiazide and chlorthalidone].
Topics: Adult; Aged; Amiloride; Chlorthalidone; Coronary Disease; Drug Therapy, Combination; Female; Humans; | 1978 |
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Dis | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Systolic hypertension in older persons.
Topics: Aged; Aging; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; | 1992 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
Variability in response to drugs.
Topics: Acute Disease; Acylation; Chlorthalidone; Chronic Disease; Depression; Diazoxide; Digoxin; Dose-Resp | 1974 |
[Hypertension--diuretics as antihypertensive agents].
Topics: Aged; Antihypertensive Agents; Arthritis; Benzothiadiazines; Blood Pressure; Chlorothiazide; Chlorth | 1970 |
408 trials available for chlorthalidone and Hypertension
| Article | Year |
|---|---|
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Topics: Aged; Albuminuria; Blood Pressure; Chlorthalidone; Creatinine; Diuretics; Double-Blind Method; Femal | 2021 |
Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2021 |
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Electronic Health Records; Human | 2022 |
Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Female; Humans; Hyperten | 2022 |
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study.
Topics: Black or African American; Chlorthalidone; Genome-Wide Association Study; Glucose; Humans; Hypertens | 2022 |
Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure; Chlorthalidone; Diuretics; Double-Blind Method; Dr | 2022 |
Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combi | 2022 |
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.
Topics: Aged; Bumetanide; Chlorthalidone; Humans; Hypertension; Middle Aged; Renal Insufficiency, Chronic; R | 2022 |
Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus-results from the TRIUMPH randomised controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diabetes Mellitus; Drug Combina | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; H | 2022 |
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Thera | 2023 |
Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial.
Topics: Adult; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Am | 2023 |
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Topics: Aged; Amlodipine; Chlorthalidone; Essential Hypertension; Female; Humans; Hypertension; Leukemia, My | 2023 |
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Topics: Adult; Black or African American; Blood Pressure; Chlorthalidone; Chromosomes, Human, Pair 2; Diuret | 2019 |
Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.
Topics: Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Double-Blind Method; Dru | 2019 |
Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone | 2020 |
Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Dru | 2020 |
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension and diabetes mellitus: results from the PREVER-treatment randomized controlled trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Diabetes Me | 2021 |
Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Dose-Response Relationship, Drug; Double- | 2020 |
Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT).
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hypertension; Treatment | 2021 |
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Dise | 2017 |
Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; | 2017 |
Echocardiographic Left Ventricular Reverse Remodeling After 18 Months of Antihypertensive Treatment in Stage I Hypertension. Results From the Prever-Treatment Study.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Atrial Function, Left; Atrial Remodeling; Blood Pre | 2018 |
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Chlorthalidone; Double-Bli | 2017 |
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Chlorthalidone; Diuretics; Double-Bli | 2018 |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Topics: Aged; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2018 |
S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ant | 2018 |
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYp
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Asian People; Black People; Chlorthali | 2018 |
Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Chlorth | 2018 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Black or Afr | 2018 |
The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation.
Topics: Alkadienes; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Calcium Channel Blo | 2019 |
Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Do | 2019 |
Evaluation of the Patient Activated Learning System (PALS) to improve knowledge acquisition, retention, and medication decision making among hypertensive adults: Results of a pilot randomized controlled trial.
Topics: Antihypertensive Agents; Chlorthalidone; Decision Making; Female; Health Literacy; Humans; Hypertens | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2013 |
Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlor | 2014 |
The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2014 |
Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; | 2014 |
Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Dr | 2014 |
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Acute Coronary Syndrome; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 2014 |
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2014 |
Should thiazide diuretics be given as first line antihypertensive therapy or in addition to other medications?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; General | 2015 |
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Female; Follow-Up St | 2014 |
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Topics: Age Factors; Aged; Amlodipine; Cause of Death; Chlorthalidone; Confidence Intervals; Dose-Response R | 2014 |
Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Ch | 2015 |
[Dynamics of the hemostasis parameters in patients with arterial hypertension in treatment with combined antihypertensive agents].
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Administration Schedule; Drug Combinat | 2014 |
The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic.
Topics: Adolescent; Adult; Aged; Allopurinol; Black or African American; Blood Pressure; Chlorthalidone; Diu | 2015 |
Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Chlorthalido | 2016 |
Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
Topics: Adult; Aged; Benzimidazoles; Chlorthalidone; Cohort Studies; Dizziness; Drug Therapy, Combination; E | 2016 |
Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidon | 2016 |
Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hypertensio | 2016 |
[No antihypertensive drugs for frail elderly?].
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cause of Death; Ch | 2016 |
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Appointments and Schedules; Black People; Chlorthalidone; | 2016 |
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Electrocardiography; Female; Humans; Hype | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Double-B | 2016 |
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Changes in serum potassium mediate thiazide-induced diabetes.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; | 2008 |
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2008 |
[Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension].
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertensi | 2008 |
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients.
Topics: Aldosterone; Analysis of Variance; Blood Pressure; Chlorthalidone; Cross-Over Studies; Diuretics; He | 2009 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Antihypertensive efficacy of metoprolol XL/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; H | 2009 |
Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2009 |
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2010 |
Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide.
Topics: Aged; Antioxidants; Blood Chemical Analysis; Blood Pressure; C-Reactive Protein; Calcium Channel Blo | 2010 |
A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.
Topics: Adult; Aged; Amiloride; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pres | 2011 |
Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Brazil; Chlorthalidone; Diuretics; | 2011 |
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Combined Modality Therapy; Diuretics | 2011 |
Association between chlorthalidone treatment of systolic hypertension and long-term survival.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Chlorthal | 2011 |
A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cross-Over Studie | 1976 |
Cardiovascular pharmacotherapy can reduce mortality.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension | 2012 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; C | 2012 |
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Chemical Analysis; Cardiovascular Diseases; Chlorth | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Black People; Blood Pressure; Chlorth | 2012 |
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Black People; Blood Pressure; Chlorth | 2012 |
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chlorthalidone; Cros | 2012 |
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressu | 2012 |
Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2013 |
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Chlorthalidone; Double-Blind Method; D | 2002 |
Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Croatia; Echocardiography; Female; Heart Ventr | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Chlorthalidone; Diuretics; | 2003 |
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2003 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone | 2003 |
Treatment of isolated systolic hypertension: the SHELL study results.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dihydropyridines; | 2003 |
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise | 2003 |
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Cohort Studi | 2004 |
Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cross-Over Studies; Da | 2004 |
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Topics: Aged; Chlorthalidone; Diabetes Mellitus; Diuretics; Double-Blind Method; Female; Follow-Up Studies; | 2005 |
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Topics: Aged; Chlorthalidone; Diabetes Mellitus; Diuretics; Double-Blind Method; Female; Follow-Up Studies; | 2005 |
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Topics: Aged; Chlorthalidone; Diabetes Mellitus; Diuretics; Double-Blind Method; Female; Follow-Up Studies; | 2005 |
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Topics: Aged; Chlorthalidone; Diabetes Mellitus; Diuretics; Double-Blind Method; Female; Follow-Up Studies; | 2005 |
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome.
Topics: Antihypertensive Agents; Blood Pressure; Capillaries; Chlorthalidone; Diuretics; Endothelium, Vascul | 2005 |
Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Chlortha | 2006 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido | 2007 |
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2006 |
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2006 |
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2006 |
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2007 |
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Canada; Chlorthal | 2007 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone; Cost | 2008 |
Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program.
Topics: Adult; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; F | 2008 |
Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study.
Topics: Aged; Aged, 80 and over; Aging; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressu | 2008 |
Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Humans; | 2008 |
Beta-receptor-blocking agents may reverse or prevent diuretic-induced increases in serum low-density lipoprotein cholesterol.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Chlorthalidone; Cholesterol; Drug Therapy, Combinati | 1981 |
Responses of catecholamines and blood pressure to beta-blockade in diuretic-treated patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Catecholamines; Chlorthalidone; Diuretics; Drug | 1982 |
[Crystepin T (Trimecryton). Multi-center evaluation of a anti-hypertensive agent containing a beta blocker].
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Dihydroergotoxine; Drug Combinations; Female; | 1983 |
Therapy of mild hypertension: an overview.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Cardiovascular D | 1984 |
[Treatment of hypertensive hyperuricemic patients with a new beta blocker-diuretic combination].
Topics: Adult; Aged; Atenolol; Celiprolol; Chlorthalidone; Drug Combinations; Drug Tolerance; Female; Humans | 1984 |
Left ventricular mass and function before and after antihypertensive treatment.
Topics: Adult; Captopril; Cardiomegaly; Chlorthalidone; Drug Therapy, Combination; Echocardiography; Female; | 1983 |
[Clinical experience with a new antihypertensive drug (captopril SQ 14.225), an oral inhibitor of converting enzyme].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Chlorthalidone; | 1981 |
Comparison of chlorthalidone and spironolactone in low--renin essential hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; | 1983 |
Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium.
Topics: Adult; Angiotensin II; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hyp | 1983 |
A crossover trial of oxdralazine in hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Thera | 1983 |
[Clinical evaluation of the effect of verapamil in hypertensive patients].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1983 |
[Treatment of refractory hypertension with a fixed oxprenolol/chlorthalidone/hydralazine combination. Results of an open multicenter trial].
Topics: Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydralazine; Hypertensi | 1983 |
[Evaluation of the antihypertensive efficacy of acebutolol, chlorthalidone and the combination of acebutolol and chlorthalidone in the treatment of mild and moderate primary arterial hypertension].
Topics: Acebutolol; Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Fema | 1983 |
Long-acting and short-acting diuretics in the treatment of hypertension.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; Furosemide; Humans; Hyperte | 1983 |
[Report on the clinical evaluation of the antihypertensive effects of Urandil A VUFB].
Topics: Adult; Aged; Amiloride; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Metho | 1984 |
Propranolol versus chlorthalidone--a prospective therapeutic trial in children with chronic hypertension.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Chlorthalidone; Chronic Disease; Clinical Trial | 1984 |
The efficacy of a potassium-sparing combination of chlorthalidone and triamterene in the control of mild and moderate hypertension. I.
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Femal | 1984 |
The efficacy of a potassium-sparing combination of chlorthalidone and triamterene in the control of mild and moderate hypertension. II.
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Femal | 1984 |
Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy.
Topics: Adolescent; Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; Huma | 1984 |
Efficacy of low-dose captopril given twice daily to patients with essential hypertension uncontrolled by a beta blocker plus thiazide diuretic.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Captopril; Chlorthalidone; Dose-Response Relationship, Dru | 1984 |
Captopril and oxprenolol in a fixed combination with thiazide diuretics: comparison of their antihypertensive efficacy and metabolic effects.
Topics: Adult; Blood Pressure; Captopril; Chlorthalidone; Cholesterol; Clinical Trials as Topic; Creatinine; | 1984 |
[Hypotensive effect of delayed-action oxprenolol and chlorthalidone in combined form in patients with primary arterial hypertension].
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; Drug C | 1984 |
Comparative antihypertensive and endocrinologic effects of clonidine and prazosin in patients with essential hypertension.
Topics: Adult; Blood Pressure; Catecholamines; Chlorthalidone; Clinical Trials as Topic; Clonidine; Double-B | 1984 |
A study on the treatment of arterial hypertension with atenolol/chlorthalidone tablets: preliminary results of a post-marketing surveillance clinical trial on 2449 patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; | 1984 |
Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthalidone) in black hypertensive patients.
Topics: Adult; Atenolol; Black People; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blin | 1984 |
Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; Double | 1984 |
Atenolol in hypertension.
Topics: Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1984 |
Effect on intra-arterial blood pressure of slow release metoprolol combined with placebo or chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; | 1983 |
Beta blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial.
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Diet, Sodium-Restricted; Double-Blind Method; | 1984 |
Pressor factors and cardiovascular pressor responsiveness after short-term antihypertensive therapy with the calcium antagonist nifedipine alone or combined with a diuretic.
Topics: Adult; Aged; Blood Pressure; Cardiovascular System; Chlorthalidone; Drug Evaluation; Drug Therapy, C | 1984 |
Biochemical changes in black and Indian hypertensive patients on diuretic therapy.
Topics: Adult; Amiloride; Blood Glucose; Blood Pressure; Chlorthalidone; Creatinine; Diuretics; Drug Therapy | 1983 |
Serum cholesterol during treatment of hypertension with diuretic drugs.
Topics: Chlorthalidone; Cholesterol; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Male; Random Allo | 1984 |
Long-acting and short-acting diuretics in mild essential hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorothiazide; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1982 |
[Long-term experiences with an antihypertensive combination].
Topics: Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydralazine; Hypertensi | 1982 |
Low doses v standard dose of reserpine. A randomized, double-blind, multiclinic trial in patients taking chlorthalidone.
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina | 1982 |
[Comparative study of the combination of chlorthalidone with verapamil and metoprolol in arterial hypertension: evaluation by cycloergometrics].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Hemodynam | 1981 |
Antihypertensive activity of once daily metoprolol alone and with chlorthalidone and comparison with a twice daily regimen.
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as To | 1982 |
[Treatment of arterial hypertension in patients refractory to therapeutic diuretics. Comparative study of verapamil and propranolol].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hyperten | 1982 |
[Crystepin CH. A multi-centre trial of an antihypertensive drug (author's transl)].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Clopamide; Dihydroer | 1981 |
Effects of low-dose antihypertensive therapy in elderly patients with predominant systolic hypertension.
Topics: Aged; Blood Pressure; Chlorthalidone; Clonidine; Drug Combinations; Humans; Hypertension; Male; Midd | 1983 |
The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone.
Topics: Adult; Aged; Amiloride; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; | 1980 |
Blood pressure response to a single daily dose of a clonidine-chlorthalidone combination.
Topics: Adolescent; Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; Drug C | 1980 |
Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.
Topics: Administration, Oral; Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topi | 1980 |
Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension.
Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as T | 1980 |
Trial of atenolol and chlorthalidone for hypertension in black South Africans.
Topics: Atenolol; Black People; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1980 |
Urinary zinc excretion during treatment with different diuretics.
Topics: Adult; Aged; Bendroflumethiazide; Bumetanide; Chlorthalidone; Clinical Trials as Topic; Diuretics; F | 1980 |
Comparison of oxprenolol plus chlorthalidone in fixed combination against chlorthalidone alone in mild to moderate essential hypertension; a clinical trial.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1980 |
[Multicenter study with a fixed combination of oxprenolol/chlorthalidone in essential arterial hypertension].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hemodynamics; Hu | 1980 |
[Clinical trial of the activity and therapeutic effectiveness of 3 drugs with diuretic and antihypertensive action].
Topics: Aged; Antihypertensive Agents; Blood; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diur | 1981 |
Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Met | 1980 |
Once daily combination therapy for hypertension.
Topics: Adolescent; Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Dr | 1980 |
Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuretics; Double-Blind Metho | 1981 |
[Nifedipine and essential arterial hypertension refractory to hypotensive therapy: results of a preliminary double-blind study].
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Human | 1981 |
[Advantages of a fixed association of oxprenolol-chlorthalidone, as opposed to chlorthalidone alone, in the treatment of chronic essential arterial hypertension].
Topics: Adult; Aged; Chlorthalidone; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Co | 1981 |
[Fenquizone in the medium term treatment of essential hypertension. Double-blind comparison with chlorthalidone and placebo].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuresis; Double-Blind Method | 1981 |
A fixed combination of metoprolol and chlorthalidone in hypertension. A clinical trial in general practice.
Topics: Adult; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Fun | 1981 |
[Double-blind comparative study of the hypotensive effect of combination therapy with chlorthalidone and metoprolol or alpha-methyldopa].
Topics: Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Hu | 1981 |
Effect of antihypertensive drugs on plasma renin activity and urinary excretion of prostaglandin E2.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dinoprostone; Female; Humans; Hydralazine; | 1981 |
[Clinical evaluation of hygroton K (author's transl)].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Female; H | 1981 |
Pindolol: effects on blood pressure and plasma renin activity.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1982 |
Pulmonary function in hypertensive patients treated with pindolol: a report of two studies.
Topics: Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hypertension; Male; M | 1982 |
Adverse reactions to pindolol administration.
Topics: Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Humans; Hydrochlorothiazide; Hyperten | 1982 |
Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, | 1982 |
Once-daily penbutolol or atenolol can replace combination therapy in essential hypertension.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1982 |
Moderate sodium restriction and various diuretics in the treatment of hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diet, Sodium-Restricted; Diuretics; | 1981 |
Chlorthalidone in mild hypertension - dose response relationship.
Topics: Adult; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Drug; Female; Humans; Hypertensio | 1981 |
A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Delayed-Action Preparations; Drug Administration Schedu | 1981 |
Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial.
Topics: Adult; Chlorthalidone; Cholesterol; Cholesterol, Dietary; Double-Blind Method; Humans; Hydrochloroth | 1981 |
The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. The SHEP Study Group.
Topics: Aged; Cardiac Complexes, Premature; Chlorthalidone; Double-Blind Method; Female; Humans; Hypertensio | 1994 |
Systolic hypertension in the elderly: long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone | 1994 |
[The midterm inefficacy of 2 different dosages of chlorthalidone (50 and 25 mg/day) in the regression of left ventricular mass in arterial hypertension].
Topics: Aged; Atenolol; Blood Pressure; Chi-Square Distribution; Chlorthalidone; Enalapril; Follow-Up Studie | 1995 |
Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Combined Modality Therapy; Diet, Sodium-Re | 1994 |
Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL).
Topics: Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Clonidine; Drug Therapy, Combination; Female; Hea | 1994 |
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlorthali | 1994 |
Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidon | 1994 |
Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Co | 1994 |
The effects of diuretic and beta-blocker treatment on cardiac and vascular structural changes in untreated essential hypertensive patients.
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Hypertrophy, Left Ven | 1993 |
Glucose and insulin levels during diuretic therapy in hypertensive men.
Topics: Adult; Aged; Blood Glucose; Chlorthalidone; Diuretics; Electrolytes; Humans; Hydrochlorothiazide; Hy | 1994 |
[Evaluation of a combination of a diuretic and nifedipine retard for the treatment of hypertensive patients refractory to nifedipine retard].
Topics: Aged; Aged, 80 and over; Chlorthalidone; Delayed-Action Preparations; Drug Therapy, Combination; Fem | 1993 |
Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.
Topics: Adult; Antihypertensive Agents; Atenolol; Black People; Chlorthalidone; Double-Blind Method; Drug Co | 1993 |
Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Male; | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss.
Topics: Adult; Chlorthalidone; Cholesterol; Cholesterol, LDL; Double-Blind Method; Humans; Hypertension; Mal | 1993 |
Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention.
Topics: Adult; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Chlorthalidone; Combined Modalit | 1993 |
Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study.
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Chlorthalidone; Double-Blind | 1995 |
Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Doxazosin; Enalapril; Female; | 1996 |
[Treatment of hypertension with a fixed combination of bopindolol and chlorthalidone (Sandoretic)].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Combinati | 1996 |
Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Diuretics; Double-Blind Method; Dru | 1995 |
Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Carbohydrate Metabolism; Chlortha | 1996 |
Effect of the ACE inhibitor ceronapril on cerebral blood flow in hypertensive patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cerebrovascular Circulation; Chlorth | 1996 |
Vascular effects of chlorthalidone in mild hypertensives.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Female; H | 1995 |
Double-blind parallel study of a combination of chlorthalidone 50 mg and triamterene 50 mg in patients with mild and moderate hypertension.
Topics: Adult; Aged; Chlorthalidone; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Fem | 1996 |
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlor | 1996 |
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Chlorthalidone; Double-Blind Metho | 1995 |
[Comparative effects of captopril and chlorthalidone on glucose tolerance and insulin levels essential hypertensives].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Glucose; Captopril; Chlorthalidone; Female; Glu | 1996 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1997 |
Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring.
Topics: Antihypertensive Agents; Benzothiadiazines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 1997 |
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Double-Blind Method; Electrocard | 1997 |
An effective approach for treating elderly patients with isolated systolic hypertension: results of an Italian multicenter study with fosinopril.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chlor | 1997 |
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Calcium Channel Blockers; Chlorthalidone; Double-Blin | 1997 |
Effect of treatment of isolated systolic hypertension on left ventricular mass.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Female; Follow-Up Studies; Heart | 1998 |
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Re
Topics: Aged; Antihypertensive Agents; Blood Glucose; Chlorthalidone; Diuretics; Double-Blind Method; Female | 1998 |
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Cerebr | 1998 |
Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Chlorthalidone; Double-Blind Method; Female; Humans; Hyp | 1998 |
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.
Topics: Adult; Anti-Arrhythmia Agents; Antihypertensive Agents; Arteriosclerosis; Basal Metabolism; Blood Pr | 1998 |
Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Chi-Square Distribution; Chlorthalidone; Drug Therapy, Combination; E | 1999 |
National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Chlorthalidone; Diuretics; Doxazosin; Female | 2000 |
[ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Coronary Dis | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program.
Topics: Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Diuretics; Female; Humans; Hypertension; Hy | 2000 |
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Aged; Antihypertensive Agents; Atenolol; Brain Ischemia; Cerebral Hemorrhage; Chlorthalidone; Double | 2000 |
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Cardiovascular Dis | 2000 |
Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Bias; Chlorthalidone; Dementia; Disabled Persons; Double-Bl | 2001 |
Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Disease; Diltiazem; Diuretic | 2001 |
Bisoprolol vs. chlorthalidone: a randomized, double-blind, comparative study in arterial hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Bisoprolol; Blood Pressure; Chi-Square | 1990 |
Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Dr | 2001 |
Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Fema | 2002 |
[The antihypertensive effect of a new beta-adrenergic blocking drug metroprolol in combination with chlorthalidone].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Drug Evaluation; | 1976 |
Cardiovascular response to exercise under increasing doses of chlorthalidone.
Topics: Adult; Blood Pressure; Carbon Dioxide; Chlorthalidone; Clinical Trials as Topic; Dose-Response Relat | 1976 |
Atenolol, methyldopa, and chlorthalidone in moderate hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy | 1977 |
Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuret | 1978 |
Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bendroflumethiazide; Chlorthalidone; Diuretics; | 1979 |
Chlorthalidone and serum cholesterol.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Cholesterol; Clinical Trials as Topic; Follow-Up Stu | 1977 |
[The effect of diuretic therapy on serum lipoproteins: an undesirable effect?].
Topics: Adolescent; Adult; Aged; Chlorthalidone; Cholesterol; Clinical Trials as Topic; Female; Humans; Hype | 1979 |
An unsuccessful attempt to treat hypertension with acupuncture.
Topics: Acupuncture Therapy; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dopamine beta-Hydroxy | 1977 |
[Results obtained using a combination of a beta blockader (sotalol) and a diuretic in the treatment of arterial hypertension].
Topics: Angiotensin II; Chlorthalidone; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination | 1977 |
Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Volume; Body Weight; Chlorthalidone; Clinical Trials | 1978 |
[Comparison using the double-blind method of the hypotensive action of indapamide and that of another salidiuretic agent, chlorthalidone].
Topics: Chlorthalidone; Clinical Trials as Topic; Diuretics; Double-Blind Method; Drug Tolerance; Female; Hu | 1978 |
Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dose-Response | 1978 |
Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertensio
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hypertensi | 1978 |
Prazosin and clonidine for moderately severe hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; Drug Therapy, Comb | 1978 |
Metoprolol with and without chlorthalidone in hypertension.
Topics: Adult; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combinat | 1979 |
Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension.
Topics: Adult; Ambulatory Care; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dose-Res | 1979 |
Atenolol and chlorthalidone in combination for hypertension.
Topics: Adolescent; Adult; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug The | 1979 |
Double-blind comparison of hydrochlorothiazide plus triameterene therapy versus chlorthalidone therapy in hypertension.
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-B | 1979 |
Antihypertensive effect of oxprenolol and chlorthalidone in fixed combination, given once daily.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug | 1979 |
Mechanism of the haemodynamic interaction between atenolol, a cardioselective beta-adrenoreceptor-blocking agent, and chlorthalidone in hypertensive patients.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method | 1979 |
[Comparative trial of combined oxprenolol-chlorthalidone and a beta-blockader and diuretic separately in primary arterial hypertension].
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; | 1979 |
Dopamine beta-hydroxylase and plasma renin activity in patients with low-, normal-, and high-renin essential hypertension.
Topics: Adult; Catecholamines; Chlorthalidone; Dopamine beta-Hydroxylase; Female; Humans; Hypertension; Male | 1979 |
Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy.
Topics: Administration, Oral; Adult; Atenolol; Blood Pressure; Chlorthalidone; Dose-Response Relationship, D | 1979 |
Improving compliance with therapeutic regimens in hypertensive patients in a community health center.
Topics: Adult; Blood Pressure; Chlorthalidone; Community Health Services; Female; Humans; Hypertension; Male | 1979 |
Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.
Topics: Adult; Age Factors; Black People; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; | 1976 |
Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Depression, Chemi | 1975 |
Optimal dose of a thiazide diuretic.
Topics: Chlorthalidone; Clinical Trials as Topic; Humans; Hypertension; Hypokalemia | 1976 |
A controlled study on the anti-hypertensive effect of a new beta-adrenoreceptor-blocking drug, metoprolol, in combination with chlorthalidone.
Topics: Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Heart Rate; Humans; Hypertensio | 1976 |
A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensives.
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1976 |
Clonidine and chlorthalidone (combipres) in hypertension.
Topics: Adolescent; Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Clonidine; Drug Combinations; Dru | 1975 |
Effect of packaging on patient compliance with an antihypertensive medication.
Topics: Antihypertensive Agents; Chlorthalidone; Drug Packaging; Humans; Hypertension; Patient Compliance | 1976 |
[Plasma renin activity in essential hypertension: different short- und long-term effects of diuretics (author's transl)].
Topics: Adult; Amiloride; Canrenoic Acid; Chlorthalidone; Clinical Trials as Topic; Diuresis; Diuretics; Fem | 1976 |
Effect of high dose spironolactone and chlorthalidone in essential hypertension: relation to plasma renin activity and plasma volume.
Topics: Adult; Aldosterone; Body Weight; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Pl | 1975 |
Comparison of the effects of pharmacological therapy and a low-sodium diet on mild hypertension.
Topics: Adult; Aged; Chlorthalidone; Clonidine; Humans; Hypertension; Middle Aged; Sodium Chloride | 1976 |
Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate.
Topics: Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Depression, Chemical; Female; Humans; Hype | 1975 |
Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Bromine; Chlorthalidone; Clinical Trials as Topic; Diet, S | 1975 |
A comparative study of the activity of a new agent, indapamide, in essential arterial hypertension.
Topics: Aged; Chlorthalidone; Clinical Trials as Topic; Diuretics; Drug Evaluation; Drug Tolerance; Female; | 1975 |
Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension.
Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Creatinin | 1975 |
Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Carotid Arteries; Chlorthalidone; Delayed-Action Prep | 1992 |
The treatment of obese hypertensive black women: a comparative study of chlorthalidone versus clonidine.
Topics: Black People; Blood Pressure; Chlorthalidone; Clonidine; Double-Blind Method; Drug Therapy, Combinat | 1992 |
[An open comparative study of captopril + hydrochlorothiazide versus chlorthalidone for the treatment of mild and moderate primary hypertension].
Topics: Adolescent; Adult; Aged; Blood Pressure; Captopril; Chi-Square Distribution; Chlorthalidone; Drug Th | 1992 |
[Regression of left ventricular mass in arterial hypertension. Efficacy of 3 different treatment protocols].
Topics: Adult; Aged; Atenolol; Blood Pressure; Cardiomegaly; Chlorthalidone; Electrocardiography; Enalapril; | 1992 |
Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Diastole; Humans; Hypertension; Middle Aged; Regression Analy | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group.
Topics: Atenolol; Chlorthalidone; Combined Modality Therapy; Energy Intake; Exercise; Female; Humans; Hypert | 1992 |
Systolic hypertension in older persons.
Topics: Aged; Aging; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; | 1992 |
Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Determinat | 1992 |
The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Interactions; Drug Therapy, C | 1991 |
The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension.
Topics: Atenolol; Black People; Body Mass Index; Chlorthalidone; Combined Modality Therapy; Female; Humans; | 1992 |
Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Chlorthalidone; Double-Blind Method; Electrocardi | 1992 |
The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Cardiovascular Diseases | 1992 |
Commentary on the Trial of Antihypertensive Interventions and Management (TAIM) Study.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Humans; Hype | 1992 |
Changes in blood pressure, serum potassium and electrolytes with a combination of triamterene and a low dose of chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combinations; Female; Follow- | 1991 |
Once-daily fosinopril in the treatment of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Combinat | 1991 |
Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension.
Topics: Atrial Natriuretic Factor; Cardiomegaly; Chlorthalidone; Delayed-Action Preparations; Echocardiograp | 1991 |
Effects of chlorthalidone and metoprolol alone or in combination (logroton) on blood pressure, lipids, lipoproteins and circulating plasma ANF levels in essential hypertension.
Topics: Atrial Natriuretic Factor; Blood Pressure; Chlorthalidone; Cholesterol, HDL; Cholesterol, LDL; Chole | 1991 |
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria.
Topics: Atenolol; Blood Pressure; Chlorthalidone; Chronic Disease; Diabetic Nephropathies; Diabetic Retinopa | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Effect of antihypertensives on sexual function and quality of life: the TAIM Study.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Cohort Studies; Combined Modality Therapy; Die | 1991 |
Antihypertensive efficacy of guanfacine and methyldopa in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, C | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
[A multicenter study comparing nitrendipine and chlorthalidone in elderly hypertensive patients].
Topics: Aged; Blood Pressure; Chlorthalidone; Drug Tolerance; Humans; Hypertension; Nitrendipine; Quality of | 1990 |
[Comparison of chlorthalidone and sustained-action nifedipine in the treatment of mild to moderate arterial hypertension].
Topics: Aged; Chlorthalidone; Delayed-Action Preparations; Drug Evaluation; Female; Humans; Hypertension; Ma | 1990 |
Special considerations in the elderly patient.
Topics: Age Factors; Aged; Aging; Atenolol; Blood Pressure; Cardiac Output; Cardiomegaly; Chlorthalidone; Do | 1990 |
[Electrocardiographic and echocardiographic changes during antihypertensive therapy].
Topics: Acebutolol; Adolescent; Adult; Aged; Antihypertensive Agents; Captopril; Cardiomegaly; Chlorthalidon | 1990 |
Low-dose clonidine administration in the treatment of mild or moderate essential hypertension: results from a double-blind placebo-controlled study (Clobass). The Clobass Study Group.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clonidine; Double-Blind Method; Female; Humans; Hyperte | 1990 |
[A comparative study of atenolol (Tenormin) and the combined preparation atenolol/chlorthalidone (Tenoretic Mite) in essential hypertension. A randomized double-blind study from general practice].
Topics: Adolescent; Adult; Aged; Atenolol; Chlorthalidone; Double-Blind Method; Drug Combinations; Drug Eval | 1990 |
Efficacy and tolerability of long term oxprenolol and chlorthalidone singly and in combination in hypertensive blacks.
Topics: Adult; Black People; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Prepar | 1990 |
[Effectiveness of long-term antihypertensive therapy with tenoretic--a combined long-acting drug].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Delayed-Action Prepa | 1990 |
Hypertension and arrhythmias: effects of slow-release nicardipine vs chlorthalidone: a double-blind crossover study.
Topics: Adult; Arrhythmias, Cardiac; Chlorthalidone; Delayed-Action Preparations; Double-Blind Method; Elect | 1990 |
Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood.
Topics: Adolescent; Black People; Child; Chlorthalidone; Drug Therapy, Combination; Female; Follow-Up Studie | 1990 |
Effects on casual and 24-h ambulatory blood pressure of slow-release nicardipine and chlorthalidone in arterial essential hypertension: double-blind, crossover study.
Topics: Adult; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Delayed-Action Preparations; Do | 1990 |
A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction.
Topics: Adrenergic beta-Antagonists; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Bl | 1986 |
Calcium antagonists and thiazide diuretics in the treatment of hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Delayed-Action Preparations; Drug Therapy, Combination; | 1987 |
Short- and long-term cerebrovascular effects of nitrendipine in hypertensive patients.
Topics: Adult; Aged; Cerebrovascular Circulation; Chlorthalidone; Clonidine; Female; Humans; Hypertension; M | 1988 |
Effects of chlorthalidone, oxprenolol, and their combination in hypertensive blacks: a randomized double-blind crossover study.
Topics: Adrenergic beta-Antagonists; Adult; Black People; Blood Pressure; Chlorthalidone; Clinical Trials as | 1989 |
[Effects of a calcium antagonist, verapamil, on mild-moderate essential arterial hypertension].
Topics: Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Verapamil | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial.
Topics: Administration, Oral; Chlorthalidone; Clonidine; Drug Administration Schedule; Humans; Hypertension; | 1989 |
Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination.
Topics: Betaxolol; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Combination; Female; H | 1989 |
Chlorthalidone does not increase the hypotensive effect of nifedipine in essential hypertensives: a crossover multicentre study.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Synergism; Drug Therapy, Comb | 1989 |
Long-term antihypertensive efficacy of ketanserin plus chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Drug Administrat | 1989 |
Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone.
Topics: Acetylcholinesterase; Blood Pressure; Catecholamines; Chlorthalidone; Clinical Trials as Topic; Doub | 1987 |
Effects of the angiotensin converting enzyme inhibitor enalapril compared with diuretic therapy in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Administrati | 1988 |
[Treatment of hypertension with a new beta blocker-diuretic combination under long-term control].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Celiprolol; Chlorthalidone; Clinical Trial | 1985 |
Age and responses to isometric exercise in hypertension: possible predictors of the antihypertensive effect of diuretics and beta-blockers.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Antihypertensive Agents; Blood Pressure; Chlo | 1985 |
Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease.
Topics: Adrenergic beta-Antagonists; Airway Resistance; Atenolol; Chlorthalidone; Drug Therapy, Combination; | 1986 |
[Uricosuric action of a new beta receptor blocker-diuretic drug combination].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Diur | 1986 |
Relaxation therapy for hypertension. Comparison of effects with concomitant placebo, diuretic, and beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Combined Modality Ther | 1986 |
Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Chlorthalidone; Drug Therapy, Combination; Female; Humans; | 1987 |
A multicenter trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker-diuretic treatment.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Captopril; Chlorthalidone; Clinical Trials as Topic; Dr | 1987 |
Possible regression of left ventricular hypertrophy during antihypertensive treatment with diuretics and/or beta blockers.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiomegaly; Chlorthalidone; Clinical Trials as Topic; Fe | 1987 |
Safety profile of celiprolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Atenolol; Celiprolol; Chlorth | 1988 |
[Antihypertensive effectiveness and tolerance of slow-release metoprolol in fixed combination with chlorthalidone. Multicenter study on 93 patients].
Topics: Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Hypertension; | 1987 |
Celiprolol--review of airways studies.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1988 |
[Normalization of ventricular compliance and hypertrophy in arterial hypertension. Double-blind study with 2 combinations of a beta blocker and diuretic].
Topics: Adult; Atenolol; Blood Pressure; Cardiomegaly; Chlorthalidone; Clinical Trials as Topic; Double-Blin | 1987 |
Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics.
Topics: Adult; Aged; Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; | 1988 |
Bronchoneutral effects in hypertensive asthmatics--celiprolol versus chlorthalidone.
Topics: Antihypertensive Agents; Asthma; Celiprolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1988 |
Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clin | 1988 |
[Chlorthalidone at low doses in the treatment of mild and moderate hypertension: analysis of efficacy, hypokalemia frequency and cardiac rhythm disorders].
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; Heart Rate; Humans; Hyperte | 1988 |
[Effect of various diuretic doses on hemodynamics in patients with hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Dose-Response Relation | 1988 |
[Chlorthalidone at low doses in the treatment of mild to moderate essential hypertension in elderly patients].
Topics: Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Female; Heart Rat | 1988 |
Addition of chlorthalidone to slow-release nifedipine in the treatment of arterial hypertension: a controlled study versus placebo.
Topics: Adult; Chlorthalidone; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hyper | 1988 |
Crossover design to test antihypertensive drugs with self-recorded blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Clinical Tria | 1988 |
Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension.
Topics: Administration, Cutaneous; Chlorthalidone; Clinical Trials as Topic; Clonidine; Dermatitis, Contact; | 1988 |
[Use of oxodoline in patients with arterial hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Prepa | 1988 |
[Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients].
Topics: Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Preparations; Drug Th | 1987 |
Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience.
Topics: Aged; Aging; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middle Ag | 1986 |
Plasma renin activity does not predict the antihypertensive efficacy of chlorthalidone.
Topics: Adult; Aldosterone; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; E | 1987 |
The systolic hypertension in the elderly pilot program: methodological issues.
Topics: Age Factors; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Doub | 1988 |
Metabolic effects of long-term therapy with muzolimine and chlorthalidone in hypertension.
Topics: Adult; Biological Transport; Chlorthalidone; Erythrocytes; Humans; Hypertension; Middle Aged; Muzoli | 1987 |
Systolic hypertension in the elderly program (SHEP). The first three months.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Clinical Trials as Topic; Double | 1986 |
Systolic hypertension in the elderly program (SHEP). The first three months.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Clinical Trials as Topic; Double | 1986 |
Systolic hypertension in the elderly program (SHEP). The first three months.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Clinical Trials as Topic; Double | 1986 |
Systolic hypertension in the elderly program (SHEP). The first three months.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Clinical Trials as Topic; Double | 1986 |
Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone.
Topics: Age Factors; Aged; Blood Glucose; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as Topic | 1986 |
A multicenter, randomized, double-blind dose-response evaluation of step-2 guanfacine versus placebo in mild to moderate hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1986 |
Usefulness of low dose guanfacine, once a day, for 24-hour control of essential hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind | 1986 |
Low-dose atenolol-chlorthalidone combination for treatment of mild hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combi | 1986 |
Chronic treatment with tibalosine in essential hypertension.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; | 1986 |
Captopril in the treatment of hypertension associated with claudication.
Topics: Blood Pressure; Captopril; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; Intermittent Cl | 1986 |
[Systolic-diastolic function of the left ventricle and flowmetry of the lower limbs in the treatment of moderate essential arterial hypertension with atenolol-chlorthalidone].
Topics: Adult; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug | 1986 |
[Results of a multicenter trial of antihypertensive treatment with atenolol, alone or in combination with chlorthalidone, of patients with mild, moderate and severe hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Thera | 1987 |
Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program.
Topics: Age Factors; Aged; Chlorthalidone; Double-Blind Method; Female; Humans; Hypertension; Male; Middle A | 1987 |
Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Body Weight; Chlo | 1986 |
Diuretics, potassium and arrhythmias in hypertensive coronary disease.
Topics: Chlorthalidone; Coronary Disease; Diuretics; Electric Stimulation; Electrocardiography; Humans; Hype | 1986 |
Use of diuretics in treatment of hypertension in the elderly.
Topics: Aged; Chlorthalidone; Creatinine; Double-Blind Method; Female; Humans; Hypertension; Hypokalemia; Ma | 1986 |
Low-dose diuretic therapy for hypertension.
Topics: Chlorthalidone; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Electrolytes; Fema | 1986 |
Effects of two doses of the fixed-combination chlorthalidone and slow-release metoprolol on blood pressure at rest and during exercise: a multicenter study.
Topics: Adult; Aged; Chlorthalidone; Double-Blind Method; Drug Combinations; Exercise Test; Female; Humans; | 1986 |
Beneficial effects from systematic dosage reduction of the diuretic, chlorthalidone: a randomized study within a clinical trial.
Topics: Blood Glucose; Blood Pressure; Chlorthalidone; Cholesterol; Clinical Trials as Topic; Humans; Hypert | 1985 |
Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial.
Topics: Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combina | 1985 |
Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Th | 1985 |
The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as Topic; D | 1985 |
The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as Topic; D | 1985 |
The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as Topic; D | 1985 |
The relationship of weight change to changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Chlorthalidone; Cholesterol; Clinical Trials as Topic; D | 1985 |
Interference on metabolism induced by muzolimine and chlorthalidone in type II hypertensive diabetics.
Topics: Aldosterone; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Chlorthalidone; Clinical Trials | 1985 |
Influence of the administration time on the antihypertensive and hypokalaemic effects of chlorthalidone in patients with primary hypertension.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Double-Blind Method; Femal | 1985 |
[A diuretic, oxodolin, in the treatment of hypertension].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension; Male; Middle Ag | 1985 |
[Therapeutic prospectives in the field of hypertension].
Topics: Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; Drug Tolerance; | 1985 |
Double-blind crossover study of fenquizone compared to chlorthalidone in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Diuretics; Double-Blind Metho | 1985 |
Drug treatment trials in hypertension: a review.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Coro | 1985 |
Third-line therapy. A cautionary note.
Topics: Atenolol; Bendroflumethiazide; Captopril; Chlorthalidone; Female; Humans; Hypertension; Male; Methyl | 1985 |
[Atenolol-chlorthalidone combination vs placebo: controlled clinical trial in patients with medium-mild arterial hypertension].
Topics: Adult; Aged; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combination; Drug Tol | 1985 |
Atenolol as an anti-hypertensive drug.
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Clinical Trials as Topic; Drug Therapy, Combinati | 1985 |
Prazosin once or twice daily?
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1985 |
[Evaluation of the hypotensive efficacy in a double-blind study of xipamide versus chlorthalidone].
Topics: Adult; Aged; Chlorthalidone; Diuretics; Double-Blind Method; Female; Humans; Hypertension; Middle Ag | 1985 |
Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone.
Topics: Aged; Blood Pressure; Chlorthalidone; Creatinine; Double-Blind Method; Feasibility Studies; Female; | 1985 |
Comparison of clonidine and methyldopa in hypertensive patients receiving a diuretic. A double-blind crossover study.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Chemical Phenomena; Chem | 1972 |
Clonidine versus methyldopa. A double blind cross-over study comparing side effects of clonidine and methyldopa administered together with chlorthalidone at a dosage producing the same blood pressure lowering effect.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; Consti | 1972 |
Comparison between alprenolol and chlorthalidone as antihypertensive agents.
Topics: Adult; Alprenolol; Amino Alcohols; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as T | 1972 |
Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients.
Topics: Adult; Aged; Alprenolol; Blood Pressure; Blood Volume; Chlorthalidone; Clinical Trials as Topic; Dru | 1973 |
[Clinical evaluation of a new pharmacological association with hypotensive effect. Statistical presentation of results].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Drug Combinations; D | 1973 |
[Treatment of hypertension with the beta-receptor-antagonist pindolol (Viskèn). A comparison with chlorthalidone (Hygroton)].
Topics: Adult; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Depression, Chemical; Humans; Hyper | 1973 |
Haemodynamic changes in long-term therapy of essential hypertension: a comparative study of diuretics, alpha-methyldopa and clonidine.
Topics: Adult; Cardiac Output; Chlorthalidone; Clinical Trials as Topic; Clonidine; Diuretics; Heart Rate; H | 1973 |
A long-term study of the antihypertensive effect of alprenolol.
Topics: Adult; Aged; Alprenolol; Blood Pressure Determination; Chlorthalidone; Clinical Trials as Topic; Del | 1974 |
A comparative study of alprenolol and alpha-methyldopa respectively in combination with chlorthalidone in hypertension.
Topics: Adult; Aged; Alprenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Delayed-Action Pr | 1974 |
Alprenolol in hypertension.
Topics: Aged; Alprenolol; Benzothiadiazines; Chlorthalidone; Clinical Trials as Topic; Digitalis; Diuretics; | 1974 |
Long-term effect of alprenolol as antihypertensive agent.
Topics: Adult; Airway Obstruction; Alprenolol; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials | 1974 |
[Antihypertensive effects of clonidine and of the clonidine-chlorthalidone combination].
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; | 1974 |
[Antihypertensive effect of clonidine alone and in combination with chlorthalidone].
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Clonidine; Drug Evaluation; Drug Synergism; Female; | 1974 |
[Clinical trials with clonidine-chlorthalidone, a combined preparation in the treatment of hypertensive diseases].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Clonidine; Diabetes Mellitus; | 1973 |
Antihypertensive efficacy of metolazone.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorthalidone; Diuretics; Edema; | 1974 |
Effect of propranolol on elevated arterial blood pressure.
Topics: Adult; Aged; Antihypertensive Agents; Bilirubin; Blood Cell Count; Blood Pressure; Blood Urea Nitrog | 1968 |
Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension.
Topics: Adult; Aniline Compounds; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hypertension; Im | 1970 |
The use of clonidine hydrochloride in ambulatory hypertensive patients.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antihypertensive Agents; Chlorthalidone; Cl | 1971 |
Effects of clonidin and chlorthalidone on blood pressure and glucose tolerance in hypertensive patients.
Topics: Adult; Aged; Aniline Compounds; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; | 1971 |
Potassium-sparing agents during diuretic therapy in hypertension.
Topics: Adult; Aged; Chlorthalidone; Diuretics; Humans; Hypertension; Middle Aged; Potassium; Potassium Defi | 1971 |
[A contribution on the use of hygroton-reserpine in daily practice].
Topics: Chlorthalidone; Clinical Trials as Topic; Humans; Hypertension; Reserpine | 1965 |
Effect of triamterene on elevated arterial pressure.
Topics: Adult; Blood Chemical Analysis; Chlorthalidone; Clinical Trials as Topic; Creatine; Female; Humans; | 1965 |
Treatment of arterial hypertensive disease with diuretics. IV. Effects of long-term high sodium intake on the response to chlorthalidone.
Topics: Adult; Chlorthalidone; Clinical Trials as Topic; Humans; Hypertension; Middle Aged; Sodium Chloride; | 1965 |
[Clinical trials with chlorthalidone in arterial hypertension].
Topics: Chlorthalidone; Clinical Trials as Topic; Humans; Hypertension | 1965 |
Treatment of hypertension with methyldopa.
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Drug Synergism; Drug Tolerance; Female; Follo | 1966 |
[On the anti-hypertensive action of the chlorthalidone-reserpine combination. Clinical contribution].
Topics: Adolescent; Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hypertension; Mal | 1965 |
Clinical study on the hypotensive action of a chlorthalidone-reserpine association.
Topics: Adult; Aged; Chlorthalidone; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Middle Ag | 1966 |
Clinical studies of methyldopa and its combination with chlorthalidone in hypertension.
Topics: Chlorthalidone; Clinical Trials as Topic; Drug Synergism; Female; Humans; Hypertension; Male; Methyl | 1967 |
[Treatment of hypertension with cyclothiazide (Doburil) and chlorthalidone (Hygroton)].
Topics: Adult; Age Factors; Benzothiadiazines; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; | 1969 |
Hemodynamic changes in long-term diuretic therapy of essential hypertension. A comparative study of chlorthalidone, polythiazide and hydrochlorothiazide.
Topics: Adult; Blood Pressure; Blood Volume; Cardiac Output; Chlorthalidone; Electrolytes; Heart Rate; Human | 1970 |
Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.
Topics: Aged; Blood Glucose; Carbohydrate Metabolism; Chlorthalidone; Cortisone; Diabetes Mellitus; Ethacryn | 1968 |
Comparative studies on spironolactone (Aldactone) and chlorthalidone (Hygroton) in the treatment of arterial hypertension.
Topics: Chlorthalidone; Female; Humans; Hypertension; Male; Natriuresis; Renal Artery Obstruction; Spironola | 1966 |
Long-term effect of probenecid on diuretic-induced hyperuricemia.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Pressure Determination; Body Weight; Chlorthalidone; Hum | 1966 |
495 other studies available for chlorthalidone and Hypertension
| Article | Year |
|---|---|
Chlorthalidone in advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Spironolactone and chlorthalidone-old drugs, new uses-but approach with caution.
Topics: Chlorthalidone; Diuretics; Humans; Hypertension; Spironolactone | 2022 |
In advanced CKD with poorly controlled hypertension, chlorthalidone reduced BP at 12 wk.
Topics: Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD. Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone and Advanced Chronic Kidney Disease.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Isolated Systolic Hyperte | 2022 |
Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Hydrochlorothiazide Versus Chlorthalidone: What Is the Difference?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2022 |
Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India.
Topics: Amlodipine; Chlorthalidone; Humans; Hypertension; India; Private Sector; Telmisartan | 2023 |
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Humans; Hydrochl | 2022 |
The 'cold case' of chlortalidone vs. hydrochlorothiazide in hypertension closed by the diuretic comparison project?
Topics: Blood Pressure; Chlorthalidone; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; H | 2023 |
[Chlorthalidone in chronic kidney disease].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2023 |
In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 y.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Chlorthalidone No Better Than Hydrochlorothiazide for Hypertension.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
[Chlorthalidone or hydrochlorothiazide as the first choice in the treatment of people with hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2023 |
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atenolol; Chlorthali | 2019 |
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Gout; H | 2020 |
Optimising TRIUMPH with 6·25 mg chlorthalidone.
Topics: Antihypertensive Agents; Chlorthalidone; Cost-Benefit Analysis; Humans; Hypertension; Sri Lanka | 2020 |
Optimising TRIUMPH with 6·25 mg chlorthalidone - Authors' reply.
Topics: Antihypertensive Agents; Chlorthalidone; Cost-Benefit Analysis; Humans; Hypertension; Sri Lanka | 2020 |
Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Mi | 2020 |
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Chlorthalidone; Col | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension-Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension | 2020 |
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Dise | 2020 |
Refractory Hypertension and Kidney Failure: Focusing on the Social Determinants of Health.
Topics: Chlorthalidone; Humans; Hypertension; Outcome Assessment, Health Care; Renal Insufficiency; Renal In | 2021 |
Risk of Electrolyte Disorders, Syncope, and Falls in Patients Taking Thiazide Diuretics: Results of a Cross-Sectional Study.
Topics: Accidental Falls; Aged; Antihypertensive Agents; Chlorthalidone; Cross-Sectional Studies; Female; Hu | 2021 |
White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Drug Resistan | 2017 |
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Black or African American; Blood Pressure; Chlort | 2017 |
Long-term safety of different antihypertensive regimens: The risk of unfair comparisons.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Do thiazide diuretics reduce central systolic blood pressure in hypertension?
Topics: Amiloride; Antihypertensive Agents; Arterial Pressure; Blood Pressure; Chlorthalidone; Diuretics; Dr | 2018 |
[Antihypertensive Efficacy of Fixed Combination Azilsartan Medoxomil / Chlorthalidone in Patients With Uncontrolled Arterial Hypertension].
Topics: Antihypertensive Agents; Benzimidazoles; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; | 2017 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Guest Editorial: How valuable are systematic reviews for primary health care practitioners?
Topics: Bendroflumethiazide; Chlorthalidone; Humans; Hypertension; Primary Health Care | 2017 |
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2018 |
Hemorrheologic effect of diuretics in the control of blood pressure in the hypertensive patient
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Chlorthalidone; Diuretics; Drug Administration Sch | 2017 |
Diuretics and left ventricular hypertrophy regression: The relationship that we commonly forget.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Hyper | 2018 |
Which thiazide to choose-A "dynamic" question with a mundane answer?
Topics: Blood Pressure Monitoring, Ambulatory; Carbonic Anhydrases; Chlorthalidone; Diuretics; Endothelium; | 2018 |
Interventricular vessel of the heart and diuretics.
Topics: Chlorthalidone; Diuretics; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, | 2019 |
Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients.
Topics: Antihypertensive Agents; Bundle-Branch Block; Chlorthalidone; Electrocardiography; Heart Conduction | 2019 |
Lessons from a patient with Turner syndrome.
Topics: Amlodipine; Blood Pressure; Chlorthalidone; Estrogens; Female; Hormone Replacement Therapy; Humans; | 2013 |
Obesity and hypertension: It's about more than the numbers.
Topics: Antihypertensive Agents; Chlorthalidone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2013 |
Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Follow-Up Studies; Hospitalization; Humans; Hydrochlo | 2013 |
Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Drug Combinations; Drug Interactions; Human | 2013 |
UK supply of chlortalidone for hypertension must be restored.
Topics: Antihypertensive Agents; Chlorthalidone; Commerce; Drug Industry; Evidence-Based Medicine; Formulari | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Chlorthalidone versus hydrochlorothiazide.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2013 |
Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Calcium; Chlorthalidone; Creatin | 2013 |
Chlorthalidone versus hydrochlorothiazide in hypertension treatment: do we have the evidence to decide?
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Male | 2014 |
Uveal effusion as a mechanism of bilateral angle-closure glaucoma induced by chlorthalidone.
Topics: Acute Disease; Administration, Oral; Adult; Antihypertensive Agents; Chlorthalidone; Diuretics; Fema | 2015 |
Considerations for dofetilide use in the elderly.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Chlorthalid | 2014 |
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell A | 2014 |
Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cohort Studies; Diuretics; Fem | 2014 |
Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Drug; Electroni | 2015 |
Indapamide: is it the better diuretic for hypertension?
Topics: Blood Pressure; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Potassium | 2015 |
Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension.
Topics: Animals; Blood Pressure; Chlorthalidone; Evidence-Based Practice; Heart Failure; Humans; Hypertensio | 2015 |
Chlorthalidone vs. Hydrochlorothiazide for Treatment of Hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Chlorthalidone; Evidence-Base | 2015 |
Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit.
Topics: Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Female; Humans; Hydrochloroth | 2016 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
Efficacy of Low-Dose Chlorthalidone Versus Hydrochlorothiazide Remains Ambiguous.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2016 |
Reply: Efficacy of Low-Dose Chlorthalidone Versus Hydrochlorothiazide Remains Ambiguous.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2016 |
Chlorthalidone Versus Hydrochlorothiazide: A New Kind of Veterans Affairs Cooperative Study.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Randomized Contr | 2016 |
Azilsartan: Novel Angiotensin Receptor Blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Ch | 2016 |
Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Determinati | 2016 |
Sudden Severe Bleeding in a Patient with Hemochromatosis: Liver Failure or Something Else?
Topics: Antihypertensive Agents; Chlorthalidone; Hemochromatosis; Hemoglobins; Humans; Hypertension; Liver F | 2016 |
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Ben | 2017 |
[Hypertensive patient with metabolic syndrome: would you prescribe a diuretic as the initial treatment? (interview by Thomas Meissner)].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cal | 2008 |
Should we prescribe diuretics for patients with prediabetes and hypertension?
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Drug Prescriptions; Humans; Hypertension; Hypogl | 2008 |
Which diuretic should be used for the treatment of hypertension?
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Practice Patterns, Physicians'; Randomize | 2008 |
All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Chlorthalidone; Diuretics; Humans; Hydrochlorothi | 2009 |
Using diuretics in practice--one opinion.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2009 |
Blood pressure drugs may raise the risk of adult diabetes. Potassium loss caused by hypertension drugs could place patients in the type 2 diabetes danger zone.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Controlled Clinical Trials as Topic; Diabetes Mellitu | 2009 |
Chlorthalidone - a renaissance in use?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug Co | 2009 |
Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Heart Failure; Humans; Hypertension; Sodium Chlo | 2009 |
The role of chlorthalidone in patients with high-risk hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug T | 2009 |
The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide.
Topics: Aged; Chlorthalidone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans | 2009 |
Choice of diuretic therapy and reconsideration for aldosterone receptors blockers.
Topics: Aldosterone; Blood Pressure; Chlorthalidone; Diuretics; Dose-Response Relationship, Drug; Humans; Hy | 2010 |
[Chlorthalidone better than hydrochlorothiazide in hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Treatment Outcom | 2010 |
Hypertension: Is there a dark side to thiazide therapy for hypertension?
Topics: Chlorthalidone; Chronic Disease; Disease Progression; Diuretics; Humans; Hypertension; Kidney Diseas | 2010 |
Strengthening diuretics' role in hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Renewed interest in chlorthalidone: evidence from the Veterans Health Administration.
Topics: Aged; Antihypertensive Agents; Chlorthalidone; Dose-Response Relationship, Drug; Drug Utilization; F | 2010 |
Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hyp | 2011 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
Managing erectile dysfunction in hypertensive patients.
Topics: Amides; Antihypertensive Agents; Benzopyrans; Chlorthalidone; Ethanolamines; Fumarates; Humans; Hydr | 2011 |
Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Electrocardiography; Humans; Hydrochlorothiazide | 2011 |
Life expectancy after treatment for systolic hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Female; Humans; Hypertension; Life | 2012 |
Guidelines for use of diuretics: a view from a member of JNC 7.
Topics: Chlorthalidone; Consensus Development Conferences as Topic; Diuretics; Dose-Response Relationship, D | 2012 |
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hyp | 2012 |
Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low?
Topics: Chlorthalidone; Female; Humans; Hypertension; Insulin Resistance; Male; Spironolactone; Sympathetic | 2012 |
Best thiazide diuretic for hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension | 2012 |
The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans.
Topics: Aged; Blood Pressure; Chlorthalidone; Cohort Studies; Comparative Effectiveness Research; Female; Hu | 2012 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
Emerging pain ameliorating effects of spironolactone: an additional benefit of its use in hypertensive and cardiac patients: recent insights.
Topics: Chlorthalidone; Female; Humans; Hypertension; Insulin Resistance; Male; Spironolactone; Sympathetic | 2012 |
Summaries for patients. Blood pressure drugs and heart failure.
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Chlorthalidone; Double-Blind Method; D | 2002 |
[Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2003 |
[ALLHAT--the most comprehensive antihypertensive treatment trial in the world. The significance of thiazide diuretics for patients older than 55 years is confirmed].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
[Consequences of ALLHAT: Thiazides rehabilitated--time to change prescription patterns].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
ALLHAT finds diuretics best for initial hypertension therapy.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Humans; Hy | 2003 |
Diuretics: first choice for treating high BP.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone | 2003 |
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Hats off to an old blood pressure drug. For treating high blood pressure, an old--and inexpensive--medication is a great place to start or a good one to add.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Humans; Hy | 2003 |
[What are the sequelae of the ALLHAT Study?].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Critical Pathways; Humans; Hype | 2003 |
High praise for an old standby. Low-cost diuretics excel in combating high blood pressure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Chlorth | 2003 |
Diuretics: older, cheaper, better.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines | 2003 |
[ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Dose-Resp | 2003 |
[The ALLHAT study: contributions, limitations and prospectives].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiov | 2003 |
Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2003 |
A cheaper way to control high blood pressure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone; Clin | 2003 |
Angiotensin-converting-enzyme inhibitors and diuretics for hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chlorthalidone; Coronary Disease; | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
[Results of clinical evidence: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hypertension; | 2003 |
[Hygroton (chlorthalidone) in hypertension].
Topics: Chlorthalidone; Diuretics; Hypertension | 1961 |
Diuretic response to chlorthalidone.
Topics: Chlorthalidone; Diuretics; Edema; Hypertension | 1961 |
[Hygroton--a new oral diuretic with protracted effect].
Topics: Chlorthalidone; Dental Care; Diuretics; Edema; Humans; Hypertension | 1960 |
[Effects of long-term hygroton treatment on hypertension].
Topics: Chlorthalidone; Diuretics; Humans; Hypertension; Long-Term Care | 1960 |
The antihypertensive effects of chlorthalidone. A comparative analysis with benzothiazide compounds.
Topics: Antihypertensive Agents; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diuretics; Hypertension | 1962 |
Hyperuricemia induced by the administration of chlorthalidone and other sulfonamide diuretics.
Topics: Chlorthalidone; Diuretics; Humans; Hypertension; Hyperuricemia; Sulfanilamide; Sulfanilamides; Sulfo | 1962 |
The effects of spironolactone and chlorthalidone on arterial pressure.
Topics: Aldosterone; Arterial Pressure; Blood Pressure; Chlorthalidone; Diuretics; Humans; Hypertension; Min | 1962 |
Studies on a new diuretic: chlorthalidone.
Topics: Chlorthalidone; Diuretics; Hypertension | 1962 |
[Results of hypertension therapy with the combined preparation of Hygroton and reserpine].
Topics: Chlorthalidone; Humans; Hypertension; Reserpine | 1963 |
[Experience in Hygroton therapy of hypertension in outpatients].
Topics: Chlorthalidone; Humans; Hypertension; Outpatients | 1962 |
[Intra-and extracellular electrolyte changes in hypertension and their alteration].
Topics: Chlorthalidone; Electrolytes; Humans; Hypertension; Sodium Chloride | 1963 |
Comparison of meralluride with a new oral diuretic.
Topics: Chlorthalidone; Diuretics; Heart Failure; Hypertension; Liver Cirrhosis; Organomercury Compounds; Or | 1963 |
Comparison of chlorthalidone, a long-acting antihypertensive and diuretic agent, with chlorothiazide. Analysis of one hundred twenty-three cases.
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Diuretics; Humans; Hypertension | 1962 |
Guanethidine and chlorthalidone in hypertension. Long-term treatment of hypertension with the combination of guanethidine (Ismelin) and chlorthalidone (Hygroton).
Topics: Chlorthalidone; Guanethidine; Hypertension | 1963 |
[Clinical experiences with a new combined preparation for the treatment of hypertension].
Topics: Chlorthalidone; Hypertension; Reserpine | 1963 |
Chlorthalidone in the treatment of hypertension.
Topics: Chlorthalidone; Humans; Hypertension | 1962 |
[Treatment of arterial hypertension with chlorthalidone].
Topics: Chlorthalidone; Humans; Hypertension | 1962 |
[On the effects and methods of clinical use of chlorthalidone].
Topics: Chlorthalidone; Diuretics; Heart Diseases; Humans; Hypertension; Kidney Diseases; Liver Cirrhosis | 1962 |
EFFECTS OF ORAL DIURETICS ON RAISED ARTERIAL PRESSURE.
Topics: Arterial Pressure; Bendroflumethiazide; Benzothiadiazines; Blood; Blood Pressure Determination; Body | 1963 |
[DRUG THERAPY OF HIGH BLOOD PRESSURE IN THE PAST, PRESENT AND FUTURE].
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Guanethidine; Humans; Hydralazine; Hyperten | 1963 |
[COMPARISON OF THE HYPOTENSIVE EFFECTS OF RENESE (POLYTHIAZIDE) AND HYGROTON (CHLORTHALIDONE)].
Topics: Antihypertensive Agents; Benzothiadiazines; Chlorthalidone; Diuretics; Humans; Hypertension; Hypoten | 1963 |
[EFFECT OF HYGROTON ON CELL ELECTROLYTES IN PATIENTS WITH ESSENTIAL HYPERTENSION].
Topics: Biopsy; Blood Chemical Analysis; Blood Pressure Determination; Chlorides; Chlorthalidone; Electrolyt | 1964 |
HYDRALAZINE IN HYPERTENSION.
Topics: Chlorthalidone; Humans; Hydralazine; Hypertension; Reserpine | 1964 |
[LONG-TERM TREATMENT OF HYPERTENSION WITH HYGROTON-RESERPINE].
Topics: Chlorthalidone; Humans; Hypertension; Long-Term Care; Reserpine | 1963 |
[CLINICAL EXPERIENCES WITH HYGROTON-RESERPINE].
Topics: Ascites; Chlorthalidone; Edema; Female; Hypertension; Pregnancy; Pregnancy Complications; Reserpine; | 1963 |
[ANTIHYPERTENSIVE PROPERTIES OF POLYTHIAZIDE].
Topics: Antihypertensive Agents; Benzothiadiazines; Chlorthalidone; Diuretics; Hydrazines; Hypertension; Met | 1963 |
TREATMENT OF ARTERIAL HYPERTENSIVE DISEASE WITH DIURETICS. III. CHLORTHALIDONE ALONE AND IN COMBINATION WITH SPIRONOLACTONE.
Topics: Bendroflumethiazide; Cardiomegaly; Chlorides; Chlorthalidone; Coronary Disease; Creatine; Creatinine | 1964 |
[TREATMENT OF HYPERTENSION WITH HYGROTON-RESERPINE].
Topics: Arteriosclerosis; Chlorthalidone; Clinical Laboratory Techniques; Electrocardiography; Guanethidine; | 1963 |
[SEVERE NEUROLOGICAL SIDE-EFFECTS IN HYPOTENSION THERAPY].
Topics: Amobarbital; Antihypertensive Agents; Arteriosclerosis; Chlorothiazide; Chlorthalidone; Guanethidine | 1964 |
THE TREATMENT OF HYPERTENSION WITH CHLORTHALIDONE ALONE AND IN COMBINATION WITH RESERPINE.
Topics: Chlorthalidone; Humans; Hypertension; Reserpine; Toxicology | 1963 |
[THE ANTIHYPERTENSIVE EFFECTS OF THE DIURETICS].
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Erythrocytes; Hypertension; Pathology; Pharmacol | 1964 |
[TREATMENT OF HYPERTENSION WITH HYGROTON-RESERPINE IN OFFICE PRACTICE].
Topics: Chlorthalidone; Humans; Hypertension; Reserpine | 1964 |
[TREATMENT OF HYPERTENSION WITH GP-37736-R 2052].
Topics: Chlorthalidone; Humans; Hypertension; Reserpine; Toxicology | 1964 |
[ANTIHYPERTENSIVE PROPERTIES OF A MONOAMINE OXIDASE INHIBITOR (DL-SERINE-N2-ISOPROPYLHYDRAZIDE: RO 4-1038). CLINICAL RESULTS AND EFFECT ON RENAL FUNCTION].
Topics: Antihypertensive Agents; Blood Pressure Determination; Chemical and Drug Induced Liver Injury; Chlor | 1964 |
[A CONTRIBUTION TO MODERN TREATMENT OF HYPERTENSION].
Topics: Chlorthalidone; Hypertension; Reserpine | 1964 |
A COMPARATIVE STUDY OF THE DIURETICS CHLORTHALIDONUM AND CYCLOPENTHIAZIDUM.
Topics: Benzothiadiazines; Bicarbonates; Biomedical Research; Blood; Chlorides; Chlorthalidone; Diet, Sodium | 1964 |
THE EFFECT OF SALURETICS ON PULSE RATE, BLOOD PRESSURE AND ELECTROCARDIOGRAM DURING EXERCISE IN NORMAL SUBJECTS.
Topics: Aspirin; Biomedical Research; Blood; Blood Pressure; Blood Pressure Determination; Chlorides; Chlort | 1964 |
[URATIC ARTHRITIS AS A COMPLICATION OF DIURETIC THERAPY].
Topics: Arthritis; Chlorothiazide; Chlorthalidone; Diuretics; Gout; Heart Failure; Hypertension; Rheumatic H | 1964 |
[CLINICAL EXPERIENCES WITH THE ANTIHYPERTENSIVE AGENT HYGROTON-RESERPINE].
Topics: Antihypertensive Agents; Arteriosclerosis; Biomedical Research; Chlorthalidone; Drug Therapy; Hypert | 1964 |
RENAL ISCHAEMIA DUE TO THROMBOSIS OF RENAL ARTERY RESULTING FROM METASTASES FROM PRIMARY CARCINOMA OF THE BRONCHUS.
Topics: Adrenal Gland Neoplasms; Angiography; Bronchi; Bronchial Neoplasms; Chlorthalidone; Diagnosis, Diffe | 1964 |
[CLINICAL TRIAL OF A HYPOTENSIVE DRUG: 3,4-DIHYDROXY-D-L-PHENYLALANINE OR METHYLDOPA].
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Eye Manifestations; Humans; Hydrochlorothia | 1964 |
THE RELATION BETWEEN HYPOPOTASSAEMIA AND ALKALOSIS DURING ADMINISTRATION OF POLYTHIAZIDE AND CHLORTHALIDONE.
Topics: Alkalosis; Biomedical Research; Chlorides; Chlorthalidone; Drug Therapy; Hypertension; Hypokalemia; | 1964 |
DIURETIC THERAPY. V. CLINICAL USE OF THIAZIDE DIURETICS.
Topics: Chlorothiazide; Chlorthalidone; Diuretics; Drug Therapy; Humans; Hypertension; Polythiazide; Quinazo | 1964 |
[CLINICAL EXPERIENCE OF 2,4,7-TRIAMINO-6-PHENYLPTERIDINE THERAPY UPON LONG TERM AND COMPOUND ADMINISTRATION WITH OTHER AGENTS].
Topics: Adolescent; Biomedical Research; Chlorthalidone; Diuretics; Drug Therapy; Edema; Geriatrics; Hydroch | 1964 |
[CHLORTHALIDONE-RESERPINE ASSOCIATION IN THE TREATMENT OF ARTERIAL HYPERTENSION].
Topics: Chlorthalidone; Humans; Hypertension; Reserpine | 1964 |
[THERAPY OF ESSENTIAL HYPERTENSION].
Topics: Benzothiadiazines; Chlorthalidone; Diuretics; Drug Therapy; Essential Hypertension; Guanethidine; Hu | 1965 |
[CLINICAL RESEARCH ON THE HYPOTENSIVE ACTION OF A CHLORTHALIDONE-RESERPINE PREPARATION].
Topics: Biomedical Research; Blood Pressure; Chlorthalidone; Diuresis; Geriatrics; Humans; Hypertension; Pot | 1964 |
THIAZIDE- AND PHTHALIMIDINE-INDUCED HYPERGLYCEMIA IN HYPERTENSIVE PATIENTS.
Topics: Amylases; Blood Chemical Analysis; Chlorthalidone; Creatine; Creatinine; Diabetes Mellitus; Drug The | 1965 |
[GP 37736-R205 IN ARTERIAL HYPERTENSION].
Topics: Chlorthalidone; Drug Therapy; Hypertension; Reserpine | 1964 |
[NEW METHODS IN THE AMBULANT TREATMENT OF HYPERTENSION].
Topics: Chlorthalidone; Drug Therapy; Hypertension; Reserpine | 1965 |
CLINICAL EVALUATION OF POLYTHIAZIDE IN HYPERTENSION AND CONGESTIVE HEART FAILURE: A COMPARATIVE DOUBLE-BLIND STUDY.
Topics: Biomedical Research; Blood Chemical Analysis; Blood Pressure; Body Weight; Chlorthalidone; Diuresis; | 1965 |
THE TREATMENT OF HYPERTENSION WITH CHLORTHALIDONE, A LONG-ACTING DIURETIC AGENT.
Topics: Blood; Blood Glucose; Chlorthalidone; Diuretics; Drug Therapy; Humans; Hypertension; Toxicology; Uri | 1965 |
THE ANTIHYPERTENSIVE ACTION OF CHLORTHALIDONE.
Topics: Antihypertensive Agents; Chlorthalidone; Drug Therapy; Humans; Hypertension | 1965 |
[CLINICAL EXPERIENCES WITH A MODERN COMBINED PREPARATION IN THE TREATMENT OF HYPERTENSION].
Topics: Chlorthalidone; Hypertension; Reserpine | 1965 |
[TREATMENT OF HYPERTENSION WITH HYGROTON-RESERPINE].
Topics: Chlorthalidone; Drug Therapy; Humans; Hypertension; Reserpine | 1964 |
[SURVEY OF THE TREATMENT OF 50 HYPERTENSIVE PATIENTS WITH A COMBINATION OF RESERPINE AND CHLORTHALIDONE].
Topics: Adolescent; Chlorthalidone; Data Collection; Drug Therapy; Geriatrics; Humans; Hypertension; Reserpi | 1965 |
VALUE OF CHLORTHALIDONE PLUS RESERPINE IN MODERATELY SEVERE AND SEVERE HYPERTENSION. A TWO-YEAR STUDY.
Topics: Antihypertensive Agents; Chlorthalidone; Drug Therapy; Electrocardiography; Humans; Hypertension; Re | 1965 |
A CONTROLLED SHORT TERM EVALUATION OF THE ANTIHYPERTENSIVE-DIURETIC AGENT, CHLORTHALIDONE, IN THE MANAGEMENT OF HYPERTENSION.
Topics: Antihypertensive Agents; Biomedical Research; Chlorthalidone; Disease Management; Diuretics; Drug Th | 1965 |
THE ROLE OF POSTGANGLIONIC SYMPATHETIC BLOCKADE IN ANTIHYPERTENSIVE THERAPY.
Topics: Antihypertensive Agents; Chlorthalidone; Drug Therapy; Ganglionic Blockers; Hypertension; Placebos; | 1965 |
[Experiences in the treatment of hypertension with chlorthalidone].
Topics: Chlorthalidone; Diuretics; Hypertension | 1962 |
[For every hypertensive patient a diuretic first? "Not advisable in diabetic patients"].
Topics: Antihypertensive Agents; Chlorthalidone; Contraindications; Coronary Disease; Diabetes Mellitus; Diu | 2003 |
[Severe perioperative hypotension after nephrectomy with adrenalectomy].
Topics: Addison Disease; Adrenalectomy; Adrenocorticotropic Hormone; Aged; Angiotensin-Converting Enzyme Inh | 2002 |
[Can hydrochlorothiazide and chlorthalidone be compared in the treatment of hypertension?].
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Sodiu | 2004 |
ALLHAT: what has it taught us so far?
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Lisinopril; Myocardial In | 2004 |
Chlorthalidone vs other low-dose diuretics.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Humans; Hypertension | 2004 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Pharmacoepidemiology of antihypertensive drugs in primary care setting of Bahrain between 1998 and 2000.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bahr | 2006 |
Chlorthalidone: has it always been the best thiazide-type diuretic?
Topics: Chlorthalidone; History, 20th Century; Humans; Hypertension; Sodium Chloride Symporter Inhibitors | 2006 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Omission of drug dose information.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2006 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
The putative link between glycemic control and cardiac arrhythmias.
Topics: Amlodipine; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Glucose; Chlorthalidone; Diabetes M | 2007 |
Maximizing diuretic therapy in resistant hypertension.
Topics: Blood Pressure; Chlorthalidone; Diuretics; Drug Resistance; Drug Therapy, Combination; Humans; Hyper | 2007 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |
Improving care in resistant hypertension: medication trends and nonpharmacologic strategies in a specialty clinic.
Topics: Adrenergic beta-Antagonists; Ambulatory Care Facilities; Antihypertensive Agents; Calcium Channel Bl | 2007 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist.
Topics: Adult; Bendroflumethiazide; Blood Pressure; Body Weight; Chlorthalidone; Female; Humans; Hyperaldost | 1967 |
Hypertensive vascular disease. The long term effect of rapid repeated reductions of arterial pressure with diazoxide.
Topics: Adult; Chlorthalidone; Diazoxide; Female; Heart Failure; Humans; Hydralazine; Hypertension; Injectio | 1967 |
[Hypertension, saluretics and glucose tolerance].
Topics: Blood Glucose; Carbohydrate Metabolism; Chlorthalidone; Diet, Reducing; Drug Tolerance; Glucose; Glu | 1967 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
[Clinical observations on the hypotensive action of the association of chlorthalidone and reserpine].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Hypertension, Renal; Male; Middle Aged; R | 1967 |
[Effectiveness of treatment with beta-blocking agents and diuretics in fixed combination, in aged hypertensive patients].
Topics: Adrenergic beta-Antagonists; Age Factors; Chlorthalidone; Diuretics; Drug Combinations; Drug Evaluat | 1980 |
Reversal or prevention of diuretic-induced alterations in serum lipoproteins with betablockers.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Chlorthalidone; Cholesterol; Cholesterol, HDL; Drug | 1982 |
[Role of renin profile and age in the choice of the therapeutic approach of arterial hypertension (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Atenolol; Chlorthalidone; Diuretics; Drug The | 1981 |
Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease: hypertension and other risk factors, Milan, 1983.
Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Chlorthalidone; Cholesterol; Cholesterol, HDL; Coron | 1984 |
Effect of prazosin on blood lipids and on thyroid function in hypertensive patients.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Heart Rate; Humans; Hyperten | 1982 |
Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias.
Topics: Adult; Aged; Ambulatory Care; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiac Complexes, Prem | 1983 |
[Circadian variability of hydrosaluretic and antihypertensive effects of a single daily 25 mg. dose of chlorthalidone].
Topics: Adult; Blood Pressure; Chlorthalidone; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle | 1984 |
Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Child; | 1980 |
[Mechanism of action of benzothiadiazides in arterial hypertension: the energetic theory].
Topics: Adenylyl Cyclase Inhibitors; Animals; Chlorthalidone; Columbidae; Cyclic AMP; Diuretics; Energy Meta | 1982 |
[Effect of guanabenz alone and in association with a diuretic on blood pressure and on the renin-angiotensin-aldosterone system in hypertensive patients].
Topics: Adult; Aged; Aldosterone; Chlorthalidone; Drug Therapy, Combination; Guanabenz; Guanidines; Heart Ra | 1984 |
Low dose thiazide combined with a beta blocker.
Topics: Atenolol; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Propanolamines | 1983 |
Diuretic regimens in essential hypertension. A comparison of hypokalemic effects, BP control, and cost.
Topics: Blood Pressure; Chlorthalidone; Cost-Benefit Analysis; Diuretics; Female; Furosemide; Humans; Hydroc | 1983 |
Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients.
Topics: Age Factors; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Combinations; Drug Tolera | 1984 |
Once-a-day therapy in patients with moderate-to-severe hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Drug Administration Schedule; Female; Humans; | 1984 |
[Clonidine-diuretic combination in patients with essential hypertension. Modification of sympathetic activity and blood pressure as well as the reaction following sudden withdrawal].
Topics: Blood Pressure; Chlorthalidone; Clonidine; Dose-Response Relationship, Drug; Drug Combinations; Epin | 1984 |
Effects of moderate salt restriction in hypertensive patients treated with oxprenolol or chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Diet, Sodium-Restricted; Female; Heart Rate; Humans; Hy | 1984 |
Hypotensive effect of the association atenolol-chlorthalidone in hypertensive diabetics.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Chlorthalidone; Diabetes Mellitus, Type 2; Dia | 1984 |
Refractory hypertension.
Topics: Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Middle Aged; Minoxidil; Nadolol; Pr | 1984 |
Intrarenal sodium handling during chronic spironolactone treatment.
Topics: Adult; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Natri | 1984 |
Different effects of metoprolol and chlorthalidone on serum lipoprotein levels in mild hypertension. Possible implications for coronary heart disease risk status.
Topics: Body Weight; Chlorthalidone; Cholesterol; Coronary Disease; Female; Heart Rate; Humans; Hypertension | 1984 |
Hemodynamic effects of once a day administration of combined chlorthalidone and metoprolol slow-release in essential hypertension.
Topics: Administration, Oral; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; Heart Rate; | 1984 |
[Slow-release oxprenolol and chlortalidone administered once daily in essential hypertension].
Topics: Adult; Chlorthalidone; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hypertension; | 1984 |
[A short-term clinical observation during the treatment of essential hypertension by atenolol composite tablets].
Topics: Adult; Atenolol; Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; | 1984 |
Experiences with Chlortalidone treatment in benign essential hypertension cases.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Male | 1984 |
Different blood pressure responses to diuretic treatment in normotensive subjects with and without a family history of hypertension.
Topics: Adult; Blood Pressure; Chlorthalidone; Diuretics; Epinephrine; Female; Heart Rate; Humans; Hypertens | 1983 |
Effect of treatment with chlorthalidone and atenolol on response to dilator agents in the forearm resistance vessels of men with primary hypertension.
Topics: Adult; Aged; Atenolol; Chlorthalidone; Forearm; Humans; Hypertension; Male; Middle Aged; Nitroprussi | 1983 |
[Prazosin in moderate or severe essential arterial hypertension not controlled with chlorthalidone. A multicenter study].
Topics: Adult; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male | 1983 |
Management of essential hypertension with oxprenolol and chlorthalidone in a fixed combination.
Topics: Adult; Blood Pressure; Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Male; Middle | 1983 |
[Effect of a metoprolol-chlorthalidone combination on arterial pressure and respiratory function].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; Heart Rate; Humans; | 1983 |
Effect of prazosin on blood pressure and plasma lipids in patients receiving a beta-blocker and diuretic regimen.
Topics: Aged; Blood Pressure; Chlorthalidone; Cholesterol; Drug Therapy, Combination; Female; Humans; Hypert | 1984 |
Step-down treatment of mild systemic hypertension.
Topics: Adult; Blood Glucose; Chlorthalidone; Drug Administration Schedule; Female; Humans; Hypertension; Li | 1984 |
[Continuous 24-hour registration of intra-arterial pressure in basal states and during therapy with a fixed slow-release oxprenolol-chlorthalidone combination, administered once a day].
Topics: Adult; Blood Pressure Determination; Chlorthalidone; Delayed-Action Preparations; Drug Combinations; | 1984 |
Potassium and diuretic-induced ventricular arrhythmias in ambulatory hypertensive patients.
Topics: Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Benzothiadiazines; Chlorthalidone; Diuretics; El | 1984 |
[Changes in body fluid spaces in hypertension patients treated with different diuretics].
Topics: Adult; Body Fluid Compartments; Body Fluids; Body Water; Chlorthalidone; Clopamide; Diuretics; Drug | 1984 |
[Initial values and drug effects].
Topics: Asthma; Bezafibrate; Blood Pressure Determination; Chlorthalidone; Cholesterol; Clenbuterol; Humans; | 1984 |
The role of aldosterone in the response to treatment of primary hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Male; Middle | 1982 |
Trasicor versus methyldopa in Pakistani hypertensive patients: a comparative study of efficacy and tolerability.
Topics: Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Methyldopa; Oxprenolol; Pakistan | 1981 |
[Withdrawal syndrome following beta blocker therapy (author's transl)].
Topics: Adult; Angina Pectoris; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Middle Aged; Myocard | 1981 |
A fixed combination of metoprolol slow-release and chlorthalidone, given once daily, in the long-term treatment of arterial hypertension.
Topics: Adult; Aged; Arteries; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Long-Term Ca | 1982 |
[Efficacy of low clonidine doses in galenic sustained-release preparations. Study with Combipresan 75 perlongettes].
Topics: Adult; Blood Pressure; Chlorthalidone; Clonidine; Delayed-Action Preparations; Drug Combinations; Fe | 1982 |
Clonidine in the elderly hypertensive. Monotherapy and therapy with a diuretic.
Topics: Aged; Blood Pressure; Chlorthalidone; Clonidine; Drug Therapy, Combination; Female; Humans; Hyperten | 1983 |
Combined diuretic and sympatholytic therapy in elderly patients with predominant systolic hypertension.
Topics: Aged; Blood Pressure; Chlorthalidone; Clonidine; Drug Combinations; Humans; Hypertension; Kidney; Ma | 1983 |
A functional abnormality of the forearm resistance vessels in men with primary hypertension.
Topics: Adult; Chlorthalidone; Forearm; Humans; Hypertension; Middle Aged; Ouabain; Regional Blood Flow; Sod | 1983 |
[Therapy compliance and plasma potassium level in patients treated with chlorthalidone].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Po | 1983 |
Hemodynamic actions of diuretic agents.
Topics: Animals; Blood Pressure; Chlorthalidone; Diuretics; Furosemide; Heart Rate; Hemodynamics; Hydrochlor | 1983 |
[Antihypertensive effect of metoprolol in essential hypertension].
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Drug Evaluation; Drug Therapy, Combination; Female; | 1983 |
[Changes in water-sodium balance in patients with hypertension subjected to different types of hypotensive therapy].
Topics: Adult; Aged; Aldosterone; Angiotensin I; Chlorthalidone; Extracellular Space; Female; Hemodynamics; | 1983 |
Total body potassium in patients receiving chlorthalidone and metoprolol for hypertension.
Topics: Adult; Chlorthalidone; Female; Humans; Hyperkalemia; Hypertension; Male; Metoprolol; Middle Aged; Po | 1983 |
[Comparative evaluation of the extended hypotensive effect of slow-released clonidine administered alone or in association with a diuretic].
Topics: Adult; Aged; Chlorthalidone; Clonidine; Delayed-Action Preparations; Drug Evaluation; Drug Therapy, | 1983 |
Changes in urinary electrolytes versus serum electrolytes during treatment of primary hypertension with chlorthalidone alone and in combination with spironolactone.
Topics: Adult; Aldosterone; Chlorthalidone; Drug Therapy, Combination; Electrolytes; Humans; Hypertension; M | 1981 |
Relationship between plasma catecholamines and urinary catecholamine excretion rates in normal subjects and certain diseased states.
Topics: Adult; Blood Pressure; Chlorthalidone; Creatinine; Diabetes Mellitus; Electrolytes; Epinephrine; Fem | 1981 |
Changes in intrarenal sodium handling during saluretic treatment in patients with essential hypertension.
Topics: Adolescent; Adult; Blood Pressure; Body Fluids; Chlorthalidone; Female; Humans; Hypertension; Kidney | 1981 |
[Hypertensive therapy. Improvement of compliance with a daily regimen of a two-drug combination].
Topics: Atenolol; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combinations; Heart Rate; Humans | 1982 |
Pindolol and systolic time intervals in patients with hypertension.
Topics: Adult; Blood Pressure; Chlorthalidone; Double-Blind Method; Female; Humans; Hypertension; Male; Midd | 1982 |
[Evaluation of the antihypertensive effectiveness of low doses of chlorthalidone].
Topics: Adult; Blood Pressure; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; | 1982 |
Minoxidil in severe and moderately severe hypertension, in association with methyldopa and chlortalidone.
Topics: Adult; Aged; Body Water; Chlorthalidone; Creatinine; Drug Therapy, Combination; Heart Rate; Humans; | 1982 |
Changes in intrarenal uric acid handling during chronic spironolactone treatment in patients with essential hypertension.
Topics: Body Weight; Chlorthalidone; Female; Humans; Hypertension; Kidney; Male; Spironolactone; Uric Acid | 1982 |
[Effect of antihypertensive therapy on oxygen consumption of the myocardium. I. Hydrochlorothiazide and chlorthalidone].
Topics: Adult; Chlorthalidone; Hemodynamics; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; M | 1981 |
[Various cycloergometric variables in patients with uncomplicated borderline arterial hypertension. Effect of chlorthalidone and propranolol].
Topics: Adult; Blood Pressure; Chlorthalidone; Exercise Test; Heart Rate; Humans; Hypertension; Male; Middle | 1982 |
Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension.
Topics: Adolescent; Adult; Chlorthalidone; Diuretics; Extracellular Space; Female; Hemodynamics; Hormones; H | 1981 |
[Experience in the ambulatory treatment of primary arterial hypertension with a fixed oxprenolol-chlorthalidone combination].
Topics: Adult; Aged; Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Oxp | 1980 |
[Comparative studies of the effects of the diuretics, fenquizone and chlorthalidone, in arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Diuresis; Female; Heart Rate; Humans; Hypertension; Mal | 1981 |
Use of the the combination labetalol plus chlorthalidone in essential arterial hypertension therapy.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Ethanolamines; Female; Human | 1981 |
Total body and serum potassium during treatment with atenolol in combination with chlorthalidone.
Topics: Adult; Antihypertensive Agents; Atenolol; Body Composition; Chlorthalidone; Drug Combinations; Femal | 1981 |
[Comparative study of the association of propranolol-chlorthalidone and the fixed combination of timolol-hydrochlorothiazide-amiloride in the treatment of arterial hypertension].
Topics: Amiloride; Antihypertensive Agents; Chlorthalidone; Diuretics; Drug Therapy, Combination; Humans; Hy | 1981 |
[Use of metoprolol and atenolol, singly or in combination with a diuretic, in the treatment of arterial hypertension].
Topics: Adult; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Meto | 1980 |
[Impotence caused by chlorthalidone (Hygroton) therapy].
Topics: Chlorthalidone; Erectile Dysfunction; Humans; Hypertension; Male | 1981 |
Treatment of Jamaican hypertensives with atenolol and chlorthalidone.
Topics: Adolescent; Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Female; Humans; Hypertension; | 1981 |
A comparison of chlorthalidone-reserpine and hydrochlorothiazide-methyldopa as step 2 therapy for hypertension.
Topics: Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; | 1981 |
[Verapamil as a hypotensive agent. Clinical, laboratory, electro- and echocardiographic study].
Topics: Adult; Aged; Chlorthalidone; Echocardiography; Electrocardiography; Female; Humans; Hypertension; Li | 1981 |
[Cardiac response to the cold pressor test in essential hypertension. Effect of saline depletion on the systolic interval].
Topics: Adult; Chlorthalidone; Cold Temperature; Diet, Sodium-Restricted; Humans; Hypertension; Middle Aged; | 1980 |
Potassium loss associated with hydrochlorothiazide versus chlorthalidone.
Topics: Adult; Aged; Chlorothiazide; Chlorthalidone; Dose-Response Relationship, Drug; Female; Humans; Hyper | 1981 |
One year efficacy and tolerability of oxprenolol slow-release and chlorthalidone on fixed combination in mild to moderate hypertension.
Topics: Adult; Aged; Chlorthalidone; Delayed-Action Preparations; Drug Combinations; Female; Heart Rate; Hum | 1981 |
[Treatment of arterial hypertension: comparative study of atenolol + chlorthalidone vs. timolol maleate-hydrochlorthiazide-amiloride association].
Topics: Adult; Aged; Amiloride; Atenolol; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Female; | 1981 |
[Evaluation of the antihypertensive effectiveness of the combination of metoprolol and chlorthalidone, using the ergometric test].
Topics: Adult; Chlorthalidone; Drug Evaluation; Drug Therapy, Combination; Exercise Test; Humans; Hypertensi | 1981 |
One and three doses of propranolol a day in hypertension.
Topics: Adolescent; Adult; Blood Pressure; Chlorthalidone; Depression, Chemical; Dreams; Drug Administration | 1980 |
The practicing physician and control of hypertension.
Topics: Adult; Aged; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Female; Heart Failure; Hum | 1980 |
Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone.
Topics: Adolescent; Adult; Chlorthalidone; Cholesterol; Female; Humans; Hypertension; Lipoproteins, HDL; Lip | 1980 |
The effect of chlorthalidone on serum lipids and lipoproteins.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Cholesterol; Female; Humans; Hypertension; Lipids; Lipo | 1980 |
Hypokalaemia and diuretics: an analysis of publications.
Topics: Chlorothiazide; Chlorthalidone; Coronary Disease; Diuretics; Dose-Response Relationship, Drug; Furos | 1980 |
Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension.
Topics: Chlorthalidone; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hypertension; Ma | 1980 |
Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
Topics: Adult; Atenolol; Chlorthalidone; Drug Therapy, Combination; Half-Life; Humans; Hypertension; Male; P | 1980 |
Chlorthalidone-induced impotence.
Topics: Chlorthalidone; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged | 1980 |
Atenolol and chlorthalidone for hypertension in black South Africans.
Topics: Atenolol; Black or African American; Black People; Chlorthalidone; Diet; Humans; Hypertension; Propa | 1980 |
Clonidine-chlorthalidone combination once and twice daily in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clonidine; Drug Administration Schedule; Drug Therapy, | 1980 |
[Treatment of hypertension with a new combination of beta blocking agents and saluretics].
Topics: Chlorthalidone; Delayed-Action Preparations; Drug Combinations; Hypertension; Oxprenolol | 1980 |
[Behavior of certain echocardiographic variables in patients with uncomplicated borderline arterial hypertension - influence of chlorthalidone and propranolol].
Topics: Adult; Chlorthalidone; Echocardiography; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Prop | 1980 |
[Rubric of good and less good drugs. Clonidine].
Topics: Chlorthalidone; Clonidine; Drug Combinations; Humans; Hypertension | 1995 |
Urapidil compared with diuretics in the treatment of mild-to-moderate essential hypertensive patients: effects on glucose metabolism, insulin sensitivity, and lipid profile.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Female; Glucose; Humans; Hydrochlorothiazide; Hypert | 1994 |
Combination products as first-line pharmacotherapy.
Topics: Betaxolol; Bisoprolol; Chlorthalidone; Drug Approval; Drug Combinations; Humans; Hydrochlorothiazide | 1994 |
[Hemodynamic effects of low doses of chlorthalidone in patients with mild systemic arterial hypertension].
Topics: Adult; Blood Pressure; Cardiac Output; Chlorthalidone; Dose-Response Relationship, Drug; Female; Hem | 1993 |
[Effect of treatment with chlorthalidone on reduction of left ventricular mass in patients with systemic arterial hypertension].
Topics: Adult; Blood Pressure; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left V | 1993 |
Effects of chlorthalidone on ventricular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Chlorthalidone; Desoxycorticosterone; Dose-Respo | 1994 |
[Thrombocytopenia from a pharmacological cause].
Topics: Atenolol; Chlorthalidone; Drug Therapy, Combination; Humans; Hypertension; Male; Middle Aged; Thromb | 1993 |
Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis.
Topics: Basal Ganglia Diseases; Biperiden; Carbidopa; Chlorthalidone; Coma; Drug Therapy, Combination; Femal | 1993 |
[Hypertension, hyperpotassemia and normal glomerular filtration (Gordon's syndrome): a case report].
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Diuretics; Electrocardiography, Ambulatory; Glomerul | 1996 |
Chlorthalidone-modulated vascular responses to vasodilator stimuli in DOCA-salt hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium; Chlorthalidone; Desoxycorticosterone; Dru | 1996 |
Effects of antihypertensive therapy on left atrial function.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atrial Function, Left; Blood Pressure; Chlorthalid | 1996 |
Evaluation of protein and peptide hydrolases in DOCA-salt hypertensive rat treated with chlorthalidone.
Topics: Animals; Antihypertensive Agents; Chlorthalidone; Desoxycorticosterone; Hypertension; Male; Peptide | 1996 |
A cautionary tale.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Calcium Channel Blockers; Ch | 1997 |
Stroke in the elderly treated for systolic hypertension (SHEP).
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlor | 1991 |
The diuretic chlorthalidone normalizes baroreceptor and Bezold-Jarisch reflexes in DOCA-salt hypertensive rats.
Topics: Animals; Atrial Natriuretic Factor; Baroreflex; Biguanides; Blood Pressure; Chlorthalidone; Desoxyco | 2000 |
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diur | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Hypertension and alpha-adrenergic blockers: preliminary ALLHAT results.
Topics: Adrenergic alpha-Antagonists; Aged; Canada; Chlorthalidone; Diuretics; Doxazosin; Female; Humans; Hy | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cause of Death; Chlorthalidone; Doxazos | 2001 |
Doxazosin, an inferior antihypertensive agent?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cont | 2002 |
[Effect of atenolol combined with chlortalidone on characteristics of 24-hour blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Circadian Rhythm | 2002 |
Effects of chlorthalidone on serum and total body potassium in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Body Weight; Chlorthalidone; Drug Therapy, Combination; Electrolytes | 1976 |
Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
Topics: Adult; Bicarbonates; Chlorides; Chlorthalidone; Diet, Sodium-Restricted; Female; Humans; Hydrogen-Io | 1978 |
[Combination of beta-blocking agents, diuretics and pressidil (minoxidil) in severe arterial hypertension resisting other therapy].
Topics: Adrenergic beta-Antagonists; Adult; Chlorthalidone; Diuretics; Drug Therapy, Combination; Female; Fu | 1978 |
[Behavior of cardiac output, plasma volume, plasma renin activity and aldosterone secretion in patients with essential hypertension treated with beta-blocking agents and diuretics].
Topics: Adrenergic beta-Antagonists; Adult; Aldosterone; Blood Volume; Cardiac Output; Chlorthalidone; Diure | 1979 |
Increase in serum-lipids during treatment of hypertension with chlorthalidone.
Topics: Chlorthalidone; Cholesterol; Diet, Sodium-Restricted; Female; Humans; Hyperlipidemias; Hypertension; | 1976 |
Plasma renin and "prorenin" in essential hypertension during sodium depletion, beta-blockade, and reduced arterial pressure.
Topics: Adult; Blood Pressure; Chlorthalidone; Clonidine; Depression, Chemical; Diet, Sodium-Restricted; Dru | 1977 |
[Treatment of hypertension with a combination of beta receptor blockers and diuretics (Trasitensin retard)].
Topics: Adult; Aged; Chlorthalidone; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Oxp | 1979 |
[Reduction of hypertensive changes in the electrocardiogram during antihypertensive treatment].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorthalidone; Electrocardiography; Fe | 1979 |
[Regression of left ventricular hypertophy in the ECG during antihypertensive treatment: preliminary observations (author's transl)].
Topics: Adult; Aged; Cardiomegaly; Chlorthalidone; Electrocardiography; Female; Humans; Hydralazine; Hyperte | 1979 |
Relationship between the hypotensive and renin-stimulating actions of diuretic therapy in hypertensive patients.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Chlorthalidone; Heart Rate; Humans; Hypertension; Middl | 1978 |
Long-term study of oxdralazine in hypertensive patients.
Topics: Antihypertensive Agents; Chlorthalidone; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; | 1979 |
[Relation between the hypotensive and renin-stimulating effect of diuretic therapy in hypertensive patients].
Topics: Adult; Aged; Angiotensin II; Chlorthalidone; Diuretics; Drug Therapy, Combination; Hemodynamics; Hum | 1978 |
Echocardiographic assessment of the effect of an antihypertensive regimen on left ventricular performance.
Topics: Adult; Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Chlorthalidone; Coronary Disease | 1979 |
[Effect of verapamil on the pressure response induced by cycloergometry in hypertensive patients].
Topics: Adult; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Exercise Test; Female; Humans; Hyp | 1979 |
Diuretics and cholesterol elevation.
Topics: Chlorthalidone; Diuretics; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Polythia | 1979 |
Drug treatment of essential hypertension. Practical guidelines.
Topics: Adult; Aged; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydralazine; Hypertension; M | 1979 |
Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Blood Volume; Chlorthalidone; Diabetes Complications; D | 1979 |
Duration of effect of different diuretics.
Topics: Aged; Biological Availability; Blood Pressure; Body Weight; Chlorothiazide; Chlorthalidone; Female; | 1979 |
Treatment of moderate and severe hypertension with minoxidil.
Topics: Adult; Chlorthalidone; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hypertension; Hyp | 1979 |
[Effects of high doses of clonidine and chlorthalidone].
Topics: Chlorthalidone; Clonidine; Drug Synergism; Female; Humans; Hypertension; Hypotension; Middle Aged | 1979 |
[Effect of labetalol and chlorthalidone on exercise tolerance in hypertensive subjects].
Topics: Adult; Chlorthalidone; Ethanolamines; Exercise Test; Hemodynamics; Humans; Hypertension; Labetalol; | 1979 |
Treatment of mild hypertension. Preliminary results of a two-year feasibility trial.
Topics: Adult; Blood Pressure; Chlorthalidone; Death, Sudden; Humans; Hypertension; Male; Mass Screening; Mi | 1977 |
Reversible acute renal failure associated with chlorthalidone therapy: possible drug-induced interstitial nephritis.
Topics: Acute Kidney Injury; Chlorthalidone; Humans; Hypertension; Male; Middle Aged; Nephritis, Interstitia | 1978 |
Incidence of chlorthalidone-induced hypercalcemia.
Topics: Chlorthalidone; Humans; Hypercalcemia; Hypertension | 1978 |
Propranolol for the treatment of hypertension in pregnancy.
Topics: Adult; Apgar Score; Chlorthalidone; Female; Fetal Death; Humans; Hypertension; Infant, Newborn; Infa | 1978 |
Chlorthalidone-induced syndrome of inappropriate secretion of antidiuretic hormone.
Topics: Chlorthalidone; Female; Humans; Hypertension; Kidney Calculi; Osmolar Concentration; Sodium; Time Fa | 1978 |
[Clinical and statistical evaluation of the hypotensive effectiveness of 3 therapeutic plans in essential hypertension].
Topics: Adolescent; Adult; Amitriptyline; Antihypertensive Agents; Chlorthalidone; Diazepam; Drug Therapy, C | 1978 |
Systemic hypertension complicating tetralogy of Fallot: effects of antihypertensive therapy.
Topics: Adult; Angiocardiography; Cardiac Catheterization; Chlorthalidone; Female; Heart Failure; Heart Sept | 1978 |
[Ergometry in the assessment of antihypertensive treatment (author's transl)].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Female; Humans; Hydralazine; Hypertension; Mal | 1978 |
[Acute interstitial nephritis and IgE].
Topics: Acute Disease; Chlorthalidone; Digoxin; Female; Humans; Hypertension; Immunoglobulin E; Middle Aged; | 1978 |
[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers].
Topics: Adult; Aldosterone; Chlorthalidone; Female; Furosemide; Hirsutism; Humans; Hypertension; Male; Middl | 1978 |
[Combined clonidine-chlorthalidone therapy of hypertension].
Topics: Chlorthalidone; Clonidine; Drug Combinations; Humans; Hypertension | 1978 |
Renin reactivity as a determinant of responsiveness to antihypertensive treatment.
Topics: Adult; Aged; Aldosterone; Antihypertensive Agents; Blood Pressure; Body Weight; Chlorthalidone; Drug | 1977 |
Hypotensive effects of sodium volume depletion and 1-sar-8-ala-angiotensin II in relation to plasma renin in hypertensive patients.
Topics: Adult; Angiotensin II; Blood Pressure; Body Weight; Chlorthalidone; Diet, Sodium-Restricted; Female; | 1977 |
Disparate patterns of aldosterone response during diuretic treatment of hypertension.
Topics: Adult; Aldosterone; Body Weight; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Pu | 1977 |
[Clinical effects of a clonidine-chlorthalidone combination in the treatment of arterial hypertension].
Topics: Adult; Chlorthalidone; Clonidine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hypert | 1976 |
Hypotension during angiotensin blockade with saralasin.
Topics: Adult; Angiotensin II; Chlorthalidone; Humans; Hypertension; Hypotension; Male; Saralasin | 1976 |
[The diuretics in the treatment of arteriol hypertension].
Topics: Amiloride; Benzothiadiazines; Chlorthalidone; Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypert | 1976 |
Clinical trail with clonidine hydrochloride.
Topics: Adult; Aged; Chlorthalidone; Clonidine; Drug Therapy, Combination; Female; Humans; Hypertension; Mal | 1976 |
[Comparative study of the hypotensive effect of a combination of oxprenolol-chlortalidone with single and fractionated administration].
Topics: Adult; Aged; Chlorthalidone; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypert | 1976 |
Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods.
Topics: Blood Pressure; Chlorthalidone; Furosemide; Humans; Hyperaldosteronism; Hypertension; Physical Exert | 1975 |
[Spironolactone combined with chlorthalidone in the treatment of essential arterial hypertension].
Topics: Aged; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Sp | 1975 |
[Diazoxide: new way in treatment of hypertension].
Topics: Adult; Chlorthalidone; Diazoxide; Diet, Sodium-Restricted; Female; Humans; Hydralazine; Hypertension | 1975 |
Combined clonidine-chlorthalidone therapy in hypertension. Two years' experience in 30 patients.
Topics: Adult; Aged; Chlorthalidone; Clonidine; Drug Therapy, Combination; Female; Humans; Hypertension; Mal | 1975 |
Combipres for hypertension.
Topics: Chlorthalidone; Clonidine; Drug Combinations; Humans; Hypertension | 1975 |
[Treatment of moderate hypertension, particularly by the general practitioner].
Topics: Adult; Aged; Antihypertensive Agents; Chlorthalidone; Diet, Sodium-Restricted; Female; Humans; Hyper | 1975 |
Some side-effects of alpha-methyldopa.
Topics: Adult; Aged; Chlorthalidone; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hydralazine; H | 1976 |
Antihypertensive action of indapamide. Comparative studies in several experimental models.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Chlorthalidone; Diuretics; Dogs; | 1975 |
Drug regimens for long-term therapy of hypertension.
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Guanethidine; Humans; Hydralazine; Hypertension; | 1976 |
The effects of therapy for mild hypertension on circulating level of dopamine beta-hydroxylase.
Topics: Blood Pressure; Catecholamines; Chlorthalidone; Dopamine beta-Hydroxylase; Female; Humans; Hypertens | 1976 |
Blood pressure in middle-aged people in Albury and Melbourne - implications for screening.
Topics: Australia; Blood Pressure; Chlorthalidone; Diuretics; Female; Follow-Up Studies; Humans; Hypertensio | 1976 |
Angiotensin converting enzymes from urine of treated and untreated essential mild hypertensive patients (EHP) with diuretic: partial purification and characterization.
Topics: Adult; Blood Pressure; Chlorthalidone; Chromatography, DEAE-Cellulose; Chromatography, Gel; Electrop | 1992 |
Effects of nifedipine-GITS on left ventricular mass and left ventricular filling.
Topics: Atrial Natriuretic Factor; Cardiomegaly; Chlorthalidone; Delayed-Action Preparations; Drug Therapy, | 1992 |
Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT.
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Cholesterol, Dietary; Coronary Disease; Electrocardi | 1992 |
Chlorthalidone reduces vascular hyperresponsiveness in DOCA-salt hypertensive rats.
Topics: Animals; Blood Pressure; Chlorthalidone; Desoxycorticosterone; Hypertension; In Vitro Techniques; Ma | 1992 |
[Acute renal failure caused by treatment with diuretics and ACE inhibitors in the absence of renal artery stenosis].
Topics: Acute Kidney Injury; Adult; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Diuretics; Ena | 1992 |
Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy.
Topics: Adult; Aged; Blood Glucose; Chlorthalidone; Creatinine; Diabetes Complications; Diuretics; Female; G | 1992 |
[Prolonged cardioselective blockade of beta-1 adrenoreceptors in combination with increased diuresis as a method of choice in the treatment of hypertension].
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Drug Combinations; Humans; Hypertens | 1991 |
Effect of thiazide-based therapy on serum alkaline phosphatase. Hypertension Detection and Follow-up Group.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Benzothiadiazines; Blood Pressure; Chlorthalidone; D | 1991 |
Isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Cerebrovascular Disorders; Chlorthalidone; Clinical Trials as Topic; | 1991 |
[The blood rheology of diuretics].
Topics: Adult; Aged; Blood Pressure; Blood Viscosity; Chlorthalidone; Chronic Disease; Diuretics; Female; Hu | 1990 |
[Do clinical parameters exist that permit predicting the need to combine a diuretic with captopril in the initial treatment of essential arterial hypertension?].
Topics: Adult; Aged; Blood Pressure; Captopril; Chlorthalidone; Diet, Sodium-Restricted; Diuretics; Drug The | 1990 |
Chlorthalidone alters the vascular reactivity of DOC-salt hypertensive rats to norepinephrine.
Topics: Animals; Chlorthalidone; Desoxycorticosterone; Hypertension; Male; Norepinephrine; Rats; Rats, Inbre | 1990 |
The effect of fosinopril sodium on cerebral blood flow in moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cerebrovascular Circulation; Chlorthalidone; F | 1990 |
Haemodynamic resistance of forearm vessels during prolonged drug treatment of essential hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clonidine; Drug Therapy, Combination | 1990 |
Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomegaly; Catecholamines; Chlorthalid | 1986 |
Do beta-blockers alter lipids and what are the consequences?
Topics: Adrenergic beta-Antagonists; Blood Pressure; Chlorthalidone; Diuretics; Female; Humans; Hypertension | 1987 |
[Intraerythrocytic potassium and diuretic therapy].
Topics: Adult; Blood Pressure; Chlorthalidone; Erythrocytes; Female; Humans; Hypertension; Middle Aged; Pota | 1989 |
[Gallopamil and chlorthalidone versus atenolol and chlorthalidone in the treatment of obstructive hypertrophic cardiomyopathy in patients with arterial hypertension: polycardiographic evaluation of the systolic and diastolic function of the left ventricle
Topics: Adult; Aged; Atenolol; Cardiomyopathy, Hypertrophic; Chlorthalidone; Diastole; Drug Evaluation; Drug | 1989 |
[Captopril from Pharmachem in the treatment of arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Captopril; Chlorthalidone; Drug Evaluation; Drug Therapy, Combination; | 1989 |
Captopril treatment in elderly hypertensive patients: efficacy and tolerability. Captopril Study Group.
Topics: Aged; Captopril; Chlorthalidone; Drug Therapy, Combination; Drug Tolerance; Female; Heart Rate; Huma | 1989 |
[Value of heart rate recordings in selecting the initial treatment of hypertension].
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; | 1989 |
Acute reduction of blood pressure in asymptomatic patients with severe hypertension. An idea whose time has come--and gone.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Clonidine; Drug Administration Schedule; Hu | 1989 |
Angiotensin converting enzyme inhibitors and diuretics in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Drug Therapy, Combination; Enalapril; Huma | 1987 |
The effect of converting enzyme inhibition on the enhanced proximal sodium reabsorption induced by chronic diuretic treatment in patients with essential hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Chlorthalidone; C | 1987 |
A comparative study of celiprolol and chlorthalidone in hypertensive patients with reversible airways obstruction.
Topics: Adrenergic beta-Antagonists; Asthma; Celiprolol; Chlorthalidone; Drug Evaluation; Humans; Hypertensi | 1985 |
Angiotensin I converting enzyme activity in hypertension. Relationship to blood pressure, renin-sodium profiles, and antihypertensive therapy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Captopril; Chlorthalidone; Fem | 1985 |
[A beta blockader-diuretic combination in long-term anti-hypertensive therapy. Undesirable effects on blood potassium].
Topics: Adrenergic beta-Antagonists; Adult; Chlorthalidone; Drug Therapy, Combination; Female; Follow-Up Stu | 1985 |
[Use of crystepin and obsidan in patients with hypertension].
Topics: Adult; Chlorthalidone; Dihydroergotoxine; Drug Combinations; Drug Therapy, Combination; Humans; Hype | 1986 |
Antihypertensive therapy with diuretics and beta-blockers at fixed dosage: comparison between the combinations labetalol plus chlorthalidone and atenolol plus chlorthalidone.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Diuretics; Drug Therap | 1985 |
[Cardiovascular response to isometric exercise test during beta blocker and diuretic treatment in essential arterial hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Chlorthalidone; Diuretics; Drug Evalua | 1988 |
[Hyponatremia caused by water intoxication induced by diuretics].
Topics: Adult; Chlorthalidone; Diuretics; Humans; Hypertension; Hyponatremia; Male; Water Intoxication | 1989 |
[Reduction of left ventricular hypertrophy and increased tolerance to exertion in hypertensive patients after antihypertensive therapy with slow-release oxprenolol and chlorthalidone].
Topics: Adult; Cardiomegaly; Chlorthalidone; Delayed-Action Preparations; Drug Therapy, Combination; Exercis | 1986 |
Psoriasiform eruption induced by captopril and chlorthalidone.
Topics: Aged; Captopril; Chlorthalidone; Drug Eruptions; Female; Humans; Hypertension; Male; Middle Aged; Ps | 1987 |
[Photoallergy to Neotri and cross reaction to tenoretic--detection by systemic photoprovocation].
Topics: Aged; Atenolol; Chlorthalidone; Diuretics; Drug Combinations; Drug Eruptions; Humans; Hypertension; | 1988 |
Effects of chronic administration of the fixed combination slow-release oxprenolol-chlorthalidone on left ventricular hypertrophy in hypertensive patients. Echocardiographic study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiomegaly; Chlorthalidone; Creatinine; Delayed-Action | 1988 |
Participation of the renin-angiotensin system in the maintenance of blood pressure during changes in posture in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Chlorthalidone; Di | 1985 |
Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril.
Topics: Aged; Aldosterone; Blood Pressure; Body Fluids; Body Weight; Chlorthalidone; Creatinine; Drug Evalua | 1986 |
Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy.
Topics: Body Fluids; Chlorthalidone; Drug Therapy, Combination; Enalapril; Female; Hemodynamics; Humans; Hyp | 1986 |
Prazosin partly blocks clonidine-induced hypotension in patients with essential hypertension.
Topics: Adult; Blood Pressure; Chlorthalidone; Clonidine; Drug Therapy, Combination; Heart Rate; Humans; Hyp | 1987 |
[Thrombocytopenia caused by drugs: new molecules as the cause].
Topics: Aged; Aged, 80 and over; Atenolol; Captopril; Chlorthalidone; Drug Therapy, Combination; Female; Hum | 1987 |
The statistical analysis of treatment effects in 24-hour ambulatory blood pressure recordings.
Topics: Activity Cycles; Ambulatory Care; Atenolol; Blood Pressure; Blood Pressure Determination; Chlorthali | 1988 |
[Effect of chlorthalidone on peripheral resistance in the treatment of arterial hypertension].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Female; Heart Rate; Humans; Hypertension; Male; Middle | 1987 |
[Hemodynamic effects of diuretics in the treatment of systemic hypertension].
Topics: Blood Pressure; Cardiac Output; Chlorthalidone; Diuretics; Hemodynamics; Humans; Hypertension; Vascu | 1987 |
[Comparison of nadolol and chlorthalidone in hypertensive subjects resistant to therapy with only captopril].
Topics: Adult; Aged; Antihypertensive Agents; Captopril; Chlorthalidone; Female; Humans; Hypertension; Male; | 1986 |
[Captopril in the treatment of arterial hypertension in the elderly patient].
Topics: Aged; Captopril; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Midd | 1986 |
Diuretic-induced hypokalemia and altered renal function.
Topics: Aged; Chlorthalidone; Glomerular Filtration Rate; Humans; Hypertension; Hypokalemia; Kidney; Kidney | 1986 |
[Potentiation of the hypotensive effect of labetalol in hypertensive patients treated to maintain sodium balance in the body].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Chlorthalidone; Combined Modality Therapy; Diet, Sodium | 1987 |
[Hypokalemic rhabdomyolysis associated with diuretic and beta blockader therapy].
Topics: Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Hypokalemia; Metoprolol; Mi | 1987 |
[Hemodynamic mechanisms of the hypotensive effect of hypothiazide and oxodolin].
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Hemodynamics; Humans; Hydrochlorothiazide; Hypertens | 1987 |
Postmarketing survey of the effects of an atenolol/chlorthalidone combination in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Chlor | 1987 |
[Clinico-therapeutic evaluation of the hypertensive patient by the isometric exertion test].
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clonidine; Female; Humans; | 1986 |
Reserpine versus beta-blocker as an additive to a diuretic in the treatment of Kenyan hypertensives.
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Drug Combinations; Drug Therapy, Combi | 1986 |
[Long-term therapy with atenolol and chlorthalidone in medium- and high-grade arterial hypertension].
Topics: Adult; Aged; Aged, 80 and over; Atenolol; Chlorthalidone; Drug Therapy, Combination; Female; Follow- | 1986 |
[Echocardiographic changes in hypertensive patients treated with a fixed combination of metoprolol and chlorthalidone].
Topics: Adult; Chlorthalidone; Delayed-Action Preparations; Drug Combinations; Echocardiography; Female; Hea | 1986 |
Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program.
Topics: Adult; Aged; Benzothiadiazines; Chlorthalidone; Creatinine; Diuretics; Female; Follow-Up Studies; Hu | 1987 |
Minoxidil in a once-a-day step-3 antihypertensive program.
Topics: Chlorthalidone; Drug Therapy, Combination; Edema; Female; Humans; Hypertension; Hypertrichosis; Male | 1985 |
The management of severe hypertension with minoxidil in a once-a-day treatment regimen.
Topics: Adult; Aged; Chlorthalidone; Creatinine; Drug Therapy, Combination; Edema; Female; Humans; Hypertens | 1985 |
Changes in blood pressure and thermographic values resulting from use of a beta-blocker plus diuretic and of an alpha-beta-blocker plus diuretic.
Topics: Adult; Atenolol; Body Temperature; Chlorthalidone; Drug Therapy, Combination; Heart Rate; Humans; Hy | 1985 |
Body sodium-blood volume state, aldosterone, and cardiovascular responsiveness after calcium entry blockade with nifedipine.
Topics: Aged; Aldosterone; Angiotensin II; Blood Volume; Calcium; Chlorthalidone; Drug Therapy, Combination; | 1985 |
Chlorthalidone treatment in patients with hypertension associated with hypokalaemia.
Topics: Chlorthalidone; Humans; Hypertension; Hypokalemia | 1985 |
Blood to interstitial fluid volume ratio in chronic hypokalaemic states.
Topics: Bartter Syndrome; Blood Volume; Chlorthalidone; Chronic Disease; Extracellular Space; Female; Humans | 1985 |
[Long-term study of the effects of chlorthalidone and amiloride on the renal excretion of electrolytes in patients with vascular hypertension].
Topics: Adult; Aged; Amiloride; Blood Pressure; Chlorthalidone; Drug Therapy, Combination; Electrolytes; Fem | 1986 |
[Sex disorders and chlorthalidone; an unexpected and little-known side effect of thiazide diuretics].
Topics: Adult; Chlorthalidone; Erectile Dysfunction; Humans; Hypertension; Male | 1985 |
[Effects of atenolol and an atenolol-chlorthalidone combination on blood pressure values in hypertensive patients].
Topics: Adult; Aged; Atenolol; Blood Pressure; Chlorthalidone; Drug Combinations; Female; Humans; Hypertensi | 1985 |
[Therapy of arterial hypertension with a delayed-action clonidine and chlorthalidone combination].
Topics: Adult; Aged; Chlorthalidone; Clonidine; Delayed-Action Preparations; Drug Combinations; Female; Huma | 1985 |
Arrhythmogenic potential of diuretic induced hypokalaemia in patients with mild hypertension and ischaemic heart disease.
Topics: Amiloride; Arrhythmias, Cardiac; Chlorthalidone; Coronary Disease; Cyclopenthiazide; Diuretics; Fema | 1985 |
Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial.
Topics: Adult; Blood Pressure; California; Chlorthalidone; Coronary Disease; Diet; Epidemiologic Methods; Hu | 1985 |
[Diuretics in the therapy of arterial hypertension].
Topics: Chlorthalidone; Diuretics; Extracellular Space; Furosemide; Humans; Hypertension | 1985 |
The static elastic properties and chemical composition of the rat aorta in spontaneously occurring and experimentally induced hypertension: the effect of an anti-hypertensive drug.
Topics: Aging; Animals; Aorta; Aorta, Abdominal; Aorta, Thoracic; Body Weight; Chlorthalidone; Collagen; Ela | 1985 |
[Lupus erythematosus disseminatus induced by alpha methyldopa].
Topics: Antibodies, Antinuclear; Chlorthalidone; Coombs Test; Drug Therapy, Combination; Female; Humans; Hyp | 1974 |
[Inhibition of natriuretic effect of angiotensin by spirolactones and salidiuretics in cirrhosis and arterial hypertension].
Topics: Angiotensin II; Chlorthalidone; Creatinine; Depression, Chemical; Diet, Sodium-Restricted; Glomerula | 1969 |
Characteristics of hypertension in the black population.
Topics: Adult; Angiotensin II; Animals; Black or African American; Cardiomegaly; Cerebrovascular Disorders; | 1974 |
Hypertension past 60.
Topics: Aged; Benzothiadiazines; Chlorthalidone; Guanethidine; Humans; Hydralazine; Hypertension; Methyldopa | 1967 |
Letter: Chlorthalidone-induced hypercalcemia.
Topics: Adult; Chlorthalidone; Female; Humans; Hypercalcemia; Hypertension | 1974 |
[Diuretics in modern treatment of hypertension].
Topics: Aged; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Potassium; Ur | 1974 |
Potassium deficiency in hypertensives treated with diuretics. Analysis of three alternative treatments by an oral test for potassium deficiency.
Topics: Adult; Aged; Chlorthalidone; Diuretics; Female; Humans; Hypertension; Male; Potassium; Potassium Def | 1974 |
Trace elements in serum and urine from hypertensive patients treated for six months with chlorthalidone.
Topics: Adult; Blood Pressure; Chlorthalidone; Depression, Chemical; Female; Humans; Hypertension; Male; Mid | 1974 |
Importance of the adrenergic nervous system in the support of cardiac function in patients with primary arterial hypertension.
Topics: Body Weight; Cardiac Output; Chlorthalidone; Digitalis Glycosides; Glomerular Filtration Rate; Guane | 1973 |
[Is essential hypertension still a disease entity? Definition of hyporeninemic hypertension].
Topics: Aldosterone; Amiloride; Chlorthalidone; Diagnosis, Differential; Drug Combinations; Humans; Hydrochl | 1974 |
Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.
Topics: Adult; Chlorthalidone; Dehydration; Diabetes Mellitus; Diabetic Coma; Diabetic Ketoacidosis; Humans; | 1972 |
Effect of chlorthalidone binding on the electrophoretic properties of human red cell carbonic anhydrase isozymes.
Topics: Blood Protein Electrophoresis; Carbonic Anhydrases; Chlorthalidone; Erythrocytes; Humans; Hypertensi | 1972 |
Clinical efficacy of fixed combinations of saluretic agents and potassium in sustained release form for the treatment of arterial hypertension.
Topics: Blood Pressure; Chlorides; Chlorthalidone; Creatinine; Delayed-Action Preparations; Drug Combination | 1972 |
[Antihypertensive agents].
Topics: Acetazolamide; Antihypertensive Agents; Bis-Trimethylammonium Compounds; Bretylium Compounds; Chlori | 1972 |
How to treat arterial hypertension.
Topics: Antihypertensive Agents; Chlorothiazide; Chlorthalidone; Cooperative Behavior; Diazoxide; Diuretics; | 1973 |
[Therapy of EPH gestosis].
Topics: Chlorthalidone; Diazepam; Diet Therapy; Eclampsia; Edema; Female; Furosemide; Guanethidine; Humans; | 1973 |
[Treatment of hypertension with hygroton and hygroton combined with reserpine].
Topics: Chlorthalidone; Diuresis; Drug Synergism; Humans; Hypertension; Muscle Tonus; Natriuresis; Potassium | 1973 |
A comparison of chlorothiazide, chlorthalidone and cyclopenthiazide in the treatment of hypertension.
Topics: Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diuretics; Humans; Hypertension; Hypokalemia | 1973 |
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Urea Nitrogen; Chlorthalidone; Creatinine; Female; H | 1973 |
Letter: Treatment for hypertension.
Topics: Chlorthalidone; Drug Synergism; Humans; Hypertension; Methyldopa; Middle Aged | 1973 |
[Effects of clonidine treatment in advanced forms of essential arterial hypertension].
Topics: Aged; Aortic Arch Syndromes; Bradycardia; Cerebral Hemorrhage; Chemical Phenomena; Chemistry; Chlort | 1973 |
Trace elements in serum and urine from hypertensive patients before and during treatment with chlorthalidone.
Topics: Activation Analysis; Adult; Arsenic; Cesium; Chlorthalidone; Depression, Chemical; Female; Humans; H | 1973 |
[The antihypertensive effects of bendroflumethiazide, hydroflumethiazide, trichlormethiazide, chlorthalidone and furosemide].
Topics: Adult; Aged; Bendroflumethiazide; Chlorthalidone; Diuretics; Female; Furosemide; Humans; Hydroflumet | 1973 |
Diuretic and diet treatment of hypertension.
Topics: Benzothiadiazines; Blood Volume; Chlorthalidone; Creatinine; Diet, Sodium-Restricted; Diuretics; Eth | 1974 |
[A comparative study of spironolactone and chlorthalidone in treatment of hypertension].
Topics: Adult; Blood Glucose; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hypertension; Male; | 1974 |
[Respective roles of hemodynamic or humoral factors and of hypotensive or salidiuretic drugs in the development of essential hypertension].
Topics: Adult; Chlorthalidone; Diet, Sodium-Restricted; Electrocardiography; Guanethidine; Humans; Hydrochlo | 1965 |
Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155).
Topics: Antihypertensive Agents; Blood Pressure; Cardiac Output; Cardiovascular System; Chlorthalidone; Dye | 1969 |
Autoantibodies related to treatment with chlorthalidone and alpha-methyldopa.
Topics: Adult; Antibodies, Antinuclear; Autoantibodies; Chlorthalidone; Coombs Test; Drug Synergism; Female; | 1970 |
[Self-control of the blood pressure in hypertension therapy].
Topics: Adolescent; Adult; Blood Pressure Determination; Chlorthalidone; Female; Humans; Hypertension; Hyper | 1972 |
Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent.
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Clonidine; District of Columbia; Diuretics; Female; Fol | 1972 |
[Cardiac insufficiency appearing in essential arterial hypertension].
Topics: Chlorthalidone; Guanethidine; Heart Failure; Humans; Hypertension; Reserpine | 1972 |
[Hypertension].
Topics: Aged; Allopurinol; Antihypertensive Agents; Benzothiadiazines; Chlordiazepoxide; Chlorthalidone; Dia | 1971 |
Chlorthalidone in the long term therapy of patients with hypertension.
Topics: Adult; Aged; Blood Chemical Analysis; Blood Glucose; Blood Pressure; Carbohydrate Metabolism, Inborn | 1970 |
Body composition changes in hypertensive subjects on long-term oral diuretic therapy.
Topics: Adult; Body Composition; Chlorthalidone; Female; Furosemide; Glucose Tolerance Test; Humans; Hydroge | 1970 |
[Carbohydrate metabolism during treatment with chlorthalidone and cyclothiazide].
Topics: Aged; Antihypertensive Agents; Benzothiadiazines; Carbohydrate Metabolism; Chlorthalidone; Cortisone | 1970 |
[Some aspects of renal metabolism of citric acid].
Topics: Adult; Age Factors; Aged; Chlorthalidone; Citrates; Heart Failure; Humans; Hydrochlorothiazide; Hype | 1970 |
Antihypertensive effect of a new imidazoline compound (clonidine) and chlorthalidone, individually and in combination.
Topics: Adult; Aged; Alkaline Phosphatase; Aniline Compounds; Antihypertensive Agents; Blood Glucose; Blood | 1970 |
[Controlled long-term study in senile hypertension].
Topics: Aged; Antihypertensive Agents; Blood Pressure Determination; Chlorthalidone; Humans; Hypertension; I | 1970 |
Failure of repeated diazoxide injections to modify the course of severe hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diazoxide; Diuretics; Guanethidine; Heart F | 1971 |
Antihypertensive effect of clonidine.
Topics: Animals; Antihypertensive Agents; Cardiac Output; Chlorthalidone; Creatinine; Dogs; Drug Synergism; | 1971 |
[Treatment of permanent arterial hypertension by a combination of reserpine and a salidiuretic].
Topics: Arteries; Chlorthalidone; Drug Synergism; Humans; Hypertension; Reserpine | 1967 |
[Prolonged treatment of arterial hypertension of arteriosclerotic origin with a combination of chlorthalidone and reserpine].
Topics: Aged; Arteriosclerosis; Blood Glucose; Chlorthalidone; Diuresis; Electrolytes; Female; Hemodynamics; | 1967 |
[Changes in blood uric acid during prolonged treatment with diuretic-hypotensive drugs in aged patients].
Topics: Aged; Arteriosclerosis; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine; | 1967 |
[On the effects and side effects of a diuretic].
Topics: Chlorthalidone; Diet, Sodium-Restricted; Edema; Humans; Hypertension; Hypokalemia | 1967 |
[Hypertension, saluretics, and glucose tolerance].
Topics: Chlorthalidone; Diabetes Complications; Furosemide; Glucose Tolerance Test; Humans; Hyperglycemia; H | 1968 |
[Decrease in neonatal mortality through treatment of essential hypertension in pregnant women].
Topics: Adult; Antihypertensive Agents; Chlorthalidone; Female; Humans; Hypertension; Infant Mortality; Infa | 1968 |
[Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid].
Topics: Aged; Carbohydrate Metabolism; Chlorthalidone; Diabetes Mellitus; Ethacrynic Acid; Female; Humans; H | 1968 |
[New theories and clinal demonstratioof the activity and usefulness of chlorthalidone-reserpine in the treatment of hypertensive diseases].
Topics: Adult; Aged; Chlorthalidone; Drug Synergism; Ergotamine; Female; Humans; Hypertension; Male; Middle | 1968 |
[Objectives and methods in therapy of essential arterial hypertension].
Topics: Antihypertensive Agents; Chlorthalidone; Diuretics; Ethacrynic Acid; Guanethidine; Humans; Hydralazi | 1968 |
[The association of chlorthalidone and reserpine in the therapy of essential arterial hypertension].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine | 1969 |
Hypotensive drugs. II. General considerations.
Topics: Adult; Aged; Chlorthalidone; Diuretics; Female; Guanethidine; Humans; Hypertension; Male; Methyldopa | 1969 |
[Clinical experiences with the antihypertensive agent Darebon].
Topics: Adult; Aged; Blood Pressure; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserp | 1969 |
Modifying elevated blood pressure: a practical office approach.
Topics: Chlorothiazide; Chlorthalidone; Diuretics; Humans; Hypertension; Methyldopa; Phytotherapy; Plants, M | 1969 |
[Hypotensive diuretics and abnormalities of carbohydrate metabolism].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carbohydrate Metabolism; Chlorthalidone; Gluco | 1969 |
[Ethacrynic acid and furosemide used in the treatment of hypertension as compared with chlorthalidone].
Topics: Chlorthalidone; Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypertension | 1965 |
[Results obtained in the treatment of permanent arterial hypertension with a combination of reserpine and a "thiazide" diuretic].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine | 1965 |
[Studies on uric acid metabolism disorders following administration of saluretics].
Topics: Chlorothiazide; Chlorthalidone; Ethacrynic Acid; Furosemide; Humans; Hydrochlorothiazide; Hydroflume | 1965 |
[Treatment of essential hypertension with hygroton-reserpine].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine | 1965 |
[A new association for the treatment of essential arterial hypertension: G 37,736 (hygroton-reserpine)].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine | 1965 |
[Clinical experimentation with Hygroton-reserpine (apropos of 58 cases)].
Topics: Adult; Aged; Chlorthalidone; Female; Humans; Hypertension; Male; Middle Aged; Reserpine | 1966 |
Potassium depletion produced by administration of chlorthalidone to nonedematous patients with arterial hypertensin.
Topics: Adult; Alkalosis; Blood Urea Nitrogen; Carbon Dioxide; Chlorine; Chlorthalidone; Creatine; Female; H | 1966 |
A comparative clinical study of hydrochlorothiazide and chlorthalidone in oedema states.
Topics: Adolescent; Adult; Chlorthalidone; Edema; Female; Humans; Hydrochlorothiazide; Hypertension; Male; M | 1966 |
[On combined therapy of hypertension and heart insufficiency. Advantages and disadvantages].
Topics: Arrhythmias, Cardiac; Chlorthalidone; Digitoxin; Drug Synergism; Heart Function Tests; Humans; Hyper | 1966 |